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Abstract 
Hepatitis C virus (HCV) is emerging as one of the leading causes of morbidity and 
mortality in individuals infected with HIV and has overtaken AIDS-defining 
illnesses as a cause of death in HIV patient populations who have access to highly 
active antiretroviral therapy.  
 For many years, the clonal analysis was the reference method for 
investigating viral diversity. In this thesis, a next generation sequencing (NGS) 
approach was developed using 454 pyrosequencing and Illumina-based 
technology. A sequencing pipeline was developed using two different NGS 
approaches, nested PCR, and metagenomics. The pipeline was used to study the 
viral populations in the sera of HCV-infected patients from a unique cohort of 
160 HIV-positive patients with early HCV infection. These pipelines resulted in an 
improved understanding of HCV quasispecies dynamics, especially regarding 
studying response to treatment. 
  Low viral diversity at baseline correlated with sustained virological 
response (SVR) while high viral diversity at baseline was associated with 
treatment failure. The emergence of new viral strains following treatment 
failure was most commonly associated with emerging dominance of pre-existing 
minority variants rather than re-infection.  
 In the new era of direct-acting antivirals, next generation sequencing 
technologies are the most promising tool for identifying minority variants 
present in the HCV quasispecies populations at baseline. In this cohort, several 
mutations conferring resistance were detected in genotype 1a treatment-naïve 
patients.  Further research into the impact of baseline HCV variants on SVR rates 
should be carried out in this population. 
 A clearer understanding of the properties of viral quasispecies would 
enable clinicians to make improved treatment choices for their patients.  
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Definitions/ Abbreviations 
ATP Adenosine triphosphate 
aa Amino acids 
bp  Base pair(s) 
cDNA complementary DNA 
DCV   Daclatasvir  
DSV   Dasabuvir 
°C Degrees celsius 
DAAs Directly Acting Antivirals 
DMEM Dulbecco’s modified Eagle’s medium  
EMCV Encephalomyocarditis virus  
E. coli Escherichia coli   
FCS  Foetal calf serum  
HD Hamming distance  
HCVcc Cell-culture-derived infectious HCV  
HCV  Hepatitis C Virus 
HCC  Hepatocellular carcinoma  
HAART Highly active antiretroviral therapy  
Huh-7 Human hepatoma cell line  
hVAP-33 human vesicle-associated protein-33  
H77 Hutchinson strain   
HVR  Hypervariable region  
IFN Interferon  
IRF-3 Interferon regulatory factor 3  
ISDR Interferon sensitivity-determining region  
IRES Internal ribosome entry site  
LDV Ledipasvir 
ML tree Maximum likelihood tree  
MSM Men who have sex with men  
μ Micro (10-6) 
Min Minutes   
Neo Neomycin phosphotransferase  
NGS   Next Generation Sequencing 
NS Non-Structural   
NF-κB  Nuclear factor kappa-light-chain-enhancer of activated B cells 
nt Nucleotides  
OBV  Ombitasvir 
ORF  Open reading frame 
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Pi  Pairwise diversity  
PTV   Paritaprevir 
PrOD Paritaprevir-ritonavir, Ombitasvir, Dasabuvir  
PegIFNα Pegylated Interferon-alpha  
PWID People who inject drugs  
PBMC Peripheral blood mononuclear cells  
PCR polymerase chain reaction  
PI Protease inhibitor 
QD Quasispecies diversity  
RLU  Relative light units 
RAMs Resistance-associated mutations  
RAVs Resistance-associated variants   
RIG-I Retinoic acid inducible gene-I   
RT Reverse transcription  
RBV Ribavirin  
RdRp  RNA-dependent RNA polymerase  
Sec Seconds 
SBS Sequencing by synthesis  
SMV   Simeprevir 
SNP Single nucleotide polymorphism  
SOF   Sofosbuvir 
SGR subgenomic replicons  
SVR    Sustained virological response 
TVR Telaprevir 
EC50 The half maximal effective concentration    
IC50  The half maximal inhibitory concentration  
3D Three-dimensional  
TLR Toll-like receptor  
TRIF Total reflection fluorescence  
UTR Untranslated region  
 WT Wild type 
WHO World Health Organisation  
ZMWs Zero-mode waveguides  
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Amino Acid Names Abbreviations 
Amino acid 
Three 
letter code 
One letter 
code 
Alanine Ala A 
Arginine Arg R 
Asparagine Asn N 
Aspartic acid Asp D 
Cysteine Cys C 
Glutamine Gln Q 
Glutamic acid Glu E 
Glycine Gly G 
Histidine His H 
Isoleucine Ile I 
Leucine Leu L 
Lysine Lys K 
Methionine Met M 
Phenylalanine Phe F 
Proline Pro P 
Serine Ser S 
Threonine Thr T 
Tryptophan Trp W 
Tyrosine Tyr Y 
Valine Val V 
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Chapter 1: Introduction 
1.1 Hepatitis C virus (HCV) 
Hepatitis C virus (HCV) is a single-stranded RNA virus that belongs to the 
Hepacivirus genus within the Flaviviridae family (Simmonds et al., 1994). The 
positive sense genome has a length of 9.6 kb.  
1.2 HCV discovery and classification 
Hepatitis C virus was identified as the causative agent of non-A, non-B hepatitis 
in 1989 (Choo et al., 1989). The virus is highly heterogeneous, due to the lack of 
proofreading ability of the RNA-dependent RNA polymerase (RdRp) that it 
encodes.  
 HCV is classified into seven genotypes and more than 90 different subtypes 
(Nakano et al., 2012). HCV genotypes differ at 30–35 % of nucleotide positions on 
average over the complete genome. Each of these seven major genetic groups 
contains a cluster of more closely related subtypes that differ in their nucleotide 
sequences by 20–25 % (Simmonds, 2004). This variation is likely the result of the 
error-prone replication of HCV and the high replication rate of 1012 viral 
particles/day (Neumann et al., 1998). The seventh genotype sequence has been 
deposited in the NCBI databases, but no clinical details associated with this 
clinical isolate have been reported (Gottwein et al., 2009).  
 Based on the time of divergence of the different genotypes, it is estimated 
that HCV originated between 500 and 2000 years ago (Simmonds, 2001).  The 
inclusion of subgenomic sequences from infected patients in 1953 in evolutionary 
analyses provides new estimates of the common ancestor of HCV (Gray et al., 
2013). 
1.3 HCV genome 
The ORF encodes ten proteins, including Core (C), Envelope (E1 and E2), p7 
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protein and six non-structural (NS) proteins (NS2, NS3, NS4A, NS4B, NS5A, and 
NS5B). Another protein termed F protein is translated from a frame-shift in the 
core coding region (Figure 1-1) (Thurner et al., 2004).  
1.3.1 5' Untranslated region (5'UTR) 
The 5'UTR contains 341 nucleotides (nt). It contains four domains, numbered I to 
IV (Brown et al., 1992). The domains II, III, IV and the first 12-30 nt of the core 
coding region form the internal ribosome entry site (IRES) that mediates the 
translation of genomic RNA by binding the 40S ribosomal subunit to form a stable 
pre-initiation complex to initiate the HCV polyprotein translation (Honda et al., 
1996). 
1.3.2 3' Untranslated region (3'UTR) 
The 3'UTR contains around 225 nucleotides; it is organised into three regions; a 
variable site of around 30-40 nt, a long poly(U)-poly(U/UC) tract and a highly 
conserved 3'X region of 98 nt (Kolykhalov et al., 1996). It interacts with the NS5B 
RdRp and is essential for RNA replication (Lee et al., 2004). 
1.3.3 Frame-shift protein 
The F (frame-shift) protein is encoded from a -2/+1 ribosomal frame shift in the 
N-terminal core-encoding region. The protein is produced during infection, and 
anti-F protein antibodies have been detected in clinical samples (Walewski et 
al., 2001). The role of the F protein remains unclear although it may play a role 
in viral persistence (Baril and Brakier-Gingras, 2005). 
1.3.4 Core protein 
HCV core is a highly conserved protein that constitutes the viral nucleocapsid. 
The immature form of the core protein is composed of three domains; the last 
20 aa works as a signal peptide for the E1 protein (Grakoui et al., 1993b). 
Domain D1 is mainly involved in RNA binding. Domain D2 is responsible for 
targeting core to the surface of lipid droplets (Suzuki et al., 2005).  
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It also interacts with some cellular proteins and pathways during the virus life 
cycle (McLauchlan, 2000).  
1.3.5 Envelope glycoproteins 
E1 and E2 are type I transmembrane glycoproteins that are essential for viral 
entry and fusion (Nielsen et al., 2004, Bartosch et al., 2003a). They have several 
properties including membrane anchoring, ER localization and heterodimer 
assembly (Cocquerel et al., 2000). E2 contains hypervariable regions ((HVR1, 
HVR2, and HVR3).  
 HVR1 consists of 27 aa, is a major neutralizing epitope, and its amino acid 
sequences differ by up to 80% between HCV genotypes (Farci et al., 1996). 
However, its overall conformation is highly conserved across all genotypes, 
indicating a vital role in the virus life cycle (Penin et al., 2001). The HVR1 also 
plays a major role in viral attachment through interaction with negatively 
charged molecules at the cell surface via positively charged residues (Flint and 
McKeating, 2000, Bartosch et al., 2003b). 
1.3.6 Protein p7 
Protein p7 is a small, 63 aa polypeptide that has ion channel activity (Kalita et 
al., 2015). Cleavage of p7 from the polyprotein is mediated by host signal 
peptidase (Lin et al., 1994). The ion channel activity of p7 is critical in the HCV 
life cycle as mutations or deletions in the p7 protein suppress infectious virus 
production (Jones et al., 2007).  
1.3.7 Non-structural proteins 
1.3.7.1 NS2 
NS2 is a transmembrane protein, which has two internal hydrophobic segments 
that are responsible for ER membrane association (Yamaga and Ou, 2002). NS2 
forms an autoprotease with the N-terminal domain of the NS3 protein that 
cleaves at the junction between NS2 and NS3 (Grakoui et al., 1993a). 
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Various studies have identified adaptive mutations in NS2 that enhance HCVcc 
virus production, but NS2 is not required for RNA replication (Jones et al., 2007). 
1.3.7.2 NS3-NS4A 
NS3 has several functions; it contains an N-terminal serine protease domain and 
a C-terminal helicase/NTPase domain. NS4A is a cofactor of NS3 protease 
activity. The NS3/4A complex plays an indispensable role in HCV life cycle and 
pathogenesis (Pawlotsky, 2006).  
 NS3/NS4A Protease 
The NS3/NS4A protease cleaves the HCV polyprotein at the NS3/NS4A, 
NS4A/NS4B, NS4B/NS5A and NS5A/ NS5B junctions. NS4A serves as a cofactor for 
NS3 serine protease activity, enabling its localisation at the ER membrane as 
well as cleavage-dependent activation (Bartenschlager et al., 1995). 
 The NS3/4A serine protease contributes to HCV immune evasion through 
blocking the phosphorylation of the interferon regulatory factor 3 (IRF-3) 
pathway, which affects interferon induction in response to a viral infection (Foy 
et al., 2003). Moreover, NS3/4A-mediated cleavage of TRIF inhibits signalling 
through the Toll-like receptor 3 (TLR3) pathway (Li et al., 2005).  
 NS3 Helicase-NTPase 
The NS3 helicase-NTPase domain consists of 442 aa at the C-terminus of the NS3 
protein. It is a multifunctional protein, as it is involved in RNA binding, and 
unwinding of secondary structure, it also has RNA-stimulated NTPase activity 
(Cho et al., 1998, Gwack et al., 1997). The introduction of adaptive mutations in 
both protease and helicase regions of NS3 improve the RNA replication of 
replicons in cell culture (Lohmann et al., 2003). 
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Figure 1-1: HCV genome.  
 
 
 
Open reading frame produces structural and non-structural proteins flanked by two untranslated regions. The length of each region is expressed in 
brackets as the number of nucleotides. 
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1.3.7.3 NS4B 
NS4B is a 261 aa integral membrane protein, it acts as a membrane anchor for 
the replication complex (Elazar et al., 2004), and inhibits cellular protein 
synthesis (Florese et al., 2002, Piccininni et al., 2002). Different substitutions in 
NS4B were reported to enhance or abolish RNA replication indicating its role in 
the regulation of HCV NS5B RdRp activity (Lohmann et al., 2003). NS4B is 
reported to play a role in virus assembly (Jones et al., 2009).  
1.3.7.4 NS5A 
NS5A is a hydrophilic phosphoprotein, its role in HCV replication is not entirely 
understood. RNA replication is inhibited by mutations within the NS5A sequence 
(Elazar et al., 2003). NS5A associates with lipid rafts derived from intracellular 
membranes, and this is essential for the HCV replication (Gao et al., 2004). 
Moreover, NS5A phosphorylation may play a fundamental role in the HCV life 
(Appel et al., 2005). 
1.3.7.5 NS5B RNA-dependent RNA polymerase 
NS5B acts as an RNA-dependent RNA polymerase (RdRp). It was shown that the 
RdRp has a classical "fingers, palm and thumb" structure. It has a typical right-
hand structure with a central palm domain harbouring the catalytic GDD motif 
and the fingers and thumb domains on either side; the resulting conformation 
allows the binding of a single-stranded RNA template (Lesburg et al., 1999, 
Bartenschlager et al., 2004). 
1.4 HCV replication 
The combination of viral proteins, cellular components, and nascent RNA strands 
forms a replication complex that involves lipid rafts through protein-protein 
interactions between human vesicle-associated protein-33 (hVAP-33) and both 
NS5A and NS5B (Gao et al., 2004, Shi et al., 2003). 
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In HCV replication, the positive-sense genome RNA serves as a template for the 
synthesis of a negative-sense replication intermediate that acts as a template to 
produce further positive-sense RNA strands. The new positive-sense RNA strands 
may be directly translated, used as a template for the synthesis of replication 
intermediate, or packaged into new virions (Bartenschlager et al., 2004). 
 The characterization of the NS5B RdRp revealed that NS5B-mediated RNA 
polymerization is initiated by priming on the template via a 'copy-back' 
mechanism. RdRp is also capable of initiating de novo RNA synthesis (Zhong et al., 
2000). 
1.5 HCV replicons 
HCV propagation in cell culture using infection with virus-containing inoculum is 
hindered by low and transient replication levels that prevent studies on HCV 
replication with natural isolates (Bartenschlager and Lohmann, 2001). However, 
it is possible to recapitulate replication through transfection of HCV RNAs 
transcribed in vitro from cDNA clones containing viral sequences that encode the 
viral NS3-NS5B replicase unit (Bartenschlager and Lohmann, 2001).  
 The first functional HCV subgenomic replicons were derived from consensus 
genotype 1b (Con1) sequences that were detected in the liver of an HCV-
infected patient. It contained: i) the HCV 5' UTR and the first 12 codons of the 
core protein linked in-frame with the neomycin phosphotransferase cassette 
(Neo) to permit selection in the presence of the cytotoxic agent G418; ii) the 
IRES region from encephalomyocarditis virus (EMCV) that initiates translation of 
the downstream HCV NS3-5B polyprotein; iii) the HCV 3' UTR (Lohmann et al., 
1999).  
1.5.1 Adaptive mutations 
The original Con1 subgenomic replicons produced a low frequency of G418-
resistant cells (~1 colony per 106 transfected cells) (Lohmann et al., 1999, Blight 
et al., 2000). The low frequency was attributed to the low number of cells 
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supporting efficient HCV replication and the necessity of acquiring adaptive 
mutations to replicate efficiently in the permissive cell line. Sequence analysis 
of Con1-derived HCV RNAs replicating in the selected cells identified highly 
adaptive mutations in the nonstructural region, mainly clustering in NS5A (Blight 
et al., 2000, Krieger et al., 2001, Lohmann et al., 2003, Lanford et al., 2003, 
Enomoto et al., 1995, Enomoto et al., 1996). 
1.5.2 Genotype 1a replicons  
Genotype 1a replicons derived from the Hutchinson strain (H77) require at least 
two adaptive mutations to replicate efficiently in cell culture systems (Blight et 
al., 2003, Grobler et al., 2003, Gu et al., 2003, Yi and Lemon, 2004). The first 
H77 replicons contained a mutation (S2204I) that allowed efficient replication in  
Huh-7.5 cell line (Blight et al., 2002, Blight et al., 2003). Analysis of these 
replicons revealed that the improved replication capacity of subgenomic H77 is 
associated with the presence of an additional substitution in NS3 gene (P1496L) 
(Blight et al., 2003).  
 Voitenleitner et al. described the generation of a robust H77 replicon 
through the introduction of extra fitness mutations, NS4A (K1691R) and NS4B 
(E1726G). These mutations considerably enhanced the signal to noise ratio, 
leading to more robust replication in transient transfections (Voitenleitner et 
al., 2012). 
1.5.3 Reporter genes 
After the development of HCV replicons, transient RNA replication assays were 
developed to permit rapid analysis of replication efficacy. Reporters such as 
luciferase and ß-lactamase were used to monitor replication following 
transfection (Blight and Norgard, 2006).  
 Luciferase activity is a reliable marker of replication as it directly 
correlates with the levels of HCV RNA synthesis. The Firefly luciferase was 
introduced to bicistronic subgenomic replicons, thus enabling assessment of 
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replication at different time points by measuring enzyme activity relative to a 
polymerase-defective replicon, which contains a mutation in the GDD RNA 
polymerase motif (GDD to GND). The adapted Con1 replicons produce luciferase 
activity at 48-72 hours that is about 100-fold higher than the negative GND 
control (Krieger et al., 2001).  
1.5.4 Permissive cell lines for HCV replication  
Although hepatocytes are the main site of HCV replication, other extrahepatic 
cells are also reported to harbour the virus, including lymphocytes, monocytes 
and dendritic cells (Laskus et al., 2000, Goutagny et al., 2003).  
 Huh-7.5 cells were produced by treatment of HuH-7 cells harbouring a 
subgenomic replicon with human interferon-α (IFNα) at a high concentration for 
long periods. They have the capacity to support high levels of subgenomic HCV 
replication in more than 75% of transfected cells, rendering it the most 
permissive subline available to date. 
 The higher permissiveness is attributed to the mutational inactivation of 
the retinoic acid-inducible gene-I (RIG-I), a protein that is involved in the 
induction of type I IFN production (Blight et al., 2002, Sumpter et al., 2005).  
 The performance of transient assays varies between different passages of 
Huh-7 cells, which may cause up to 100-fold difference in replication efficiencies 
of subgenomic RNAs. This difference is independent of the adaptive mutations 
introduced or the quality of RNA (Lohmann et al., 2003). Moreover, there is an 
association between stage of the cell cycle and the replication of subgenomic 
replicons (Blight et al., 2002, Blight et al., 2000).   
1.5.5 Applications of the HCV replicon system  
The development of the replicon system has been instrumental in defining the 
functions of individual proteins, and enabling studies on virus-host interactions. 
One of the applications is estimating the in vitro replication fitness of replicons 
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after the introduction of resistance-associated mutations (RAMs) by comparing 
replication efficacy with that of the wild-type (WT) replicon based on transient 
replication assays.  
1.6 Epidemiology of Hepatitis C virus infection 
An estimated 185 million individuals have been infected with HCV worldwide 
(Thomas, 2013). The host immune response against HCV infection fails to 
prevent chronicity in 50%-80% of cases resulting in approximately 135 million 
people with chronic infection. 
 Our understanding of global HCV epidemiology is imperfect, as it has been 
shaped by seroprevalence studies performed in selected populations, such as 
blood donors. Although population-based studies representative of an entire 
community would be useful, they are not feasible to perform, so in many 
countries, the exact magnitude of the problem is not clear.  
 Currently available data show that the prevalence of HCV varies across the 
globe with the highest reported in Egypt where the seroprevalence rate is 
estimated at 22% of the total population (Shepard et al., 2005). This high 
prevalence rate is a result of the national antischistosomal treatment 
programme, which until the 1970s involved intravenous administration of drugs 
using reusable syringes (Frank et al., 2000).  
 The geographic distribution of HCV is available using the Los Alamos online 
database at http://hcv.lanl.gov (Figure 1-2). The prevalence of HCV is 3–4% in 
some Asian countries, almost 2% in North America, and above 10% in regions of 
Central Africa. The seroprevalence in England and Wales in the adult population 
aged 15-59 is estimated to be less than 0.6% (Thomson, 2009).  
 Genotypes 1-3 have a worldwide distribution and account for almost all 
infections in developed countries with 1a and 1b being the most common (Figure 
1-3). Genotypes 4 and 6 remain the most diversified genotypes (Nakano et al., 
2012).  
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HCV genotype 5a has been transmitted in South Africa and Belgium 
independently Africa for more than a century (Verbeeck et al., 2006), while HCV 
genotype 7 is reportedly originating from central Africa (Murphy et al., 2015).  
 Patients who have received injected medical treatments including blood 
products before the introduction of screening blood for HCV are at highest risk 
globally for HCV infection. In developed countries, the vast majority of new 
cases are associated with unsafe injections in people who inject drugs (PWID). 
Sexual transmission of HCV infrequently occurs in HIV-negative couples but is 
more common in HIV-positive patients, particularly in men who have sex with 
men (MSM) (Danta et al., 2007).  
 This thesis is based on the study of a cohort of HIV-positive MSM with acute 
HCV infection in reported in urban centers in the UK, Germany, France, the 
Netherlands and the USA (Gilleece et al., 2005, Vogel et al., 2005, Dominguez et 
al., 2006). The majority of these patients have been asymptomatic and have 
been diagnosed after detection of deranged liver function tests at routine HIV 
follow-up clinics. Sexual transmission in these patients was associated with 
exposure risk factors including sexual practices with a high risk of mucosal 
trauma, unprotected anal intercourse, multiple partners, sex under the 
influence of drugs, and internet-arranged sex (Danta et al., 2007). Heterosexual 
spread of HCV in HIV-infected patients may be higher than in HIV-negative 
couples. The higher transmission could be attributed to a higher HCV viral load 
in genital secretions (D'Oliveira et al., 2005). 
1.7 Studying the viral population within infected patients 
The RNA viruses do not follow the evolutionary dynamics of traditional 
population genetics, as RNA viruses are characterised by high replication rate, 
large (close to infinite) population size, and high mutation rates (Holland et al., 
1982). 
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Figure 1-2: prevalence of hepatitis C virus genotypes in different regions.  
 
The figure represents the frequency in the NCBI HCV Database; the color code is the same used in Figure 1-2. Geographic and subtype distribution is 
shown for the 102516 sequences available online at http://hcv.lanl.gov/components/sequence/HCV/geo/geo.comp, accessed on 05/09/2015. 
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Figure 1-3: Global distribution and prevalence of hepatitis C virus genotypes. 
 
The figure represents the frequency in the NCBI HCV Database as an estimate of 
population prevalence. The geographic and subtype distribution is shown for the 102516 
sequences http://hcv.lanl.gov/components/sequence/HCV/geo/geo.comp, accessed on 
5/9/2015.   
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1.7.1 Replicative homeostasis hypothesis 
The replicative homeostasis hypothesis (RH) states that dynamic RNA polymerase 
has a reduced replication fidelity, which results in a high intracellular 
concentration of mutant genomes, and consequently a spectrum of mutant 
proteins. The protein products interact with RdRp to regulate its processivity 
and fidelity. This regulation leads to the establishment of replicative 
homeostasis (Sallie, 2007). This regulatory mechanism links the dynamic RdRp 
with quasispecies diversity, creating a stable but reactive replicative equilibrium 
(Sallie, 2007).  
 The replicative equilibrium provides a sequence space that tolerates 
mutations; the variation in viral sequence space is controlled by factors such as 
viral fitness and the host's immune system (Sallie, 2005). The homeostatic 
regulation requires three main components: i) a pathway that initiates a 
response to any disturbance of the replicative equilibrium; ii) a feedback 
pathway that measures the system’s response to this disturbance; iii) 
mechanism(s) of viral auto-regulation (Sallie, 2005). 
1.7.2 Quasispecies theory 
Quasispecies theory has been defined as ‘dynamic distributions of non-identical 
but closely related mutant and recombinant viral genomes subjected to a 
continuous process of genetic variation, competition and selection, and which 
act as a unit of selection’ (Domingo et al., 2005). 
 Quasispecies theory described the evolutionary dynamics of RNA viruses and 
was validated experimentally in model systems (Duffy et al., 2008). Quasispecies 
theory considers certain characteristics of RNA viruses: i) a high mutation rate; 
ii) a small genome size; iii) a large population; iv) an equilibrium state where 
the effects of mutations and selection are equal (Comas et al., 2005, Biebricher 
and Eigen, 2006).  
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The defining feature of quasispecies theory is ‘the survival of the flattest’, as 
the high error rates result in a mutational drive, which in turn leads to natural 
selection at the population level rather than at the individual level. This 
selection results in the outgrowth of populations with variants exhibiting similar 
viral replication capacity rather than a population in which variants have a 
higher replicative fitness. This feature distinguishes the process within the 
quasispecies from the traditional notion of ‘survival of the fittest’ (Wilke et al., 
2001). 
 Data are suggesting that quasispecies theory does not apply to RNA viruses 
as, although RNA viruses mutate rapidly, mutation rates may not reach a 
sufficient threshold to have a significant impact on quasispecies dynamics (i.e. 
‘the survival of the flattest’) (Holmes, 2010). However, the circulation of 
multiple genetically related but not identical variants within an infected host 
has major implications on the outcome of infections and the progression of the 
disease. 
1.7.3 Methods of quasispecies analysis 
The major issues associated with the identification of viral variants present in 
any clinical sample are the viral complexity and the detection of minority (low 
frequency) variants. The development of next-generation sequencing (NGS) 
platforms has provided a better understanding of intra-host viral populations, 
rendering NGS a potential alternative to conventional methods (Cruz-Rivera et 
al., 2013). 
1.7.3.1 Sanger sequencing 
Viral RNA is extracted from a clinical sample or from an in vitro system and 
amplified by reverse transcription-polymerase chain reaction (RT-PCR). The 
amplified PCR product (amplicon) is then sequenced directly using Sanger 
sequencing. Data analysis determines the consensus sequence of all variants 
within the population.  
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Automated sequencing platforms identify the most common base at each 
position in the sequence. If two or more bases are present with similar 
frequencies at a particular position, automated sequencing software may fail to 
identify the single most common base (an issue known as miscalling). In some 
cases, such discrepancies can be resolved by reviewing the chromatogram 
accompanying the sequencing results. Doing this can also provide indications as 
to the variation within the population. 
1.7.3.2 Clonal analysis 
Clonal analysis is a powerful research tool, as it can be used to measure viral 
diversity by sampling sequences that are circulating in the host. However, the 
process is labour-intensive and expensive. The PCR product is cloned into a 
plasmid vector that is introduced to bacteria. Transformed bacteria are grown 
on agarose plates at a low density to allow for the selection of individual 
colonies. The individual colonies are assumed to contain one plasmid only and 
thus only one viral variant. The sequence of a single variant can be obtained by 
sequencing the plasmid DNA extracted from a single bacterial colony. 
 The number of clones required to identify all variants circulating in the 
viral quasispecies is not well defined. It has previously been estimated that 20 
clones are sufficient to sample 95% of the major variants (those with at least 10% 
frequency in the population) (Fishman and Branch, 2009). Another factor that 
can influence the number of clones needed to identify the circulating variants 
could be the variability of the studied region of the genome (Fishman and 
Branch, 2009). For studying HVR1, it has been reported that 99 clones are 
required to identify 95% of any variants present at a frequency above 3% within 
the viral population (McCaughan et al., 2003). However, most minor variants 
would remain undetected using this threshold, therefore excluding a significant 
proportion of the viral complexity. 
 PCR may introduce errors if a non-proofreading enzyme is used which 
creates a biased profile of the viral population. This bias can be avoided by using 
a limiting dilution PCR approach, but it is a time-consuming process, and not 
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suitable for large-scale studies. Other sources of errors include reverse 
transcription, bacterial cloning, and the sequencing reaction.  
 Bidirectional sequencing may reduce the error rate at the sequencing 
stage; however, this approach results in an increase in cost. Primer selection 
bias may also be a problem, particularly when primers are designed to anneal 
with highly diverse regions such as HVR1. This design will result in some variant 
strains being omitted and unamplified. The use of multiple primer sets or 
degenerate primers may help to overcome this problem. 
1.7.3.3 Next generation sequencing (NGS)  
The development of NGS has revolutionised the analysis of viral populations. NGS 
provides a detailed analysis of circulating variants with much higher coverage 
compared to conventional Sanger sequencing. However, it requires a short PCR 
step that may introduce errors, and different sequencing platforms have their 
instrumental errors (Poh et al., 2013). Another difference between Sanger 
sequencing and NGS data is the read length (the number of nucleotides obtained 
from each sequenced fragment). The signal-to-noise ratio limits read length on 
NGS platforms, all of which produce shorter reads than Sanger sequencing. 
 NGS technology has introduced the possibility of using metagenomics to 
discover viruses. The metagenomics has led to the discovery of the aetiology of 
Merkel cell cancer. A viral transcript corresponding to a novel polyomavirus was 
identified, and the virus was named as the Merkel cell polyomavirus (Feng et al., 
2008). Additional contributions were the identification of a bunyavirus in 
patients with thrombocytopenia and leukopenia syndrome (Xu et al., 2011). 
Metagenomic sequencing was also used to determine the human virome in acute 
febrile diarrhea in children (Wylie et al., 2012). The possibility of detection of 
viruses in chronic infection is a major challenge that requires highly sensitive 
methods, as the viral burden may be diminished with disease progression. An 
example of this has been demonstrated in cirrhotic patients (Duvoux et al., 
1999). 
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1.8  Next generation sequencing 
The NGS process is a sequence of reactions including: i) the addition of 
nucleotides; ii) a detection step to identify the incorporated nucleotides on each 
fragment being sequenced; iii) a wash step to remove fluorescent labels or 
blocking groups to prepare for the next reaction (Mardis, 2011).  
1.8.1 Digital data 
NGS platforms use a library of fragmented DNA bound covalently to synthetic 
DNA sequences (adapters). These adapters are universal sequences that are 
subsequently used to amplify library fragments during the sequencing process. 
Amplification is carried out on a solid surface (either a bead or a flat glass 
microfluidic channel depending on platform) that is covalently bound to adapter 
sequences complementary to those on the library fragments. Each amplified 
fragment produces a single cluster of data (Mardis, 2011). 
 Paired-end sequencing has improved the NGS sequencing results: it 
produces sequence data from both ends of each library fragment, improving the 
alignment step in data analysis by offering a duplicate of each nucleotide site, 
thus confirming the placement of each read relative to the reference genome. 
Most alignment programs take into account the average length of fragments in 
the sequencing library to achieve the most accurate placement (Korbel et al., 
2007). 
 The digital nature of NGS data means that each read originates from a 
single cluster, which in turn is created by the amplification of a single library 
fragment. This process enables the quantification of abundance, hence in 
population-based studies, where NGS is used to study the individual species 
present in an isolate, the presence of each species may be quantified as a 
proportion of the total population (Human Microbiome Project, 2012). 
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1.8.2  Sources of noise and error models 
As observed in Sanger sequencing, enzymatic amplification may introduce 
systematic errors during library preparation. These errors are independent of the 
instrument used and could be minimised by using a high-fidelity polymerase 
and/or by reducing the number of amplification cycles. The signal to noise ratio 
is the main limitation to read length in NGS platforms. Noise accumulates as the 
signal from the nucleotide incorporation results from a false signal from a prior 
reaction or incorrect incorporation episodes (Mardis, 2013).  
 The ‘error model’ is defined by the interaction between different sources 
of noise and the resulting sequencing errors. It is instrument- and chemistry-
specific. An important variable in determining the error model is the depth 
(number of sequence reads covering the analysed region) (Mardis, 2008). A 
control sample of known sequence is usually used in each sequencing run to 
determine read-length limitations and error types (Hillier et al., 2008). Using the 
control enables: i) identification of the error model; ii) the detection of 
different types of error (substitutions, insertions,  or deletion errors); iii) 
coverage bias (the complete or partial lack of representation of certain regions) 
(Mardis, 2013). 
1.8.3 454 Pyrosequencing  
The first NGS platform was launched in 2005 by 454 Life Sciences. It is based on 
the detection of DNA polymerase activity using a chemoluminescent enzyme. It 
has an average read length up to 800bp.   
 The library preparation involves adapter ligation, the short adapters 
providing priming sequences for both the amplification and the sequencing of 
library fragments. One adaptor contains a biotin tag to permit the 
immobilisation of the DNA library on streptavidin-coated beads. The bead-bound 
library undergoes an emulsion PCR for library preparation (Zheng et al., 2010). 
The beads are added into a picotiter plate. The wells contain a mixture of 
enzymes; DNA polymerase, ATP sulfurylase, and luciferase. 
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The library is sequenced by using the single-stranded DNA fragments as a 
template for the synthesis of complementary strands. Nucleotides are added to 
the plate, one nucleotide at a time (Voelkerding et al., 2009).  
 Nucleotide incorporation releases pyrophosphate, which is converted to 
adenosine triphosphate (ATP) by ATP sulfurylase. ATP acts as a substrate for the 
luciferase-mediated conversion of luciferin to oxyluciferin. This process causes 
the emission of light that is detected by a camera and analysed in a pyrogram.  
(Ronaghi et al., 1998). The detected signal is proportional to the amount of ATP. 
Hence, the light intensity corresponds to the number of incorporated bases. If 
several similar nucleotides may be incorporated in a single cycle, the accurate 
number of incorporated bases cannot be estimated. Thus, in regions containing 
long homopolymers, a high percentage of insertion and deletion errors may be 
introduced. The insertion and deletion errors were estimated to represent 65%-
75% and 20%-30% of all sequencing errors respectively (Astrovskaya et al., 2011).  
1.8.4 Illumina
®
 technology 
This Illumina technology was launched in 2007 by Solexa and was afterwards 
acquired by Illumina® (Bentley et al., 2008). The library workflow starts by 
fragmentation of DNA and ligation of specific adapters. Illumina® uses a flow cell 
composed of flat glass with eight microfluidic channels as a solid surface. The 
library fragments are amplified on the flow cell surface by bridge amplification, 
resulting in clusters for sequencing.  
 The Illumina® platform uses reversible dye terminator sequencing. In this 
process, all four fluorescent-labelled nucleotides are present in each sequencing 
cycle, and the fragmented DNA (which all carries the same adapter) is primed 
with a complementary synthetic DNA primer to provide a free 3-OH group, which 
can be extended in subsequent stepwise sequencing reactions. Each single 
nucleotide has a blocking group at the 3-OH position of the ribose sugar to 
prevent chain elongation. 
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The sequencing step includes a series of events: i) the addition of a fluorescent-
labelled nucleotide; ii) a wash step for the removal of unincorporated 
nucleotides; iii) recording the fluorescent signal; iv) the chemical cleaving of 
fluorescent groups; v) chemical de-blocking at the 3-OH position.  
 Sequencing errors are mainly substitution errors, in which an incorrect 
nucleotide identity is assigned due to two main sources of noise: i) incomplete 
de-blocking or a lack of de-blocking in prior cycles causes some fragments within 
the same cluster to fall out of phase; ii) interference noise resulting from 
incomplete fluorescent label cleavage in previous cycles (Mardis, 2013).  
1.8.5 Ion Torrent ™ technology 
Ion Torrent platform was commercialised in 2010 (Rothberg et al., 2011).The Ion 
Torrent™ platform is based on the detection of hydrogen ions during the 
sequencing reaction. The change in pH due to the release of hydrogen ions as 
by-products of nucleotide incorporation is quantified by coupled silicon 
detector.  
 The library preparation includes DNA fragmentation and adapter ligation. 
After quantification, the library fragments are mixed in equimolar concentration 
with beads and PCR reagents to undergo emulsion PCR (Dressman et al., 2003). 
 The emulsion PCR uses beads as a solid surface for the amplification 
reaction; the beads have covalently-linked adapter complementary sequences on 
their surfaces to facilitate amplification of the fragments. The emulsion is 
formed by a mixture of beads and library fragments in oil micelles that contain 
PCR reagents.  
 After amplification, the retrieved beads are deposited into the wells of a 
specialised silicon chip (Ion Chip), designed to detect pH changes within 
individual wells as the sequencing reaction progresses. The sequencing reaction 
starts by introducing native nucleotides in a systematic order.  
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The calibration of pH measurement is performed by measuring the signal 
strength due to the incorporation of four single bases downstream of the 
primer’s 3-OH in the adapter sequence in a sequence that matches the first four 
individual nucleotide added to the chip. 
 The average read length is 200 bp, produced as single-end reads. The error 
model of Ion Torrent™ sequencing is defined by insertion or deletion errors that 
are most prevalent at fragments with multiple bases of the same identity 
(homopolymers) due to issues surrounding accurate quantitation and ultimately 
the saturation of the pH detector. Substitution errors occur at a very low 
frequency due to contamination effects from the prior incorporation cycle. 
Overall, an average error rate of the Ion Torrent is 1 in 100 bases (Mardis, 2013). 
1.8.6 Single-molecule DNA sequencing  
Several issues must be considered when working with sequencing platforms that 
use polymerase-amplified libraries, such as primer selection bias, the 
introduction of polymerase errors, and the preferential amplification of 
particular fragments in the library. Currently, the signal to noise ratio limits the 
read length to 200-800 bp. Therefore, there is a need for a superior platform 
that obtains sequence data from individual molecules of a DNA isolate and has 
longer reads.  
 The single-molecule real-time (SMRT) method was developed in 2010 by 
Pacific Bioscience (Menlo Park, CA, USA). It makes use of modified enzymes and 
sequencing is obtained through the direct observation of the enzymatic reaction 
in real time (Eid et al., 2009).   
 SMRT Sequencing has some features that enabled the technology to 
overcome the major challenges facing single-molecule DNA sequencing. The 
method has been used to detect accurately the low signal produced from an 
individual molecule during the sequencing process using zero-mode waveguides 
(ZMWs), phospholinked nucleotides, and engineered DNA polymerase.  
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The library fragments are bound with DNA polymerase molecules immobilised at 
the bottom of a ZMWs chip (SMRT Cell) using a diffusion-mediated process. DNA 
polymerase produces an entirely natural DNA strand by incorporating the 
nucleotide into the complementary strand and cleaves off the fluorescent dye 
previously linked with the nucleotide. ZMWs restrict illumination to the bottom 
of the well where the polymerase/template is fixed. The optics system scans the 
active site of each ZMW-bound polymerase during the addition of fluorescent 
nucleotides to the SMRT cell surface, thus detecting the nucleotide 
incorporation into synthesised  DNA strand, by sensing the signal from its laser 
light–stimulated emission (Liu et al., 2012).  
 The read lengths obtained can be quite long (up to 10,000 nucleotides). 
The error model is mainly considering insertion and deletion errors. There are 
several sources of errors that contribute to an overall high error rate in single-
molecule sequencing, mostly related to the detection method used. An error in 
nucleotide preparations can lead to the lack of the fluorescent label, and hence, 
nucleotides are not detected when incorporated during sequencing.  
 The interaction between the nucleotides and the DNA polymerase active 
may cause different types of errors: i) insertion error occurs when nucleotides 
remain in the active site long enough to be detected but are not incorporated or 
falsely indicate that multiple incorporations have taken place; ii) deletion error 
happens when nucleotides that do not remain in the active site long enough to 
be detected yet are incorporated into the synthesized strand (Mardis, 2013).  
 The main advantages of SMRT sequencing are the long read lengths and the 
random nature of the error process. The error rate is approximately 15 bases per 
100 (Mardis, 2013). As the errors are randomly distributed across the target, it is 
possible to obtain an accurate consensus sequence if sufficient depth is achieved 
(Roberts et al., 2013).  
1.9 Analysis of deep sequence reads 
Following the emergence of NGS technologies, many tools have been created for 
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the large-scale mapping of short fragment reads to a reference sequence. The 
identification of single nucleotide polymorphisms (SNPs) and the detection of 
variants can be carried out using a variety of methods. Such tools are extremely 
powerful but are limited by biases inherent in NGS technology (Flicek and 
Birney, 2009, Metzker, 2010, Schwartz et al., 2011).  
1.9.1 Mapping 
Deep sequencing generates short reads. Various mapping tools can analyse these 
short reads. These tools use two different types of algorithm: i) Burrows-
Wheeler transform (BWT); ii) Hash-seed extension (Miller et al., 2010, Wajid and 
Serpedin, 2012). The BWT based mapping programs (e.g. BWA) are fast and 
require low computational power, but they are less sensitive than hash-based 
programs (e.g. Novoalign). 
 There are two common biases that interfere with mapping NGS data: i) 
nucleotide per cycle bias where the distribution of sequenced nucleotides varies 
across the position of each read; ii) mappability bias as regions vary in 
complexity, resulting in varying coverage across the target genome (Hillier et 
al., 2008, Dohm et al., 2008).  
1.9.2 Haplotype reconstruction 
A haplotype is a group of genes that are inherited from one parent. In this study, 
the term is used to refer to the viral genome. New algorithms are required to 
achieve the complete reconstruction of individual viral haplotypes to explore the 
dynamics of viral quasispecies. NGS enables the detection of SNPs with an 
ability to detect minority variants in the viral population even in low abundance 
haplotypes. However, to reconstruct haplotypes accurately, the real diversity 
needs to be distinguished from noise signals in the NGS data. In addition, the 
limited read length produced by current NGS platforms makes it difficult to 
determine which SNPs are present in the same haplotype. Therefore, viral 
diversity is only assessed by SNPs calling or the detection of several mutations 
within the read length produced by the platform.  
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Numerous bioinformatics tools have been developed to apply error correction 
models to the error-prone NGS data and to reconstruct, from an alignment of 
short reads, the haplotypes that constitute the viral population (Giallonardo et 
al., 2014). HCV represents a major challenge in dealing with this issue due to its 
high mutation rate and quasispecies diversity (Astrovskaya et al., 2011). 
 De novo assembly methods are designed to reconstruct a single genome 
sequence but are not suitable for reconstructing a viral quasispecies due to the 
closely related genomes of the circulating variants.  Mapping-based approaches 
to HCV haplotype reconstruction are preferred to de novo assembly since 
reference genomes are available and the ability to reconstruct closely related 
haplotypes. However, the mapping-based approach requires high depth across 
the genome, which is feasible with the current NGS platforms due to the short 
length of viral genomes.  
 Eriksson et al. proposed an algorithm that involves three steps: i) error 
correction via clustering; ii)  haplotype reconstruction via chain decomposition; 
iii) haplotype frequency estimation (Eriksson et al., 2008).  An example of tools 
developed for quasispecies reconstruction is ShoRAH, which has been applied to 
HIV data (Eriksson et al., 2008, Zagordi et al., 2010a). The phases of the process 
of reconstructing a population from NGS data and the importance of overlaps in 
the data are described in Figure 1-4. Prediction programs perform better when 
they analyse paired-end data with overlaps (Schirmer et al., 2014). 
1.10 HIV and hepatitis C virus co-infection 
It is estimated that 3–4 million people are infected with HCV each year (WHO, 
2011). Around 35 million people are living with HIV (WHO, 2009). Liver disease 
has recently overtaken AIDS-defining illnesses as a cause of death in many 
patient populations following the successful introduction of highly active 
antiretroviral therapy (HAART) for the treatment of HIV (Bica et al., 2001). 
 45 | P a g e  
Figure 1-4: Schematic diagram representing the process of reconstructing viral haplotypes from next-generation sequencing data. 
 
The first column represents two haplotypes occurring at different abundances with one SNP in common. The next column displays a set of observed 
reads obtained from NGS technologies including sequencing noise. The third presents different scenarios that can occur during reconstruction. In the 
first scenario, the reconstruction is successful. Two reads that contain SNPs and have sufficient overlap are assembled correctly into a contig of the first 
haplotype. In the second, the distance between SNPs exceeds the read length that means that the reads do not map to a haplotype based on read 
overlap. In the third, noise is mistaken for diversity. In the fourth, we cannot infer the origin of the read as the SNP occurs on both haplotypes. 
Reproduced with permission from Dr Melanie Schirmer (Schirmer et al., 2014). 
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Co-infection with HCV is observed in up to 30% of HIV-infected individuals with 
higher prevalence rates in different populations (Vallet-Pichard and Pol, 2006). 
At least 4-5 million people have HCV/HIV co-infection, this is attributed to 
shared routes of transmission (Alter, 2006). The prevalence of HCV infection in 
HIV-infected haemophiliacs is 60-90% and 50-70% in HIV-infected PWID 
(Rockstroh and Spengler, 2004).  
 An epidemic of sexually transmitted acute HCV infection in HIV-positive 
MSM has been reported in the Netherlands, Germany, France, the USA, and the 
UK in the last decade. More than 1000 cases of acute HCV/HIV-positive MSM have 
been reported worldwide (Vogel et al., 2011). Phylogenetic analysis of HCV 
variants obtained from infected patients provided evidence of an extensive 
international network of HCV transmission in this population (van de Laar et al., 
2009).  
1.10.1 The influence of HCV on HIV infection. 
The impact of HCV on the progression of HIV-disease remains controversial. The 
Swiss HIV Cohort study revealed that HCV infection was significantly associated 
with an increased risk of progression to AIDS, although a similar use of HAART in 
both HIV mono-infected group and HCV/HIV co-infected group (Greub et al., 
2000). HIV mono-infected patients are more likely to achieve a CD4 count rise of 
at least 50 cells/ml within one year of starting HAART than HCV/HIV co-infection 
patients with a hazard ratio of 0.79 (0.72-0.87) for HCV-seropositive patients 
(Greub et al., 2000).  
 The HCV/HIV co-infected patients have an increased likelihood of having a 
CD4+ cell count of <200 cells/mm3, compared with infection with HIV-1 alone 
(hazard ratio, 1.52; 95% confidence interval, 1.07–2.17) (Stebbing et al., 2005, 
Sullivan et al., 2006). Several studies have reported no increased risk of clinical 
progression to AIDS in HCV/HIV co-infected individuals. However, the mortality 
rate due to liver disease is increased in HCV/HIV co-infected patients (Rockstroh 
et al., 2005, Sullivan et al., 2006). 
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1.10.2 The influence of HIV on HCV infection.  
There is a reported delay in the diagnosis of acute HCV in HIV-positive 
individuals due to delayed seroconversion. There was no difference in 
seroconversion time between spontaneous clearers and progressors, but the 
delay in diagnosis and treatment of HCV may affect the outcome of the 
infection. Seroconversion time in spontaneous clearers and progressors was not 
significantly different (Thomson et al., 2009). The introduction of HCV core 
antigen testing as a screening assay for HIV-infected patients may shorten this 
diagnostic window period. 
 There is a potentially higher rate of HCV transmission in HCV/HIV co-
infected patients as they have higher HCV viral loads by a magnitude of 0.3–1.08 
log RNA copies/ml in blood and other body fluids compared with HIV-1 mono-
infected subjects (Shire and Sherman, 2005, Dionne-Odom et al., 2009, Mohsen 
et al., 2002). Persistence of HCV infection is more common in HCV/HIV co-
infected patients, which is probably related to a failure of host immune 
responses to HCV infection (Danta et al., 2008). 
 The level of CD4 immunosuppression has emerged as one of the most 
important determinants of progression to liver fibrosis. Patients with a low CD4 
count or who have had an AIDS diagnosis are at increased risk of severe liver 
disease (Mohsen et al., 2002). There is growing evidence that progression to liver 
cirrhosis occurs at a faster rate in HCV/HIV co-infected patients. The median 
time to cirrhosis was estimated at 32 years and 23 years from the time of 
acquisition in HCV-infected, and HCV/HIV co-infected individuals, respectively 
(Mohsen et al., 2003). 
 The HIV infection accelerates the development of hepatocellular carcinoma 
(HCC) in patients with HCV-related cirrhosis, as it occurs at a younger age and 
within a shorter time scale, compared to the estimated rate of 1–4% per annum 
in HCV mono-infected patients (Garcia-Samaniego et al., 2001, Singal and 
Anand, 2009). 
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Antiretroviral therapy does not induce a decline in HCV viral load during the first 
six months of treatment. However a decrease in concentration of HCV RNA of 
about 1 log10 was seen in HIV/HCV co-infected individuals after receiving 12 
months of HAART, the decline being attributed to the improvement of the host 
immune response (Rockstroh and Spengler, 2004). 
1.11 Treatment of acute HCV in HIV-positive patients  
Interferon-based HCV antiviral therapy has established but limited efficacy and a 
decreased likelihood of success in HIV/HCV co-infection (Gilleece et al., 2005, 
Dominguez et al., 2006, Serpaggi et al., 2006, Braitstein et al., 2004, Torriani et 
al., 2004, Hadziyannis et al., 2004). Lack of early virological response (EVR) at 
Week 12 of therapy is highly predictive of treatment failure among HIV/HCV co-
infected patients. 
 Standard therapy in most of the world is still a combination of 
PegIFNα/RBV; the duration of treatment varies from 16–72 weeks, based on HCV 
genotype, baseline viral load and early viral response to therapy (Soriano et al., 
2011).  
 The World Health Organisation (WHO) will issue updated HCV treatment 
guidelines that will not recommend IFN-based therapy as the first line of 
treatment due to: i) low efficacy, less than 50% of individuals infected with HCV 
genotypes 1 or 4 achieved an SVR with IFN-based therapy as compared with 85% 
of patients infected with genotypes 2 or 3; ii) high toxicity, as PegIFNα/RBV 
therapy is frequently associated with serious undesirable side effects, including 
depression, anaemia, and decompensation with advanced disease (Soriano et al., 
2011).  
 In numerous clinical trials, rates of treatment discontinuation have ranged 
between 15% and 30%, and substantial proportions of patients required dose 
reductions of PegIFNα or RBV (Rockstroh and Spengler, 2004).  
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In the new era of direct-acting antivirals (DAAs), differences in treatment 
response between HCV mono-infected and HCV/HIV co-infected patients have 
not been detected (Sulkowski et al., 2014b, Sulkowski et al., 2013). Thus, 
treatment recommendations for both patient groups are the same although 
extra consideration needs to be given to drug-drug interactions. 
1.11.1 Predictors of treatment response in HIV-positive individuals with 
acute HCV infection. 
Due to the current limited number of studies, the identification of predictors of 
treatment response in HIV-infected patients with acute HCV is difficult. Acute 
HCV has a favourable outcome in the majority of HIV-negative patients but is 
less easy to treat in HIV-positive patients (Gilleece et al., 2005). Early treatment 
of HCV/HIV co-infected patients with PegIFNα/RBV results in improved SVR rates 
(59%) but does not match the 98% treatment success rate reported in HIV-
negative patients (Torriani et al., 2004, Gilleece et al., 2005). The reason for 
this discrepancy is not clear, but impaired immune control and high rate of viral 
evolution in HIV-infected patients are possible explanations. SVR rates have 
improved dramatically since the introduction of DAAs (Cooper and Klein, 2014). 
1.11.1.1 HCV genotype 
HCV genotype has been established as the strongest predictor of successful 
treatment in chronic HCV mono-infection. However, the small number of acute 
HCV/HIV cases has limited the studies that can demonstrate an effect of 
genotype on treatment outcome in acute HCV/HIV co-infected patients.  
 The majority of participants in studies reporting the outcome of therapy in 
the HCV/HIV population have been infected with HCV genotype 1a or 4d with an 
overall SVR rate of 57%. This result compares to an overall SVR rate of 87% in 
genotype 2/3 participants and suggests that genotype may have an effect on 
treatment response in a similar way to that observed in chronic HCV mono-
infection (van de Laar et al., 2010).  
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These data are less concerning following reports of the high efficacy of DAAs in 
HIV/HCV co-infection with SVR rates of 76-98% across genotypes (Sulkowski, 
2014, Wyles et al., 2015).  
1.11.1.2 Viral load dynamics during early HCV infection  
Following acute infection, three different patterns of HCV RNA evolution have 
been reported: i) persistent high viral load; ii) rapid decline in viral load with 
subsequent clearance; iii) fluctuating viral load. Spontaneous clearance usually 
occurs within three months of diagnosis in both HIV-infected and uninfected 
cohorts (Santantonio et al., 2006, Page et al., 2009). The pattern of viraemia 
may help to identify those patients who are likely to clear HCV spontaneously 
(Danta et al., 2008). In a UK-based cohort of HCV/HIV co-infected patients, the 
drop in HCV viral load within 100 days of the first positive test was strongly 
predictive of spontaneous clearance with an odds ratio (OR) per log10 drop=1.78  
(Thomson et al., 2011). 
1.11.1.3 Viral diversification within the host 
Clonal analysis was used to study viral diversity during HCV infection. Studies of 
the HVR1 region in a small group of acute HCV infection have shown that high 
quasispecies diversity is associated with progressive disease while spontaneous 
clearance could be predicted in the presence of a narrowed quasispecies 
repertoire (Thomson et al., 2011). The increased prevalence of escape 
mutations and resistant variants will lead to progression to chronicity and 
treatment failure. 
1.11.1.4 Transmission bottleneck 
Spontaneous clearance of HCV is more likely in HIV-infected patients who 
acquired HCV sexually than those infected via intravenous drug use (21.9% and 
11.6 % respectively). This could be explained by smaller, less diverse inocula, 
and possibly due to local effects at the mucosal level.  
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However, individuals who reported homosexual contact have a clearance rate 
similar to PWID, which could be interpreted by increased mucosal trauma during 
sex (Shores et al., 2008). 
1.11.1.5 Compartmentalization 
Compartmentalisation of peripheral blood mononuclear cells (PBMCs)-specific 
variants has been reported in HIV-infected individuals. These variants were 
genetically distinct from those detected in plasma. The virus detected in these 
patients may originate from a cellular reservoir including NK cells, monocytes, 
and B-cells. Detection of minority variants is further compounded by the fact 
that viral strains may also be compartmentalised and replicate in PBMCs and 
extrahepatic compartments including the central nervous system (Forton et al., 
2004a, Forton et al., 2004b).  
1.11.1.6 Host genetic factors 
A single nucleotide polymorphism (rs12979860) has been identified in the IL28B 
gene that encodes the type III interferon IFN-λ3. The CC genotype is associated 
with the spontaneous clearance of HCV infection; it is the strongest genetic 
predictor of spontaneous clearance of HCV infection which highlight the possible 
role of IL28B in clearance of HCV infection (Thomas et al., 2009). 
 The favourable impact of IL-28B genotype CC was genotype dependent as it 
was stronger in patients infected with genotype 1 or 4 than those who acquired 
genotype 3 infection. The same conclusion was reported with treatment 
outcome as patients bearing IL-28B genotype CC had a favourable treatment 
outcome (Neukam et al., 2011).   
 Polymorphisms in both IL6 and tumor growth factor (TGF) genes have been 
reported to be associated with treatment outcome in acute HCV/HIV co-
infection (van de Laar et al., 2010). The development of a decision-making 
model integrating clinical variables and IL28B genotype would be of value in 
predicting the treatment outcome (O'Brien et al., 2011). 
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1.12 A new era of antivirals for HCV infection 
The non-structural NS3/4A, NS5A and NS5B proteins of HCV are the primary 
targets of DAAs. NS3/4A protease inhibitors (PIs) are competitive inhibitors by 
blocking the protease active site or allosteric inhibitors that affect the substrate 
cleavage by interfering with conformational changes (Steinkuhler et al., 1998, 
Delang et al., 2013, Romano et al., 2012, Rupp and Bartenschlager, 2014). NS5A 
inhibitors interact with domain 1 of NS5A, although the exact mechanism of 
action is still unclear. Nucleos(t)ide analogue NS5B polymerase inhibitors are 
incorporated into the elongating RNA strand and cause chain termination by 
inhibiting the incorporation of the next nucleotide; non-nucleoside NS5B 
polymerase inhibitors inhibit polymerase activity by allosteric mechanisms of 
action through interaction with either the thumb 1, thumb 2, palm 1, or palm 2 
domain of NS5B (Pawlotsky, 2013b, Gerber et al., 2013). 
 DAAs currently licensed for use in the European Union are Simeprevir 
(SMV), Daclatasvir (DCV), Sofosbuvir (SOF), Ledipasvir (LDV), Ritonavir-boosted 
Paritaprevir (PTV), Ombitasvir (OBV), and Dasabuvir (DSV). This section will 
describe treatment options for genotype 1a in both HCV mono-infection and 
HCV/HIV co-infection according to the recent recommendation on the treatment 
of HCV published by European Society for Study of the Liver (EASL).  
1.12.1 Simeprevir 
SMV is an NS3/4A protease inhibitor. It is metabolised by the hepatic CYP3A 
system and eliminated mostly via biliary excretion. SMV has an excellent 
tolerability profile with no reported differences in the type and incidence of 
adverse events between SMV and placebo groups.  
 In clinical trials, the most common side effects (>10%) reported during a 12 
weeks full course in  combination with SOF were fatigue (25%), headache (21%), 
nausea (21%), insomnia (14%), pruritus (11%) and rash (11%). When treatment 
was extended for 24 weeks, dizziness and diarrhea were reported in 16% of 
patients (EASL, 2015). 
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There is a lack of data on the efficacy and safety of SMV in end-stage renal 
disease (Lawitz et al., 2014a). Few patients have reported mild reversible 
transient increases in bilirubin levels while receiving SMV treatment (Hayashi et 
al., 2014b). 
 Drug-drug interaction is an important issue with some antiretroviral drugs 
in HCV/HIV co-infected patients. As the primary enzyme involved in the 
metabolism of SMV is CYP3A4, co-administration of SMV with substances that are 
moderate or strong inducers or inhibitors of CYP3A4 is not recommended to 
avoid any significant effect on the exposure of SMV. A number of drugs are 
contra-indicated in patients receiving SMV, including any HIV protease inhibitor, 
boosted or not by ritonavir (EASL, 2015).  
1.12.2 Daclatasvir  
Daclatasvir is an NS5A inhibitor. DCV is mainly excreted in the faeces. DCV does 
not require any dose adjustment for patients with any degree of renal or hepatic 
impairment (EASL, 2015). The most common adverse events are fatigue, nausea, 
and headache. DCV exposure is reduced if co-administered with strong CYP3A4 
or P-gp inducers while drugs that strongly inhibit the CYP3A4 system increase the 
plasma levels of DCV. Therefore, dose adjustments of DCV are required 
(Bunchorntavakul and Reddy, 2015). DCV can be administered safely with 
antiretroviral drugs including raltegravir, dolutegravir and maraviroc (Wyles et 
al., 2015). 
1.12.3 Sofosbuvir 
Sofosbuvir is an oral nucleotide inhibitor of the HCV NS5B RdRp enzyme. SOF is 
the main component in available combination therapy in all HCV genotypes due 
to its pan-genotypic activity (Abraham and Spooner, 2014). 
 SOF is mainly excreted via the kidneys. End stage renal disease leads to 
high drug exposure while liver impairment increases SOF plasma level slightly. 
Therefore, there is no dose recommendation for patients with severe renal 
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impairment. The most common adverse events observed during SOF treatment 
are mainly due to the combination with PegIFNα/RBV such as fatigue, headache, 
nausea, insomnia, and anaemia. There is no reported contraindication to 
administration of SOF with antiretroviral agents (EASL, 2015). 
 SOF is available in a two-drug fixed dose combination with LDV in a single 
tablet. LDV is eliminated via biliary excretion. Cirrhosis (including 
decompensated cirrhosis) has no clinically relevant effect on exposure to LDV. 
The most frequent side effects reported with SOF/LDV combination are fatigue 
and headache. Since the combination contains LDV and SOF, any interactions 
identified with the individual drugs will apply to the combination. As both LDV 
and SOF are transported by P-gp, co-administration of any potent P-gp inducers 
will decrease drug exposure of both drugs and consequently a reduced efficacy 
of the regiment. However, LDV/SOF may be given with all antiretrovirals (EASL, 
2015). 
1.12.4 PrOD combination (Paritaprevir, Ombitasvir, and Dasabuvir) 
The PrOD combination consists of ritonavir-boosted paritaprevir (PTV), 
ombitasvir (OBV), and dasabuvir (DSV). PTV is an NS3-4A protease inhibitor. It is 
eliminated mainly in the faeces. As PTV is metabolised by CYP3A4, it is co-
administered with ritonavir, which is a CYP3A inhibitor, resulting in increased 
PTV drug exposure, allowing an administration of lower dose and a once daily 
regimen. OBV is an NS5A inhibitor that is predominantly eliminated in the 
faeces. DSV is a non-nucleoside NS5B polymerase inhibitor that is mostly cleared 
by biliary excretion and in the faeces.  
 The most common adverse events encountered with the PrOD combination 
were pruritus, fatigue, nausea, asthenia and insomnia. The more frequent side 
effects are considered to be related to RBV, but pruritus is considered to be 
related to PrOD. Severe adverse events occurred in <2.5% of cases and treatment 
discontinuation due to adverse events occurred in 1–2%. Only 1-2% discontinued 
treatment in clinical trials, and severe adverse events occurred in less than 2.5% 
of patients.  
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The PrOD combination is contraindicated in patients with severe hepatic 
impairment (Child-Pugh C) (EASL, 2015). The administration of ritonavir 
increases the likelihood of occurrence of many drug-drug interactions. As 
ritonavir is a strong inhibitor of CYP3A4, a number of drugs that are metabolised 
by this enzyme are contraindicated to avoid toxicity and serious adverse events 
including HIV PIs (EASL, 2015). 
1.13 The HCV available treatment regimens 
The treatment options for HCV have evolved rapidly in recent years, and DAA 
regimens have reached SVR rates of up to 97-100% in genotype 1a patients. The 
main clinical trials studying the efficacy of various DAAs in achieving viral 
clearance in HCV genotype 1 patients are discussed in this section including 
interferon-containing regimens and interferon-free options. Published results are 
listed below (Table 1-1 to Table 1-4).  
 Due to the rapid evolution of available treatments, options are regularly 
updated with the latest EASL recommendations published in May 2015. A brief 
overview of currently recommended regimens is shown in Table 1-5. 
1.13.1 Interferon-containing regimens 
1.13.1.1 Simeprevir/ Pegylated Interferon/Ribavirin  
Treatment-naïve patients, who received SMV for 12 or 24 weeks with PEG-
IFNα/RBV for 24 or 48 weeks (according to response-guided therapy), achieved 
SVR rates of 77–92% (Hayashi et al., 2014a). A similar response rate was achieved 
in treatment-experienced patients, who received SMV for 12, 24, or 24 weeks 
with PegIFNα/RBV for 48 weeks, with SVR rates of 61–80% (Akuta et al., 2014).  
 SMV in a combination with PegIFNα/RBV is well tolerated and associated 
with improved SVR rates in most treatment-naïve, HCV genotype 1 infected 
patients (Hayashi et al., 2014b). Two Phase III clinical trials in treatment-naïve 
patients; Quest-1 and Quest-2, demonstrated overall SVR rates in genotype 1 
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infected patients of 80% and 81%, respectively, with a similar outcome for 
patients infected with subtype 1b (85%) and subtype 1a (84%). However, there 
was a reduction in SVR rate (58%) when a Q80K substitution was detectable as a 
dominant variant at baseline. SMV was associated with a higher SVR rate (84%) in 
non-cirrhotic patients compared to 60% in cirrhotic patients (Jacobson et al., 
2014, Manns et al., 2014). 
 SMV was used to retreat patients who relapsed after PegIFNα/RBV therapy;  
genotype 1a patients achieved an SVR24 of 70% (Forns et al., 2014). In HCV/HIV 
co-infected patients, SVR was achieved in 79% of treatment-naïve patients 
receiving SMV/PegIFNα/RBV. A direct comparison between TVR and SMV in 
retreatment of a group of patients who failed to respond to PegIFNα/RBV 
showed that SVR12 was achieved in 70% of prior partial responders and 44% of 
null responders who received a triple combination including SMV. In the TVR 
arm, SVR12 occurred in 68% of prior partial responders and 46% of prior null 
responders (Reddy et al., 2015).  
1.13.1.2 Sofosbuvir/ Pegylated Interferon/ Ribavirin 
A combination of PegIFNα/RBV and SOF for 12 weeks was administered to 
genotype 1 treatment-naïve patients in the NEUTRINO trial. The overall SVR rate 
was 92% for subtype 1a and 82% for subtype 1b. Cirrhotic patients had a lower 
response rate (80%) than the non-cirrhotic patient (92%) (Lawitz et al., 2013). 
 Real life observational studies showed variability in treatment outcome. 
SVR4 was achieved in 90% of non-cirrhotic patients compared to 70% reported in 
cirrhotic patients (Jensen et al., 2014). Similar outcomes occurred in a similar 
mixed cohort that included 58% treatment-naïve and 42% treatment-experienced 
patients, as 77% of the treatment-experienced non-cirrhotic patients achieved 
SVR12 while 62% of cirrhotic patients achieved SVR12 (Dieterich et al., 2014a). 
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1.13.2 Interferon-free options 
1.13.2.1 Sofosbuvir/ Ledipasvir  
This combination achieved excellent efficacy in the ION-1 study; an SVR12 of 99% 
was achieved in treatment-naïve patients after a course of 12 weeks of the 
fixed-dose combination of SOF/LDV/RBV. SVR12 rates were 99% and 98% after 24 
weeks of therapy with and without RBV respectively. The study group included 
16% of patients with compensated cirrhosis (Afdhal et al., 2014b). 
 The duration of treatment may be further reduced to 8 weeks without a 
high drop in SVR rate; SVR12 rates were 94% without RBV for 8 weeks, 93% with 
RBV for 8 weeks and 95% without RBV for 12 weeks. In this study, baseline viral 
load was used to guide the duration of treatment, and further analysis suggested 
that a shorter duration of treatment (8 weeks) was successful in patients with an 
HCV RNA level <6 million (6.8 Log10) IU/ml at baseline (Kowdley et al., 2014). 
The lack of the accuracy of viral load measurement and inter-laboratory 
variation with this range of value may restrict the use of such a threshold for 
deciding the treatment strategy. Further studies are needed to confirm the 
efficacy of the 8-week regimen. 
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Table 1-1: Directly acting antivirals efficacy studies (Part 1)  
Trial Name Patients Study groups Study outcome (SVR) References 
Simeprevir (SMV)  
CONCERTO-1 
Treatment-naïve        
Genotype 1     
SMV 12 Wks + PR 24/48                                       
Placebo 12Wks + PR48  
SVR12: SMV 12 Wks + PR 24/48 (88.6%)                                      
Placebo 12Wks + PR48 (61.7%)  
(Hayashi et al., 2014a) 
PILLAR  
Treatment-naïve      
Genotype 1    
SMV 75/150 mg 12/24 Wks + PR 24/48                                       
Placebo 24 Wks + PR48  
SVR12: SMV (74.7%-86.1%)                                     
Placebo (64.9%)  
(Fried et al., 2013)  
ATTAIN 
Treatment failure  
(PegIFNα/RBV) 
SMV 150mg 12 Wks+ PR 48 Wks                       
TVR150mg 12 Wks+ PR 48 Wks 
SVR12: SMV (54%) vs TVR (55%) (Reddy et al., 2015) 
QUEST-1 
Treatment naïve       
Genotype 1     
SMV 150 mg 12 Wks + PR 24/48                       
Placebo 24 Wks + PR48                 
SVR12:SMV+PR (80%)                                                  
Placebo + PR (50%)  
(Jacobson et al., 2014) 
QUEST-2  
Treatment naïve      
Genotype 1 
SMV 150 mg 12 Wks + PR 24/48                            
Placebo 12 Wks + PR48  
SVR12: SMV+PR: SVR12 [81%]                                                
Placebo + PR: SVR12 [50%]  
(Manns et al., 2014) 
NCT01479868 
HIV +ve with Genotype 1                
Treatment naïve or 
experienced  
 SMV 150 mg 12 Wks + PR 24/48                             
SVR12: Treatment-naïve (79.2%),                 
Null responders (57%), Relapsers (87%) 
(Dieterich et al., 2014b) 
The Dragon 
Treatment-naïve                                                    
Genotype 1 
SMV 50/100 mg 12/24 Wks + PR 24                                       
Control: PR48  
SVR24                                                         
SMV (77%-92%), PR48 (45.5%)  
(Hayashi et al., 2014b) 
The table is limited to clinical trials addressing the clinical efficacy of DAAs against HCV genotype 1 with published results. Source: Clinical trials.org, 
last accessed 07/11/2015. (PR): PegIFNα/RBV, (Wks): weeks. 
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Table 1-2: Directly acting antivirals efficacy studies (Part 2) 
Trial Name Patients Study groups Study outcome (SVR) References 
Paritaprevir (PTV), Ombitasvir (OBV), and Dasabuvir (DSV)   
PEARL IV Treatment-naïve - Genotype 1  PTV+OBV+DBV ± RBV 12Wks 
PTV+OBV+DSV (90%)                         
PTV+OBV+DSV+RBV (97%) 
(Ferenci et al., 2014) 
TURQUOISE-II  
Cirrhotic treatment-naïve and 
experienced - Genotype 1 
PTV+OBV+DSV + RBV 12/24 Wks 
PTV+OBV+DSV+RBV 12 Wks (92%)                         
PTV+OBV+DSV+RBV 24 Wks (96.5%) 
(Poordad et al., 2014) 
SAPPHIRE-II Treatment failure  PTV+OBV+DSV + RBV 12 Wks SVR 12: PTV+OBV+DSV+RBV  (96.3%) (Zeuzem et al., 2014b) 
Sofosbuvir (SOF)   
Fission 
 Treatment-naïve                     
Genotype 1, 4, 5, or 6  
SOF+RBV 12 Wks                                           
PR 24 Wks 
SVR12                                                     
SOF+RBV (67%), PR 24 (67%) 
(Lawitz et al., 2013) 
Neutrino 
Treatment-naïve                       
Genotype 1, 4, 5, or 6 
SOF+ PR12 Wks                                SVR12 (91%)                                (Lawitz et al., 2013) 
ATOMIC 
Treatment-naïve                   
Genotype 1, 4, 5, or 6  
SOF+PR 12 Wks                                   
SOF+PR 24 Wks 
SVR 12: SOF+PR 12 Wks (90.4%)                
SOF+PR 24 Wks (92.7%) 
(Kowdley et al., 2013) 
PHOTON-1 
Treatment naïve (TN)                           
(or) Treatment experienced 
(TE)                    
 (Genotypes 1,2,3)                       
HIV positive patients  
SOF+RBV 12/24 weeks   
SVR12: TN Gen1 SOF + RBV 24 Wks (76%)                   
TN Gen2 SOF + RBV 12 Wks (88%)                        
TN Gen3 SOF + RBV 12 Wks (67%)                
TE Gen2 SOF + RBV 24 Wks (92%) 
TE Gen 3 SOF + RBV 24 Wks (88%) 
(Sulkowski et al., 2014b) 
The table is limited to clinical trials addressing the clinical efficacy of DAAs against HCV genotype 1 with published results. Source: Clinical trials.org, 
last accessed 07/11/2015. (PR): PegIFNα/RBV, (Wks): weeks. 
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Table 1-3: Directly acting antivirals efficacy studies (Part 3) 
Trial 
Name 
Patients Study groups Study outcome (SVR) References 
Sofosbuvir (SOF) + Ledipasvir (LDV) 
ION-1  Treatment-naïve    SOF+LDV 12/24 Wks ± RBV 
SVR24: LDV+SOF 12 Wks (98.6%)                                               
LDV+SOF + RBV 12 Wks (97.2%)                 
LDV+SOF 24 Wks (98.2%)                         
LDV+SOF+RBV 24 Wks (99%) 
(Afdhal et al., 2014b) 
ION-2 Treatment failures on PR ± PIs  SOF+LDV 12/24 Wks ± RBV 
SVR24: LDV+SOF 12 Wks (93.6%)              ,                                                       
LDV+SOF + RBV 12 Wks (96.4%)               
LDV+SOF 24 Wks (99%)                         
LDV+SOF+RBV 24 Wks(99%) 
(Afdhal et al., 2014a) 
ION-3  Treatment-naïve    
SOF+LDV 8 weeks ± RBV                        
SOF+LDV 12 weeks 
SVR24: LDV + SOF 8 weeks (94%)                      
LDV + SOF + RBV 8 weeks (93%)                       
LDV-SOF 12 weeks (96%). 
(Kowdley et al., 2014) 
LONESTAR 
Cohort A non-cirrhotic,             
treatment naïve,                        
Cohort B PI failures                        
(55% compensated cirrhosis)    
SOF+LDV± RBV 8/12 weeks     
SVR24: In cohort A, SOF + LDV 8 Wks (95%)                            
SOF+ LDV+RBV 8 Wks (100%)                               
SOF+LDV 12 Wks (95%)                                            
In cohort B,  OF + LDV 12 Wks  (95%)                                                              
SOF + LDV + RBV 12 Wks (100%).  
(Lawitz et al., 2014b) 
SIRIUS 
Cirrhotic treatment experienced 
(Gen 1)  
SOF+LDV+ RBV 12 weeks             
SOF+LDV 24 weeks  
SVR 24: LDV+SOF+ RBV 12 weeks (96%)  
LDV+SOF 24 weeks (97.4%) 
(Bourliere et al., 2015) 
Sofosbuvir (SOF) + Simeprevir (SMV) 
The COSMOS 
Non-responders: F0-F2, 
Treatment naïve: F3-F4 
SMV 150mg + SOF 400 mg                     
12/24 weeks +/- RBV 
SVR12: Non-responders (92%)                             
SVR12: Treatment naïve (94%)  
(Lawitz et al., 2014a) 
The table is limited to clinical trials addressing the clinical efficacy of DAAs against HCV genotype 1 with published results. Source: Clinical trials.org, 
last accessed 07/11/2015. (PR): PegIFNα/RBV, (Wks): weeks. 
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Table 1-4: Directly acting antivirals efficacy studies (Part 4) 
Trial Name Patients Study groups Study outcome (SVR) References 
Daclatasvir (DCV) 
HEPCAT 
Treatment-naïve                       
Genotype 1 and 4  
DCV 20/60 mg 12 Wks + PR 24/48                                       
Placebo 12 Wks + PR 48  
SVR24                                                          
DCV (60%), Placebo (37.5%)  
(Hezode et al., 2015) 
Sofosbuvir (SOF)  + Daclatasvir (DCV) 
A1444040 
Treatment-naïve or experienced 
(genotypes 1,2,3)     
Different dose regimens SOF+DCV  
SVR12: 98% in Genotype 1                          
SVR12: 92% in Genotype 2                          
SVR12: 89% in Genotype 3 
(Sulkowski et al., 2014a) 
ALLY 1 
Post-liver transplant                       
Cirrhotic patients 
DCV+SOF+RBV for 12 Wks  
SVR12: 95.1% in post-transplant                 
SVR12: 82.2% in cirrhotic patients 
(Poordad et al., 2015) 
ALLY-2 
 HIV co-infected                           
Treatment-naïve or experienced                                            
DCV 60mg +SOF 400mg 8/12 Wks                              
SVR12: 96.4% in treatment-naïve                        
SVR12: 97.7% in treatment experienced 
(Wyles et al., 2015) 
The table is limited to clinical trials addressing the clinical efficacy of DAAs against HCV genotype 1 with published results. Source: Clinical trials.org, 
last accessed 07/11/2015. (PR): PegIFNα/RBV, (Wks): weeks. 
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Table 1-5: EASL Recommendations on Treatment of Hepatitis C 2015. 
IFN-free regimens 
Options Genotype 
SOF+RBV 2,3 
SOF/LDV (±RBV) 1,4,5,6 
OBV/Paritaprevir/Ritonavir+ DSV (±RBV) 1 
SOF + SMV (± RBV) 1,4 
SOF + DCV (± RBV) All 
OBV/ Paritaprevir/ Ritonavir (±RBV) 4 
IFN-containing regimens 
PegIFNα + RBV + SOF All 
PegIFNα + RBV + SMV 1,4 
Treatment recommendation for HCV/HIV co-infected patients with chronic hepatitis C 
with compensated (Child-Pugh A) cirrhosis. 
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The combination achieved high SVR rates in treatment-experienced patients, 
including 20% with cirrhosis; after 12 weeks of treatment with and without RBV, 
the SVR12 rates were 96% and 94%, respectively. After prolonging treatment for 
another 12 weeks, the SVR rates were the same in both groups at 99% (Afdhal et 
al., 2014a). The combination of SOF/LDV was given for 12 weeks to HCV/HIV co-
infected patients, and the SVR12 rate was 98% (Townsend et al., 2014). 
 The administration of SOF/LDV combination with or without RBV in 
different trials showed an overall SVR rate of 95% after 12 weeks of treatment. 
The prolonged 24-week course increased the overall SVR rate to 98%. No safety 
issues were reported in this patient population and the safety profile was similar 
to that reported in non-cirrhotic patients (Bourliere et al., 2014b). The addition 
of RBV to the combination did not have an impact on SVR12 in treatment-naïve 
patients (SVR12 rates between 96% and 100%). However, the duration of 
treatment and the addition of RBV improved the SVR12 in treatment-
experienced patients. The overall SVR was 90% after 12 weeks of treatment 
without RBV and increased to 100% after prolonging the treatment to 24 weeks 
with RBV included in the combination (Bourliere et al., 2014b). 
 In the SIRIUS study, four different regimens of SOF/LDV were evaluated in 
patients with compensated cirrhosis who failed to achieve an SVR after triple 
therapy containing either TVR or BOC. The patients were assigned to two groups;  
SOF/LDV for 12 weeks with RBV or 24 weeks without RBV. The SVR12 rates were 
96% and 97%, respectively (Bourliere et al., 2014a). Thus, the addition of RBV 
can shorten the treatment duration in cirrhotic patients. 
 Clinical trials have demonstrated the safety and efficacy of LDV/SOF in 
HCV/HIV co-infected patients receiving antiretroviral therapy including tenofovir 
and emtricitabine with rilpivirine, raltegravir or efavirenz. These patients were 
infected with HCV genotypes 1 and 4 (Osinusi et al., 2015). 
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1.13.2.2 Paritaprevir, ritonavir, Ombitasvir, Dasabuvir (PrOD) 
The PrOD combination was evaluated in the SAPPHIRE-I study. In this study, a 
cohort of non-cirrhotic, treatment-naïve patients was treated with PrOD and RBV 
for 12 weeks. SVR12 rates were 95% in subtype 1a and 98% in subtype 1b patients 
(Feld et al., 2014). The efficacy of PrOD combination was evaluated in both 
subtype 1a and 1b separately.  
 In PEARL-IV, treatment-naïve non-cirrhotic subtype 1a patients had SVR12 
rates of 97% and 90%, with and without RBV, respectively. In PEARL-III, 
treatment-naïve non-cirrhotic subtype 1b patients achieved SVR12 rates of 99% 
both with and without RBV (Ferenci et al., 2014).  
 The TURQUOISE-I study included HCV/HIV co-infected, treatment naïve 
patients. SVR12 rates were 93% and 91% after 12 or 24 weeks of treatment, 
respectively; SVR12 was achieved in 91% of subtype 1a and 100% of subtype 1b 
patients (Wyles et al., 2014b). The patients received antiretroviral regimens 
containing atazanavir or raltegravir. 
 Non-cirrhotic, treatment-experienced (PegIFNα/RBV failures) patients were 
included in the SAPPHIRE-II trial in which patients were treated with PrOD and 
RBV for 12 weeks. There was no difference in response between subtype 1a and 
subtype 1b; the SVR12 rates were 96% and 97%, respectively. (Zeuzem et al., 
2014b). The addition of RBV in this cohort of patients is considered unnecessary 
as SVR12 was achieved in 100% of cases without RBV and 97% with RBV in 
patients infected with subtype 1b receiving this combination in the PEARL-II trial 
(Andreone et al., 2014). 
 RBV was added to the PrOD combination to treat patients with 
compensated cirrhosis. The study cohort included treatment-naïve and 
treatment-experienced patients, and overall SVR rates were 92% after 12 weeks 
and 96% after 24 weeks of the combination of PrOD and RBV (Poordad et al., 
2014).  
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1.13.2.3 Sofosbuvir and Simeprevir 
This combination has been evaluated in several patient populations. In one 
study, non-cirrhotic, prior null responders to PegIFNα/RBV therapy were offered 
treatment for 12 or 24 weeks, with or without RBV. SVR12 rates were 93% and 
96% for 12 weeks of therapy with and without RBV, respectively, and 93% and 
79% for 24 weeks of therapy with and without RBV, respectively.  
 In the second cohort, treatment-naïve patients and treatment –experienced 
(null responders) with a METAVIR score of F3–F4 were treated with the same 
regimens as above. The SVR12 rates were 93% and 93% for 12 weeks of therapy 
without and with RBV, respectively, and 100% and 93% for 24 weeks of therapy 
without and with RBV, respectively (Lawitz et al., 2014c). 
 Two large-scale real-life studies with SOF and SMV indicated that the 
SOF/SMV regimen is well tolerated, but SVR rates were lower than those 
reported in the COSMOS trial, especially in individuals with advanced stages of 
liver disease (EASL, 2015). In both studies, the overall SVR4 rate was 
comparable; 81% and 89 %. However, a higher SVR was reported in non-cirrhotic 
patients (92%) compared to cirrhotic cases (87%) in the HCV TARGET study. SVR4 
was more frequent in subtype 1b than 1a patients (Jensen et al., 2014). Similar 
results were shown in the preliminary analysis of the TRIO real-life study, as in 
treatment-naïve patients SVR was higher in non-cirrhotic patients (88%) 
compared to cirrhotic cases (75%) (Dieterich et al., 2014a). 
1.13.2.4 Sofosbuvir and  Daclatasvir 
An interferon-free treatment regimen containing SOF and DCV with or without 
RBV was investigated for previously untreated genotype 1–3 patients and 
genotype 1 patients with prior TVR or BOC triple therapy treatment failure. 
Genotype 1-infected patients achieved a higher SVR compared to genotype 3- 
infected patients, SVR rates were 98% and 89% respectively (Sulkowski et al., 
2014a). SVR rates were 100% with or without RBV in treatment-naïve patients 
with 24 weeks of therapy, compared with 98% in treatment-naïve patients who 
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received 12 weeks of therapy without RBV. In the treatment-experienced group 
who did not respond to triple therapy with either TVR or BOC, SVR rates were 
100% and 95% with and without RBV, respectively (Sulkowski et al., 2014a).  
 Data were derived from studies that included 335 HCV treatment-naïve and 
treatment-experienced HIV/HCV-co-infected persons as well as those with or 
without cirrhosis. The efficacy and safety of SOF/LDV for 12 weeks have been 
confirmed in clinical trial data in HIV-infected individuals with HCV genotype 1 
or 4 infection, similar efficacy and safety were demonstrated by PrOD 
combination [paritaprevir (PTV), ombitasvir (OMV) and dasabuvir (DSV)] with or 
without RBV for 12 weeks (Osinusi et al., 2015, Sulkowski et al., 2015). 
1.14 HCV drug resistance 
As discussed above, DAAs target different viral functions, specifically the NS3/4A 
protease, the NS5A protein and the RNA-dependent NS5B polymerase. Drug 
resistance may play a fundamental role in patients with failure to DAA-
containing regimens (Schneider and Sarrazin, 2014). Current combinations of 
DAAs are highly effective; however, antiviral potency, safety issues, posology, 
drug interactions, and resistance are major determinants of treatment success.  
 Resistance-associated mutations (RAMs) occur in patients treated with DAAs 
due to the error-prone nature of the HCV RdRp either before treatment as 
naturally occurring polymorphisms or as de novo mutations under drug selection 
pressure. The risk of outgrowth of resistance-associated variants (RAVs) is 
related to multiple factors including high replication rates, error-prone RdRp, 
selective pressure of the drug, role of replication space, replication capacity of 
RAVs, the genetic barrier to drug resistance (Halfon and Locarnini, 2011). Poor 
adherence is another indirect factor as it lowers drug exposure thereby affecting 
antiviral efficacy (Sarrazin and Zeuzem, 2010).  
 Resistance-associated mutations (RAMs) have been identified by in vitro 
replicon systems and, less frequently, in patients who fail DAA treatment in 
clinical trials.  
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The discrepancies between the reported in vitro and in vivo RAMs are mainly 
attributed to two factors: i) the replication capacity of the RAVs and their ability 
to persist in the quasispecies; ii) the level of resistance conferred by RAMs as 
low level of resistance can still respond to suppressive effect of the drug 
(Soriano et al., 2011).   
1.14.1 Genetic barrier for resistance 
The genetic barrier is ‘the threshold probability that the virus will mutate and 
escape from the selective action of the drug’. A simplified definition is the 
number of mutations required to acquire antiviral resistance. The genetic barrier 
for resistance is correlated with the number of RAMs needed to confer resistance 
against a certain class of drugs (Halfon and Locarnini, 2011).  
 A low genetic barrier resistance is one that involves a primary mutation 
that comes at a low fitness cost to the virus and can emerge quickly. In contrast, 
a higher genetic barrier is one that involves mutations with a high fitness cost to 
generate ‘‘total’’ resistance. Moreover, other mutations may be required to 
restore fitness of these low-fitness/high resistance variants. Drugs with a high 
genetic barrier to resistance are less likely to be associated with clinically 
meaningful resistance (Halfon and Locarnini, 2011). 
 In the case of the PIs, the genetic barrier is influenced by the HCV subtype 
(either 1a or 1b). Two nucleotide changes are required to generate an amino 
acid change in position 155 in subtype 1b isolates: R155K [CGG---AAG] while only 
one (R155K [AGG---AAG]) is needed for subtype 1a (Sarrazin and Zeuzem, 2010). 
As of today, the circulating HCV variants did not demonstrate any emergence of 
drug resistance against the current nucleoside analogue polymerase inhibitors; 
this may be due to significantly reduced replication capacity of the resistant 
variants (S282T of NS5B) or different binding sites of nucleoside and non-
nucleoside inhibitors (Hang et al., 2009). 
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1.14.2 Natural polymorphisms 
The most common form of genetic variation is a SNP.  A central issue in HCV is 
whether the presence of minority subpopulations containing RAVs would help to 
determine the treatment regimen. Both Sanger sequencing and NGS have 
identified mutations that confer resistance in patients who have not previously 
been exposed to DAAs (Gregori et al., 2013). Dominant, naturally occurring DAAs 
resistance mutations are common in HCV genotype 1 infected treatment-naïve 
patients. 
 The likelihood that a DAA will select for and allow outgrowth of RAVs 
depends on the DAA’s genetic barrier to resistance, the level of drug exposure, 
the patient population and the viral fitness of the resistant variant (Fridell et 
al., 2010, Gao, 2013). The prevalence of baseline polymorphisms, which are 
natural substitutions that may differ in their prevalence by genotype, subtype, 
and subtype clade, can also greatly affect the efficacy of specific DAAs (Paolucci 
et al., 2012). 
 The detection of RAVs depends primarily on the method used for 
sequencing as different platforms have different sensitivities. For Sanger 
sequencing, clonal analysis, and NGS sequencing, variants below frequencies of 
approximately 25%, 5% and 0.5% respectively cannot be detected (Halfon and 
Sarrazin, 2012).  
 Viral loads are high in the majority of patients carrying natural 
polymorphism mutations, suggesting that such viruses might achieve replicative 
capacities comparable to non-resistant strains in vivo (Kuntzen et al., 2008). 
1.14.2.1 NS3/4A Protease Inhibitors 
The HCV protease is characterised by a solvent-exposed substrate binding site, 
requiring small molecule inhibitors to rely on few specific interactions to achieve 
tight binding with the enzyme (Romano et al., 2012). The 3D structure has 
shown that RAVs bearing substitutions located in close vicinity to the NS3 
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protease catalytic triad reduce the drug inhibitory effect by lowering the drug’s 
affinity for the enzyme’s catalytic site (Pawlotsky, 2011).  
 Protease inhibitor-RAVs have recently been shown to have reduced in vitro 
fitness due to inability to produce infectious virions (Shimakami et al., 2011). 
However, there is growing evidence that acquisition of RAMs may not necessarily 
be associated with reduced in vivo viral fitness (Kuntzen et al., 2008). This is 
demonstrated in NS5A RAVs, where RAVs persist for a long time after stopping 
the treatment. 
 Naturally occurring amino acid changes in NS3, associated with reduced 
drug susceptibility, have been observed at baseline in treatment-naïve patients 
(Bartels et al., 2013, Kuntzen et al., 2008). In fact, it is foreseen that all single 
drug-resistant mutations and double/triple combinations pre-exist before 
treatment in most patients (Rong and Perelson, 2010). Because of the intrinsic 
fitness cost of resistant mutations, RAVs regularly emerge, but are not fixed in 
the absence of selective pressure, and remain detectable at low frequency in 
untreated patients (Rong and Perelson, 2010). 
 Bartonili et al. observed natural amino acid changes in NS3 associated with 
reduced protease inhibitor susceptibility using Pyrosequencing in treatment-
naïve chronically infected genotype 1 patients with or without HIV coinfection. 
RAVs were observed in 85.7% of patients (Bartolini et al., 2013). 
 Recently developed PIs, such as SMV and PTV, exhibit improved genetic 
barriers to resistance and enhanced antiviral activity against different HCV 
genotypes. However, the efficacy of these PIs is still substantially reduced by 
substitutions at amino acids R155 and D168 (Romano et al., 2012, Schinazi et al., 
2014). For PTV and SMV, the rate of naturally occurring NS3 resistance mutations 
is low (0.1–3%). However, for SMV one additional variant to confer medium level 
resistance (Q80K) is observed in 9–48% of treatment naïve genotype 1a infected 
patients with the highest incidence in North America. Patients with the Q80K 
variant achieve consistently lower SVR rates with SMV triple therapy (Schneider 
and Sarrazin, 2014). 
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The most commonly observed substitutions in genotype 1a–infected patients who 
do not achieve SVR with NS3 inhibitors are R155K and D168E/V. NS3 amino acid 
substitutions frequently detected in genotype 1b–infected patients who do not 
achieve SVR are Q80R and D168E/V. For both subtypes, the substitutions 
Q80K/R, S122A/G/I/T, R155Q, and D168F were not observed at the time of 
virological failure alone but rather in combination with other substitutions at 
positions 80, 122, 155, and/or 168 (Lenz et al., 2010, Manns et al., 2014, 
Jacobson et al., 2014, Forns et al., 2014).  
 The impact of the presence of resistance mutations to HCV NS3 protease 
inhibitors in <1% of the viral quasispecies is minimal as >1000-fold viral load 
reduction upon treatment is achieved; this low impact is attributed to the 
reduced replicative fitness of the variants carrying these mutations in vitro.  
 Meanwhile, an R155K protease mutation was detected as the dominant 
variant in a treatment-naïve patient, raising concerns about pre-existing PI drug 
resistance (Kuntzen et al., 2008). The PROMISE study in relapsers as well as the 
QUEST trials in treatment-naïve subjects illustrated the impact of pre-existent 
Q80K in genotype 1 patients on treatment outcome (Lenz et al., 2015, Jacobson 
et al., 2014, Forns et al., 2014). 
 In the majority of patients (83.7%) in phase IIb and III studies with genotype 
1a and baseline Q80K, an emerging single R155K-variant at the time of 
treatment failure was detected, suggesting that the presence of Q80K alone is 
not sufficient to explain treatment failure (Schneider and Sarrazin, 2014). 
  For PTV, the NS3 amino acid substitutions most commonly observed in 
genotype 1a–infected patients, who did not achieve SVR were D168A/V/Y. NS3 
amino acid substitutions frequently detected in genotype 1b–infected patients, 
who did not achieve SVR were Y56H and D168V (Feld et al., 2014, Zeuzem et al., 
2014b, Poordad et al., 2014). 
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1.14.2.2 NS5A Inhibitors 
The mechanism of action of NS5A inhibitors is not entirely understood. Current 
NS5A inhibitors are characterised by broad genotypic coverage and a relatively 
low barrier to resistance. Certain key RAMs like Y93H are detected as natural 
baseline polymorphisms in some patients (Gao, 2013, Fridell et al., 2011, Dore et 
al., 2015, Lawitz et al., 2015b). 
 NS5A amino acid substitutions most commonly observed in genotype 1a–
infected patients who do not achieve SVR after treatment with DCV are M28T, 
Q30E/H/R, L31M, H58D, and Y93H/N. The NS5A amino acid substitutions most 
commonly observed in genotype 1b–infected patients who do not achieve SVR 
are L31M/V and Y93H (Nelson et al., 2015, Dore et al., 2015). 
 Genotype 1a–infected patients with LDV treatment failure most commonly 
have Q30E/R, L31M, and Y93C/H/N RAVs. The NS5A amino acid substitution most 
commonly observed in genotype 1b–infected patients who do not achieve SVR is 
Y93H (Lawitz et al., 2012, Wong et al., 2013, Afdhal et al., 2014b). 
 Amino acid substitutions most commonly observed in genotype 1a– infected 
patients who do not achieve SVR despite treatment with OBV are M28T and 
Q30R. Y93H is the most commonly observed NS5A mutation in genotype 1b–
infected patients who do not achieve SVR (Poordad et al., 2014, Zeuzem et al., 
2014b, Feld et al., 2014). 
1.14.2.3 NS5B Polymerase Inhibitors 
Nucleos(t)ide inhibitors have a high resistance barrier (Gentile et al., 2014b, 
Schinazi et al., 2014). NS5B non-nucleoside analogue inhibitors bind outside of 
the polymerase active site and can be further sub-classified based on their 
allosteric binding sites (Palm 1, Palm 2, Thumb 1, and Thumb 2) (Gerber et al., 
2013). In vitro studies have shown that the substitution of serine 282 with 
threonine (S282T) is the main resistance mutation that results in reduced 
susceptibility of HCV to SOF (Wohnsland et al., 2007). This mutation confers 
reduced replicative capacity due to decreased functional ability of the NS5B 
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polymerase, a phenomenon also demonstrated by the absence of the S282T 
mutation in treatment-naïve patients (Kuntzen et al., 2008). In the ELECTRON 
study, one patient with genotype 2b infection who relapsed following treatment 
with SOF monotherapy developed the S282T mutation, but the mutation was 
undetectable 12 weeks after completion of treatment (Gane et al., 2013). 
Additionally, SOF maintains activity against HCV with mutations conferring 
resistance to other classes of agents (Abraham and Spooner, 2014).  
 L159F and V321A substitutions were selected in several subjects during a 
pooled analysis of SOF phase III trials including HCV genotype 3 infected patients 
who failed treatment. These variants alone conferred 1.2- to 1.6-fold reduced 
phenotypic susceptibility to SOF in vitro. However, these variants require 
further investigation to elucidate their association with viral resistance (Zeuzem 
et al., 2014a, Donaldson et al., 2015, Svarovskaia et al., 2014). 
 While pre-existence of naturally occurring resistance S282T mutations have 
not been described in treatment naïve or PegIFNα/RBV failure patients even by 
deep sequencing analysis (Schneider and Sarrazin, 2014), other treatment-
emergent NS5B substitutions (L159F, E341D, L320F) have frequently been 
observed in patients relapsing with SOF-based regimens. None of these 
substitutions have been associated with a phenotypic change in SOF or RBV 
susceptibility, however (Degasperi and Aghemo, 2014). 
 The S282T mutation is difficult to detect in vivo; Pyrosequencing has been 
used to detect NS5B RAVs in 16 treatment naïve, genotype 1 patients.  None of 
the patients harboured the S282T variant, which is in agreement with the 
reported high genetic barrier of nucleoside analogue NS5B polymerase inhibitors 
(Franco et al., 2013). Similarly, the S282T mutation was not present at baseline 
in 71 treatment-naïve HCV-infected patients tested using 454 pyrosequencing 
(Margeridon et al., 2011).  
 C316N/H/F substitutions were found to be present at baseline in six 
subjects infected with HCV genotype 1b who failed treatment. These 
substitutions were also observed during treatment in one HCV genotype 1a- 
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infected patient who experienced a relapse. However, more studies are needed 
to assess the role of this substitution in resistance to SOF (Donaldson et al., 
2015). 
 DSV is a non-nucleoside analogue inhibitor of palm I. NS5B amino acid 
substitutions most commonly observed in genotype 1a–infected patients who do 
not achieve SVR are M414T and S556G. The N5SB amino acid substitution, most 
commonly observed in genotype 1b–infected patients who failed to achieve SVR 
is S556G (Poordad et al., 2014, Zeuzem et al., 2014b, Feld et al., 2014). 
1.14.3 Persistence of resistance-associated variants  
In contrast to HIV infection, HCV RAVs are not archived as integrated proviral 
DNA, so the possible long-term effect of selected variants needs further 
investigation.  
 Protease inhibitor-RAVs progressively clear and become undetectable by 
Sanger sequencing within a few months to 2 years after drug discontinuation. 
The EXTEND study has shown that nearly 90% of drug resistance mutations 
selected on TVR therapy disappeared within the first two years following the end 
of treatment.  However, minority variants might have been missed in this study 
(Soriano et al., 2011).  
 In the long-term follow-up, patients who failed TVR treatment had 
undetectable RAVs using population sequencing, after  22 months (85%) and 89% 
after 29 months (Schneider and Sarrazin, 2014, Sherman et al., 2011).  A faster 
disappearance of RAVs in subtype 1b versus 1a variants has been observed 
(Sullivan et al., 2013). Similar results have been reported with BOC (Pawlotsky, 
2011), but faster clearance of RAVs and reversion to the wild-type virus were 
reported in the majority of patients 6 to 14 months after drug discontinuation 
(Barnard et al., 2013). RAVs emerging during SMV treatment at NS3 positions 80, 
122, 155, and/or 168 were no longer detectable by population sequencing in 50%  
of patients after a median follow-up of 28.4 weeks (Lenz et al., 2015). 
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The median time until loss of emerging R155K mutation was 36 and 24 months 
for genotype 1a and 1b, respectively. Interestingly, the median time to lose the 
mutation for the R155K variant without baseline Q80K was 64 months compared 
to 32 months for patients who had emerging R155K and baseline Q80K 
substitutions (Schneider and Sarrazin, 2014). 
 In contrast, viruses resistant to NS5A inhibitors are fit and can remain 
dominant, after they have been selected by a regimen including an NS5A 
inhibitor (McPhee et al., 2013, Sullivan et al., 2013, Wang et al., 2013, Lenz et 
al., 2015, Krishnan et al., 2014, Sarrazin et al., 2014).  
 Pre-existence of NS5A inhibitor-resistant substitutions compromise the 
response to DCV, and treatment failure is associated with the emergence of both 
NS5A-L31/Y93 and NS3-D168 variants. NS5A-L31/Y93 variants remain at high 
frequency 103 to 170 weeks post-treatment (Yoshimi et al., 2015). 
1.14.4 Factors influencing resistance before treatment 
1.14.4.1 The role of natural occurring RAVs 
Naturally occurring RAVs in treatment-naïve patients are known to influence 
treatment outcome in some patients (Kuntzen et al., 2008). The incidence of 
resistant variants is variable and depends on the binding domain and HCV 
genotypes and subtypes present. Nearly all described RAVs within the NS3/ 4A 
gene can be detected using NGS analysis (Verbinnen et al., 2010). 
 To date, RAVs at very low frequencies have not been found to have an 
impact on treatment response. Treatment-naïve patients with TVR-resistant 
variants before treatment achieved similar SVR-rates compared to patients 
without RAVs (Bartels et al., 2013).  
 Further analysis of TVR and BOC phase III studies emphasised that 
treatment response is independent of the presence of pre-existing RAVs if there 
is responsiveness to the PegIFNα/RBV backbone.  
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On the other hand, patients with baseline RAVs, who are also poor PegIFNα/RBV 
responders (<1 log10 decrease in HCV-RNA during lead-in-phase) showed lower 
SVR rates compared to poor PegIFNα/RBV responders without baseline RAVs (22% 
vs. 37%) (Schneider and Sarrazin, 2014). Prior null responders with the pre-
existing variants T54S or R155K treated with TVR in the REALIZE-study always 
failed therapy whereas prior relapsers achieved SVR in most cases (De Meyer et 
al., 2012). 
1.14.4.2 The influence of the HCV genotype/subtype 
The phase 3 studies of TVR, BOC, and SMV showed lower SVR rates for HCV-
genotype 1a compared to genotype 1b (TVR 71% vs. 79%, BOC 59–62% vs. 66–73%, 
FDV 69–76% vs. 83–84%, SMV 71% vs. 90% for treatment-naïve patients) (Jacobson 
et al., 2011, Schneider and Sarrazin, 2014). Pre-existing dominant resistance 
mutations are more common in treatment-naïve patients infected with genotype 
1a (cumulative incidence 8.6% vs. 1.4%) compared to genotype 1b- infected 
patients (Kuntzen et al., 2008).  
1.14.4.3 Cross-resistance  
Cross-resistance occurs when resistance mutations are selected that are common 
to more than one drug within each class. This is typical for inhibitors that bind 
the same pocket but not necessarily for inhibitors with the same mechanism of 
action (Halfon and Locarnini, 2011).  
 The genotyping analysis shows an overlapping cross-resistance profile for 
PIs. The A156T RAV confers high levels of resistance with reduced viral fitness. It 
is mainly selected in vitro, but also occasionally occurs in vivo. The R155K 
mutation confers low levels of resistance to linear PI compounds but results in 
high-level resistance to the macrocyclic group and is frequently found in vivo. 
This change is costly for the virus resulting in loss of fitness.  
 Prevention of DAA-resistant virus outgrowth is based on the use of 
combinations of potent antiviral drugs with no cross-resistance (Halfon and 
Sarrazin, 2012). 
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There is a growing database identifying the profiles of resistance and cross-
resistance between antiviral agents; this will be necessary for decisions on 
treatment choices to achieve the highest cure rate.  
1.14.4.4 In vivo fitness of viral populations 
Replication fitness has been defined as the ability to produce offspring in the 
setting of natural selection (Richman, 2000). Viral fitness is defined as the 
replication efficiency of resistant variants, in proportion to the replication 
efficiency of WT-HCV. The viral fitness of resistant variants influences the 
emergence of resistance.  
 The replication capacity of HCV variants is typically assessed in vitro using a 
transient replicon system, or can be examined by comparing colony formation 
efficiency of the mutant replicon RNA with that of WT variants in co-culture 
growth competition assays (Bartenschlager and Lohmann, 2000). It is important 
to consider that replicon-based assays may underestimate the loss of fitness 
caused by PI-resistance mutations because some mutations in the NS3 protease 
domain specifically impair late steps in the viral life cycle that involve 
intracellular assembly of infectious virus (Shimakami et al., 2011). 
 RAVs must have the capacity to propagate to fill the replication space left 
vacant by susceptible wild-type virus during drug exposure. The poor viral fitness 
decreases the clinical significance of highly resistant variants, hence a less 
resistant but fitter virus affect the outcome of treatment if it can replicate 
efficiently in the presence of the drug. However, the viral fitness could be 
restored after the introduction of compensatory mutations that permit the 
resistant variant to replicate efficiently in the presence of the drug. (Pawlotsky, 
2011). 
1.14.4.5 Selective pressure of HCV treatments   
EC50 (50% effective concentration) and IC50 (50% inhibitory concentration) are 
used early in the discovery process to evaluate the suitability and performance 
of drugs.  
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Drug exposure is the in vivo concentration achieved by the administered drug 
relative to the EC50 / IC50 values of resistant variants. RAVs will be inhibited if a 
drug exposure is sufficiently higher than its EC50 / IC50 values, even if they confer 
resistance in vitro.  
 Antiviral efficacy in vivo may not be affected if a resistant variant naturally 
replicates at low levels and/or if the drug retains partial efficacy (particularly if 
drug exposure is high) (Pawlotsky, 2011). 
 The incidence of resistance is inversely correlated with SVR; the compound 
with the highest antiviral activity results in the strongest suppression of viral 
replication, and complete suppression of viral replication prevents resistance 
emergence because mutagenesis is replication dependent (Halfon and Locarnini, 
2011). 
 Pre-existing RAVs can be selected to outgrow other circulating variants 
under selective drug pressure, and can become the dominant variant in the viral 
quasispecies. The identification of the resistance pattern for an antiviral agent is 
performed by studying the viral quasispecies before, during and after treatment; 
RAVs are identified by detection of new variants that emerged under drug- 
selective pressure. This can enable tailoring treatment to avoid treatment 
failure (Sarrazin and Zeuzem, 2010). 
 Since monotherapy exerts varying degrees of antiviral activity directed at a 
single target site, it results in the highest probability of selecting for drug 
resistance (Sarrazin et al., 2007). The ideal combination therapy exerts antiviral 
activity at variable steps in the viral life cycle to decrease the possibility of the 
emergence of RAVs.  
 Replication space for a virus can be described as the potential of the liver 
(hepatocytes) to accommodate new transcriptional templates for that virus. This 
means that the outgrowth of any possible RAV requires the clearance of WT 
variant and the proliferation of hepatocytes to produce new space for infective 
RAVs.  
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Hepatocyte turnover in the normal liver is slow, displaying an average half-life 
of over 100 days, but this can be reduced to less than ten days in the setting of 
increased necroinflammatory activity or associated toxicity (Halfon and 
Locarnini, 2011). 
1.15 Prevention of treatment failure with DAAs 
In vivo, viral resistance is influenced by three major factors: i) the genetic 
barrier to resistance; ii) viral fitness of the variant population, and 3) drug 
exposure (Pawlotsky, 2011). Prevention of DAA-resistant virus outgrowth is based 
on the use of combinations of potent antiviral drugs with no cross-resistance 
(Pawlotsky, 2011). Prevention of resistance can be achieved by adopting a 
strategy with several rules: i) drug choice with the lowest incidence and 
prevalence of drug resistant mutants in clinical trials; ii) high patient adherence; 
iii) use combinations of drugs as in the HIV treatment model (Halfon and 
Locarnini, 2011). 
 The appearance of RAMs after a few days of treatment limits the usage of  
DAAs monotherapy because RAMs result in virological rebound and treatment 
failure. Thus, clinicians should use DAA combinations targeting different viral 
functions for which there is no cross resistance, an approach that has been 
successfully applied to prevent resistance in HIV treatment.  
1.15.1 HCV drug monitoring resistance tools 
Antiviral resistance testing is performed using two methods; genotypic and 
phenotypic assays. Data from clinical trials carried out so far have indicated that 
sensitive methods should be adopted to assess HCV drug resistance (Halfon and 
Locarnini, 2011). NGS is a potential tool for detection of RAVs due to its higher 
sensitivity in detecting minority variants (Verbinnen et al., 2010).  
The FDA has recommended that resistance testing begins in preclinical 
development to provide a tool for monitoring as drugs are introduced to clinical 
practice. It is possible that pre-treatment screening for baseline RAMs might be 
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warranted to enable individual tailoring of treatment. This is more controversial, 
however than the use of screening for RAVs in those who have already failed DAA 
treatment (Thompson et al., 2009).  
Except testing for baseline Q80K polymorphisms in genotype 1a HCV-
infected patients before treatment with SMV, routine testing for RAVs before 
initial treatment is not currently recommended. Emerging data suggest that 
assessment for RAVs in patients whose treatment with NS5A-containing regimens 
failed is warranted for those who require retreatment (AASLD/IDSA, 2015). 
Previous reports have described the advantages of NGS, including faster 
processing and large-scale sequencing, in addition to providing a better 
understanding of the dynamics of variants in HCV quasispecies (Hiraga et al., 
2011, Nasu et al., 2011, Ninomiya et al., 2012). A recent study based on TVR-
based therapy showed that it was difficult to predict the emergence of TVR-
resistant variants during triple therapy at baseline testing, even with the use of 
NGS sequencing (Akuta et al., 2013). 
1.16 Retreatment of HCV  
Several studies demonstrated that the previous exposure to treatment with 
PegIFNα/RBV does not influence the treatment outcome with IFN-free regimens 
when compared to treatment-naïve patients (EASL, 2015). Thus, such patients 
should be retreated with an IFN-free regimen (Zeuzem et al., 2014b, Bourliere 
et al., 2015). 
The experience of retreatment of patients infected with HCV genotype 1 
who did not achieve an SVR after treatment with the triple combination of 
PegIFNα, RBV, and either TVR or BOC with the combination of SOF and SMV, with 
or without RBV, for 12 weeks is limited to on-going observational real-life 
cohorts (EASL, 2015). In the TARGET study, the impact of the presence of RAVS 
before starting retreatment is unknown, but the previous failure of PI-containing 
regimen was a significant negative predictor of SVR4 (Jensen et al., 2014).  
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Meanwhile, in the TRIO Network study, retreatment with a combination of SOF 
and SMV achieved an SVR rate of 82% in patients who failed on triple 
combination therapy, which was close to SVR rate (80%) achieved in patients 
who failed on PegIFNα and RBV alone (80%). Retreatment with the combination 
of PegIFNα/RBV and SOF of such patients yielded SVR rates of 73% and 67%, 
respectively (Dieterich et al., 2014a). 
In non-cirrhotic patients who failed triple combination therapy, 24 weeks of 
combined SOF and DCV yielded SVR rates of 95% and 100% with and without RBV, 
respectively (Sulkowski et al., 2014a). In the ION-2 trial, the SVR rates in 
patients without cirrhosis re-treated with SOF and LDV for 12 weeks, without or 
with RBV, were 96% and 100%, respectively. Finally, the SVR rate was 97% and 
100% after 24 weeks of therapy with and without RBV, respectively (Afdhal et 
al., 2014a). 
Interestingly, in the ION-2 trial, SVR rates in cirrhotic patients retreated 
with SOF and LDV for 12 weeks, with or without RBV, were 86% and 85%, 
respectively. SVR rates increased to 100% after prolonged treatment of 24 weeks 
regardless of using RBV (Afdhal et al., 2014a). In the SIRIUS study, the SVR rates 
with SOF plus LDV, for either 12 weeks with RBV or 24 weeks without RBV, were 
96% and 97%, respectively (Bourliere et al., 2014a). 
Clinically resistant HCV variants have been reported with SOF, which 
rapidly disappear after treatment cessation. Re-treatment options should, 
therefore, include SOF as re-treatment with 12 weeks of SOF plus LDV with RBV 
yielded SVR in 98% of genotype 1 patients who failed prior treatment with SOF 
plus placebo, or SOF plus RBV, or SOF plus PegIFNα-a and RBV (Wyles et al., 
2014a). 
 Patients who fail on the PrOD combination should be re-treated with a 
SOF-based regimen. The value and safety of re-treatment strategies combining 
three drugs, including SOF, a protease inhibitor, and an NS5A inhibitor, is 
unknown. 
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Current retreatment recommendations are based on indirect evidence (HCV 
genotype, known resistance profiles of the administered drugs, the number of 
drugs used, use of RBV, treatment duration, and disease status). The role of 
resistance testing before retreatment remains unknown, although it is 
recommended in NS5A treatment failure in the USA (AASLD/IDSA, 2015).  
Patients who fail on a DAA-containing regimen should be retreated with an 
IFN-free combination including an agent with a high barrier to resistance, plus 
one or two other drugs, ideally with no cross-resistance with drugs previously 
administered. Based on results in difficult-to-cure patient populations, re-
treatment should be for 12 weeks with RBV or extended to 24 weeks with or 
without RBV (EASL, 2015). 
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1.17 Aims and hypotheses  
A cohort of 160 HIV-positive MSM with acute HCV was available to address the 
following research hypotheses:  
 HCV viral diversity predicts the outcome of treatment of early HCV 
infection in a cohort of HIV-infected individuals.  
 Next generation sequencing is superior to conventional Sanger sequencing 
for detection of low-frequency variants in serum samples and is a better 
diagnostic tool. 
 Natural direct-acting antiviral resistance-associated variants are 
frequently seen in HIV/HCV co-infected individuals  
The aims were to: 
 Develop a next generation sequencing pipeline for full HCV genome 
sequencing using the Illumina® platform (Chapter 3). 
 Understand viral dynamics in HCV/HIV co-infected patients who failed 
treatment including the role of viral diversity in the prediction of treatment 
outcome (Chapter 4). 
 Develop a new tool to study natural polymorphisms associated with 
resistance to new antivirals against HCV (Chapter 5). 
 Develop an in vitro HCV genotype 1a replicon model for studying the 
replicative fitness of known resistance-associated mutations and to predict in 
silico new mutations conferring resistance to DAAs (Chapter 5). 
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   Chapter 2: Materials and Methods 
2.1 Patient cohort  
A cohort of 160 patients with HIV and acute HCV was prospectively recruited 
between 2005 and 2014 in a single centre (St Mary’s Acute HCV Cohort). Plasma 
and peripheral blood mononuclear cell (PBMC) samples were obtained 
prospectively at 1-3-monthly intervals. Patients were offered 24-48 weeks of 
treatment with PegIFNα and weight-based RBV (800-1200mg) 12-24 weeks 
following HCV diagnosis administered according to British HIV Association 
(BHIVA) guidelines available at the time of treatment (Brook et al., 2010) unless 
this was contraindicated or spontaneous clearance occurred. 
 Informed consent in writing was obtained from each patient, and the study 
protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki. 
This work was conducted as part of a study approved by the St Mary's Hospital 
Research Committee and the Riverside Research Ethics Committee (Reference 
number 05/Q0401/17) granted ethical approval. Each patient was assigned a 
study number starting with letter (P) followed by a unique number (e.g. P101) 
Blood samples were obtained in EDTA-containing vacutainer tubes. Plasma was 
separated by centrifugation and stored in 2ml tubes at -80°C.   
2.1.1 Clinical groups and definitions 
Acute HCV diagnosis was defined as a positive HCV RNA result by RT-PCR within 
six months of a preceding negative RT-PCR or an antibody test. The date of 
infection was estimated as the midpoint between the last negative and first 
positive test. 
2.1.1.1 Patient groups based on viral load monitoring 
Samples for measuring HCV viral load and liver function (ALT, bilirubin, and 
albumin) were taken at monthly intervals for three months following diagnosis 
and at three monthly intervals thereafter. CD4 count and HIV viral load were 
assessed at three monthly intervals.  
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Spontaneous clearance of HCV was defined as two successive negative RT-PCR 
tests (<12 IU/ml) 3 months apart. Sustained virological response (SVR) was 
defined as a negative HCV RNA by RT-PCR (<12 IU/ml) 24 weeks after the end of 
treatment with PegIFNα and RBV. Patients who did not respond to treatment 
were divided by mode of failure. The null response was defined as a decrease 
of less than 2 log10 IU/ml in HCV viral load at week 12 of therapy. Partial 
response was defined as a reduction of at least 2 log10 IU/ml in HCV RNA by 
week 12 of therapy but detectable HCV RNA at week 24. Viral breakthrough was 
defined as the recrudescence of HCV RNA at any time during treatment after a 
negative result. Relapse was defined as detectable HCV RNA within 24 weeks 
after the end of treatment following negative results on treatment (EASL, 2014). 
2.1.1.2 Treatment outcome groups based on phylogenetic analysis 
Sequences obtained from paired samples pre- and post-treatment were 
considered similar or different based on two criteria: i) Phylogenetic signal 
defined as a monophyletic or non-monophyletic lineage; ii) Genetic distance of 
greater than 10% between sequences; this was calculated as the pairwise 
distance between aligned sequences. Based on these criteria, treatment 
outcomes were defined as i) Persistent infection: the presence of at least one 
variant present in the pre-treatment sample persisting after treatment. This 
could be associated with new dominance; the outgrowth of a minority strain 
found in the pre-treatment sample or the presence of a new variant representing 
superinfection; ii) Reinfection: the presence of a new variant(s) in the post-
treatment sample with no evidence of similar pre-existing strains (Abdelrahman 
et al., 2015).  
2.1.2 Treatment outcome subgroups 
The first study subgroup included ten patients with an SVR matched with ten 
patients who did not respond to treatment. This subgroup was used to 
investigate the role of viral diversity in the prediction of treatment outcome as 
detailed in Section 4.2.1. 
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A second subset (carried out later in the study) analysis of 15 treatment non-
responders was performed to look for evidence of mixed infection before and 
after treatment. Of these, six were null responders, three partial responders and 
six were relapsers. Paired samples from each patient pre- and post-treatment 
were analysed as described in Section 4.2.2.  
2.1.3 Antiviral resistance study cohort 
Serum samples were obtained from 16 HCV genotype 1a co-infected treatment-
naïve HIV-positive patients in the St Mary's Acute HCV cohort (Thomson et al., 
2011) and 18 HCV genotype 1a treatment naïve patients in the STOP HCV 
project. The samples obtained from STOP HCV project were sequenced by Dr 
Chris Hinds and Dr Walt Adamson and the sequencing data were provided as raw 
data. Local Research Ethics Committees granted ethical approval. 
2.2 Extraction of viral RNA from plasma samples  
Plasma stored at -80°C was thawed on ice and nucleic acid extraction performed 
using two different methods; manual extraction using a QIAamp® Viral RNA kit 
(Qiagen) and automated extraction using magnetic bead technology (EasyMAG®). 
Automated nucleic acid extraction was selected once available to improve 
workflow and decrease variability.  
2.2.1 Manual RNA extraction  
Manual RNA extraction was carried out with a QIAamp® Viral RNA kit (Qiagen). 
An aliquot (140 μL) of plasma was added to 560 μL cell lysis solution (buffer AVL) 
containing 5.6 μL carrier RNA and incubated for 10 min at room temperature. 
Ethanol (560 μL) was added, and the sample applied to columns and centrifuged 
at 8,000g. Two further centrifugation steps were carried out using 500 μL of 
wash buffers AW1 and AW2. Finally, extracted viral RNA was eluted in 60 μL of 
buffer AVE (RNase-free water containing 0.04% sodium azide). 
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2.2.2 Automated RNA extraction  
Extraction with the easyMAG® NucliSENS extractor platform was carried out 
according to manufacturer’s recommendations; 400 µL of each sample was 
placed in a disposable sample vessel that was loaded onto the extractor. After 
initial lysis incubation, 100 µL of magnetic silica was added to each sample, and 
the extractor was restarted. Samples were eluted in 60 µL. All samples were 
transferred to a 1.5 ml microcentrifuge tube and stored at -80°C. 
2.3  cDNA Synthesis 
cDNA synthesis was carried out using Superscript III or Maxima H kits. 
2.3.1 Superscript III 
®
 reverse transcriptase  
A Superscript III RT-PCR kit (Invitrogen, Life Technologies, Carlsbad, CA) was 
used to reverse transcribe extracted RNA into complementary DNA (cDNA) using 
random hexamers. 15 µL of RNA, 1 µL of random hexamers and 9 µL of 10mM 
dNTPs were mixed and heated at 70°C for 5 min. The mixture was then placed 
on ice for 2 min. A reverse transcription master mix was made by adding 9 µL of 
5X First-strand Buffer, 2 µL of 0.1M DTT, 4 µL of RNAse OUT (20u/µL) and 1 µL of 
Superscript III enzyme. This mixture was added to the previous reaction mix and 
incubated at 50 ºC for 1.30 hrs. Following this, 1 µL of Superscript III was added 
and the temperature increased to 55 ºC for a further 1.30 hrs. The reverse 
transcriptase enzyme was inactivated at 70 ºC for 15 min, then 1 µL of RNase H 
was added and incubated for 20 min at 37 ºC. Finally, cDNA was stored at –20 ºC. 
2.3.2 Maxima H Minus Reverse Transcriptase
®
 
Complementary DNA was also prepared using Maxima H minus Reverse 
Transcriptase® (Thermo Scientific). A master mix was prepared using random 
hexamers and nucleoside triphosphates (NTPs); 1 µL of random hexamers, 1 µL 
of NTPs were added to 13 µL of total RNA, then incubated at 65°C for 5 min. 
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The reaction was chilled on ice, briefly centrifuged and placed back on the ice. 
Four µL of 5x Reverse Transcriptase buffer, 1 µL Reverse Transcriptase enzyme 
were added and then incubated for 10 min at 25°C followed by 60 min at 65°C. 
Finally, the reaction was terminated by heating at 85°C for 5 min. The cDNA was 
stored at –20°C. 
2.4 DNA second strand synthesis 
Double stranded cDNA was prepared with a NEBNext® mRNA Second Strand 
Synthesis Module kit (New England Biolabs). 15 μL from the inactivated cDNA 
reaction was placed on ice and 48 μL nuclease-free water, 8 μL of 10X Second 
Strand Synthesis Reaction Buffer and 4 μL Second Strand Synthesis Enzyme Mix 
were added. The reaction was then incubated in a thermal cycler for 2.5 hours 
at 16°C.  
2.5 PCR amplification 
Universal precautions to avoid PCR contamination were followed at all times and 
PCR mixes were prepared in an allocated room separate from clinical samples.  
2.5.1 PCR error rate estimation using different enzymes 
Error rates of several PCR enzymes were estimated using clonal sequence 
analysis of a single plasmid containing a single HVR1 region insert. Bacterial 
cloning was carried out as described in Section 2.11.2. The enzyme that 
demonstrated the highest fidelity was used to perform all further PCR reactions. 
The error rate was calculated by counting all nucleotide variants of plasmid 
reads in the alignment that did not correspond to the sequence of the clone 
determined by Sanger sequencing. The three different enzymes tested in this 
study were; AccuStart® Taq DNA Polymerase HiFi and the proof-reading enzymes 
Phusion® High-Fidelity PCR enzyme and KOD Hot Start DNA Polymerase®. These 
were compared with an error rate of MegaMix® Blue PCR Taq polymerase 
estimated by Dr Emma Thomson using the same method. 
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2.5.1.1 MegaMix® Blue PCR Taq polymerase  
MegaMix® Blue (Microzone) contains recombinant Taq polymerase in reaction 
buffer (2.75 mM MgCl2 with 220 μM dNTPs, blue agarose loading dye & 
stabiliser). Cycling conditions were as follows: initial denaturation step: 95°C for 
3 minutes (min) followed by 30 cycles of 1. Denaturation: 95°C for 30 seconds 
(sec), 2. Annealing: Optimal primer annealing temperature for 30 sec, 3. 
Extension: 72°C for 60 sec and a final extension at 72°C for 10 min then hold at 
4°C.  
2.5.1.2 Phusion® High-Fidelity PCR enzyme 
Phusion® High-Fidelity PCR Master Mix with HF Buffer (New England Biolabs) 
contains a high fidelity enzyme. 25 µL of 2X Phusion Master Mix, 2.5 µL of 10 µM 
Forward Primer, 2.5 µL of 10 µM Reverse Primer, DNA template, and nuclease-
free water were added to produce a final volume of 50 µL. Cycling conditions 
were as follows: initial denaturation step: 98°C for 2 min followed by 30 cycles 
of 1. Denaturation: 98°C for 10 sec, 2. Annealing: Optimal primer annealing 
temperature for 30 sec, 3. Extension: 72°C for 15-30 sec per kb, and a final 
extension at 72°C for 10 min, then hold at 4°C.  
2.5.1.3 KOD Hot Start DNA Polymerase®  
KOD Hot Start DNA Polymerase® (Novagen) is a premixed complex of the high 
fidelity KOD DNA Polymerase and two monoclonal antibodies that inhibit the DNA 
polymerase and 3'5' exonuclease activities at ambient temperatures.   
 The PCR reaction contains 5 μL of 10X Buffer for KOD Hot Start DNA 
polymerase, 3 μL of 25 mM MgSO4, 5 μL of  dNTPs (2 mM each), 1.5 µL of 10 µM 
Forward Primer, 1.5 µL of 10 µM Reverse Primer, DNA template, 1 μL KOD Hot 
Start DNA Polymerase (1U/μL) and nuclease-free water, resulting in a final 
volume of 50 µL. Cycling conditions were as follows: polymerase activation step: 
95°C for 2 min followed by 30 cycles of 1. Denaturation: 95°C for 20 sec, 2. 
Annealing: Optimal primer annealing temperature for 10 sec, 3. Extension: 70°C 
for 10 sec per kb, and a final extension at 72°C for 10 min, then hold at 4°C. 
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2.5.1.4 AccuStart® Taq DNA Polymerase HiFi 
AccuStart® Taq DNA Polymerase HiFi is an enzymatic mixture of recombinant Taq 
DNA polymerase, a thermostable DNA polymerase with 3'5' exonuclease 
activity, and monoclonal antibodies that bind to the polymerase and keep it 
inactive before PCR thermal cycling.  
 The PCR reaction contains 5 μL of 10x OptiBuffer, 2 μL of MgCl2 (50 mM 
Solution), 2.5 μL of 20 mM dNTP Mix, 1.5 µL of 10 µM Forward Primer, 1.5 µL of 
10 µM Reverse Primer, DNA template, 2 μL of DAp GoldStar® DNA polymerase (4 
U/ μL) and nuclease-free water resulting in a final volume of 50 µL.  
 Cycling conditions were as follows: polymerase activation step: 95°C for 2 
min followed by 30 cycles of 1. Denaturation: 95°C for 20 sec, 2. Annealing: 
Optimal primer annealing temperature for 10 sec, 3. Extension: 70°C for 60 sec 
per kb, and a final extension at 72°C for 10 min, then hold at 4°C. 
2.5.2 Amplification of the E2 HVR1 region 
Amplification of a 220 bp region including the E2 hypervariable region-1 (HVR1) 
was carried out by nested PCR using a combination of genotype-specific primers 
as shown in Table 2-1 (Thomson et al., 2011). The first-round PCR products were 
further amplified with “fusion primers” composed of the 454 primer keys, with 
different multiple identifiers for each sample, and the HCV HVR1-specific 
primers. Primer binding sites, adapters and multiplex identifiers (MIDs) for 
sample barcoding were included in the inner primer design to create fusion 
primers compatible with pyrosequencing (Figure 2-1). The outer primer set 
contained genotype-specific versions of primers E4 and E5 and the inner primer 
set contained genotype-specific 214 and E3 primers. 
 The resulting PCR products were purified using 2% agarose gel 
electrophoresis containing SYBR safe® DNA gel stain (Life Technologies) with lane 
markers and a 100bp small fragment ladder® (Thermo Scientific). DNA bands 
were visualised under ultraviolet light and bands of appropriate size (225 bp) 
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were extracted and purified using a GeneJet® extraction kit (Thermo Scientific). 
Purified amplicons were quantified using Qubit® fluorometric quantification. 
Amplicons were diluted to create a multiplexed library in equimolar 
concentrations.  
 The library was sent for Roche 454 FLX second-generation pyrosequencing 
using Titanium chemistry (Roche Applied Science, Indianapolis, IN) by Beckman 
Coulter Genomics, USA. 
2.5.3 Quantitative real-time PCR assays  
Real-time PCR (RT-PCR) reactions were amplified under universal conditions on a 
7500 Fast Real-Time® PCR machine and data analysed using 7500 Fast System 
Software (SDS v1.3.1, ABI). The RT-PCR reaction mix total volume was 18 L, 
prepared using: 1 L of 18 m forward primer; TCTGCGGAACCGGTGAGTAC (final 
concentration 900nM), 1 L of 18m reverse primer; GCACTCGCAAGCACCCTATC 
(final concentration 900 nM), 1 L of 5m FAM Probe; FAM-
AAAGGCCTTGTGGTACTG-MGB (250nM), 10 L of TaqMan Fast Universal Mix® (2x), 
5 L of nuclease-free water and 2 L cDNA in a 96 well plate. The plate was then 
sealed with an adhesive cover and centrifuged for one minute at 1000 RPM. 
 The following thermal cycler protocol cycling conditions were used:  Stage 
1: hold at 95°C for 20 sec; stage 2 (40 cycles): step 1: hold at 95°C for 3 sec, 
step 2: hold at 60°C for 30 sec. 
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Table 2-1: Genotype-specific primers used for nested PCR. 
Primer Primer sequence 
Nucleotide 
position, 
relative to H77 
214 5'-CACTGGGGAGTCCTGGCGGGC-3' 1395-1415 
214(2) 5’-CAYTGGGGYGTSRTGTTYGGC-3’ 1395-1415 
E3 5'-GGGCAGTGCTGTTGATGT-3' 1603-1620 
E3(1a) 5'-AGGCCGTGCTATTGATGT-3' 1603-1620 
E3(2) 5’-GGCMGTSCGGTTKATGTGCC-3’ 1604-1623 
E3(4) 5'-GGGCAGTCCTATTTATATGCC-3' 1603-1623 
E4 5'-GGTGTGGAGGGAGTCATTGCAGTT-3' 1623-1646 
E5 5'-GCTTGGGATATGATGATGAACTGGTC-3' 1296-1321 
The outer primer set (E4, E5), the inner primer set (214, E3). 
Figure 2-1: Design of fusion primers.  
 
454 primer keys, containing different multiple identifiers for each sample and HCV 
HVR1-specific primers. Primer binding sites, adapters and multiplex identifiers (MIDs) 
for sample barcoding were included in the inner primer design to create fusion primers 
compatible with pyrosequencing. 
 
 
Chapter 2: Materials and Methods 
92 | P a g e  
2.6 Gel electrophoresis  
This method was employed to purify DNA fragments produced by PCR or 
following restriction enzyme digestion. PCR products were mixed with 0.1 
volumes of 10X BlueJuice® Gel Loading Buffer (Invitrogen) before being loaded 
into the wells of a 1% or 2% agarose gel containing Syber Safe® (Invitrogen) or 
ethidium bromide (1μg/ml) with lane markers and a 100bp or 1Kb ladder 
(Promega) depending on the size of fragments that needed to be excised. 
 Gels were prepared using 1 x TAE buffer (a buffer solution containing a 
mixture of Tris base, acetic acid, and EDTA). Gels were typically run at 110 V; 
DNA bands were visualised under ultraviolet light and bands of appropriate size 
were cut out using a clean scalpel blade. These bands were next purified to 
remove extraneous products. 
2.7  Purification of DNA 
2.7.1  Isolation and Purification of DNA from Agarose Gels 
DNA was purified from excised gel slices using a GeneJet® gel extraction kit 
(Thermo Scientific). The gel slice was placed in a pre-weighed 1.5 ml tube and 
weighed, then a 1:1 volume of binding buffer added to the gel slice (volume: 
weight) and the gel mixture incubated at 60°C for 10 min or until the gel slice 
was completely dissolved. The chaotropic agent in the binding buffer dissolves 
agarose denatures proteins and promotes DNA binding to the silica membrane in 
the column. 800 μL of solubilised gel solution at a time was transferred into a 
purification column and centrifuged for 1 min at 13,000 rpm in a 
microcentrifuge. The flow-through was discarded, and the column placed back 
into the same collection tube. 100 μL of binding buffer was next added to the 
purification column and centrifuged for 1 min at 13,000 rpm.  
 The flow-through was discarded, and the column placed back into the same 
collection tube. 700 μL of wash buffer was added to the purification column and 
centrifuged for 1 min. The flow-through was discarded, and the column placed 
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back into the same collection tube. The empty purification column was 
centrifuged for an additional 1 min to remove residual wash buffer completely. 
For elution, 50 μL of elution buffer was added to the centre of the purification 
column membrane, the purification column transferred into a clean 1.5 ml 
microcentrifuge tube and centrifuged for 1 min. The purified DNA was then 
stored at -20°C. 
2.7.2  DNA purification using Agencourt AMPure XP
®
 beads 
The volume of Agencourt AMPure XP® for a given reaction was calculated using 
the following equation: (Volume of Agencourt AMPure XP per reaction) = 1.8 x 
(Reaction Volume), the constant (1.8) was changed according to the size 
selection protocol. The sample was mixed by pipetting up and down ten times; 
then it was placed on a magnetic plate for 5–10 min to separate the beads from 
the solution. The cleared supernatant was aspirated from the reaction plate and 
discarded. 200 μL of fresh 80% ethanol was used to wash the beads twice without 
disturbing the beads. Finally, purified DNA was eluted in 40 μL nuclease-free 
water (Figure 2-2). 
2.8  Fluorometric measurement of nucleic acid concentration   
A fluorescent dye working solution was prepared in a plastic tube, using a mix of 
200 µL of buffer and 1 µL of dye for every sample. After vortexing, an aliquot of 
190 µL of working solution was added to two 0.5 ml Eppendorf tubes and are 
labelled standards, then 10 µL of each Standard 1 (0 ng/ µL) and standard 2 (10 
ng/ µL) was added to the corresponding tube and mixed by vortexing. 
Meanwhile, a 198 µL aliquot of working solution in 0.5 ml Eppendorf tubes was 
mixed with 2 µL of each sample by vortexing. 
 After incubation at room temperature for 2 min, the nucleic acid 
concentration was measured using a Qubit® 2.0 Fluorometer; readings were 
always carried out following calibration with two standards. To measure DNA 
quantity, a Qubit® ds DNA HS Assay Kit was used, while for RNA quantification, a 
Qubit® RNA Assay Kit was used. 
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2.9  Nucleotide sequencing and analysis 
2.9.1  Sanger sequencing and analysis 
Sanger sequencing was performed commercially by Beckman Genomics, UK using 
BigDye® version 3.1 chemistry (Applied Biosystems, Carlsbad, CA) using a 
corresponding forward or reverse primer. Chromatograms were checked for 
miscalled nucleotides by visual inspection of chromatograms using BioEdit v7·1·3 
software. Sequences were aligned using MUSCLE (Edgar, 2004), and maximum 
likelihood phylogenetic trees constructed using MEGA 6 (Tamura K et al., 2011). 
Trees were generated following gap exclusion and corrections for multiple 
substitutions using the best-fit substitution model for the data set detected by 
MEGA 6 (Kimura, 1980).  
 The statistical robustness and reliability of the branching order within each 
phylogenetic tree were confirmed by bootstrap analysis using 1000 replicates. 
Bootstrap values >70% were considered to be reliable.   
2.9.2  454 Pyrosequencing analysis  
Amplicon sequencing was performed on a 454/Roche GS FLX platform following 
manufacturer’s instructions. Each sample was amplified independently with 
fusion primers, including 454 primer keys (A and B for forward and reverse 
primers, respectively), a different multiple identifier (MID) for each sample and 
HCV-specific primers. 
 454 pyrosequencing reads were de-multiplexed using a custom Perl script 
that identified the forward and reverse barcodes allowing a single mismatch in 
the reverse barcode. Each read was compared to a reference set of sequences 
from the Los Alamos HCV database and quality checked by comparing it in a 
pairwise alignment to the best reference match (Kuiken et al., 2008). The 
quality of the reads was assessed by a Phred quality score which is a measure of 
the quality of the identification of the bases generated by automated DNA 
sequencing (Table 2-2). Phred quality scores are defined as a property which is 
logarithmically related to the base-calling error probability (Ewing and Green, 
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1998, Ewing et al., 1998). A read was excluded from the dataset if it had 
mutations relative to the reference below a Phred score of 25, and if there was 
only a single copy of the read, thus keeping a conservative set of sequences with 
high-quality scores.  
 All scripts were created by Dr Joseph Hughes and are available on Github 
(https://github.com/josephhughes/HCVtoolbox). The sequences obtained from 
each patient sample were then aligned against a complete reference set of HCV 
sequences using MAFFT (Katoh and Standley).  
 All valid reads were clustered using CD-HIT with a parameter of similarity 
of 90% to assign different variants detected in each sample (Fu et al., 2010). 
These variants were aligned with post-treatment variants that had been 
detected using clonal analysis as well as reference sequences of different 
genotypes from Los Alamos HCV database using MUSCLE (Edgar, 2004).  
 Maximum likelihood phylogenetic trees were constructed using MEGA 6 
(Tamura K et al., 2011). All sequences generated were submitted to the 
European Nucleotide Archive (ENA; study accession PRJEB4613).   
2.9.3 Illumina
®
 sequencing and analysis 
For the preparation of libraries for Illumina® deep sequencing, pooled amplicons 
in equimolar concentration were generated using either a Nextera XT® DNA 
sample preparation kit (Illumina®) or a KAPA HiFi Real-Time PCR Library 
Amplification® and Index kit (Illumina®) according to modified versions of the 
manufacturer’s protocol. The optimisation of the sequencing platform was 
carried out in High Throughput Sequencing (HTS) facility in MRC- University of 
Glasgow Centre for Virus Research in collaboration with Dr Gavin Wilkie.  
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Figure 2-2: Workflow for PCR Purification using Agencourt AMPure XP® beads. 
 
1. AMPure XP. 2. Bind DNA fragments to paramagnetic beads. 3. Separation of beads + 
DNA fragments from contaminants. 4. Wash beads + DNA fragments twice with 70% 
Ethanol to remove contaminants. 5. Elute purified DNA fragments from beads. 6. 
Transfer to a new tube (Source: Beckman Coulter user guide 2013). 
Table 2-2: Phred quality scores. 
Phred Quality Score Probability of incorrect base call Base call accuracy 
10 1 in 10 90% 
20 1 in 100 99% 
30 1 in 1000 99.90% 
40 1 in 10,000 99.99% 
50 1 in 100,000 100.00% 
60 1 in 1,000,000 100.00% 
The scores are logarithmically linked to error probabilities. 
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2.9.3.1 KAPA® HiFi Real-Time PCR Library Amplification kit 
PCR amplicons were washed, purified and size-selected using Agencourt Ampure 
XP® beads (Beckman Coulter) and subsequently quantified on a Qubit® 2.0 
Fluorometer using a Qubit® dsDNA High-Sensitivity kit (Invitrogen, Life 
Technologies). Library preparation including end repair, A-tailing, and adapter 
ligation was performed using the KAPA® HiFi Real-Time PCR Library Amplification 
kit for Illumina® libraries (KAPA Biosystems), with wash and purification steps, 
carried out using Agencourt Ampure XP® beads.  
 The A-tailed PCR amplicons were ligated to NEBNext® Multiplex Oligos for 
Illumina® (New England Biolabs) using a strict 10:1 molar ratio of adapter to PCR 
amplicon. End-repair of the forked adapters was carried out using either Index 
Primer Set 1 or 2 (New England Biolabs) and the qPCR reaction was stopped 
between fluorescent standards 2 and 3 as recommended in the KAPA HiFi Real-
Time PCR Library Amplification kit.  
 Adapter ligated products were size-selected using Ampure XP® beads and 
visualised on an Agilent 2200 TapeStation system using a D1K ScreenTape® 
(Agilent Technologies). The adapter-ligated libraries were then quantified using 
the KAPA SYBR® FAST ABI Prism qPCR library quantification kit (KAPA 
Biosystems). A library with equimolar concentrations of different samples was 
then processed on the MiSeq platform. 
2.9.3.2 Nextera XT® DNA sample preparation  
The Nextera XT® DNA Sample Preparation kit contains a synthetically engineered 
transposome, which is used to cut DNA strands into  an average of 300 base pair 
(bp) fragments and simultaneously tag the DNA with adapter sequences. The 
adapter sequences contain binding sites for dual index sequences unique to each 
sample library as well as two flow cell attachment sites (Figure 2-3).  
 Input DNA Quantitation and tagmentation 
The Nextera XT® DNA Sample Preparation library preparation procedure utilizes 
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a biological DNA fragmentation step and is a more sensitive way to fragment DNA 
than mechanical fragmentation methods. In addition, only 1 ng input DNA is 
needed. A fluorometric based method specific for duplex DNA (Qubit® dsDNA BR 
Assay) was used for accurate quantification of the DNA library as detailed in 
Section 2.8.  During the tagmentation step, DNA is “tagmented” (tagged and 
fragmented) using the Nextera XT® transposome. The transposomes fragments 
input DNA and add adapter sequences to the ends of each DNA fragment. The 
DNA fragments are amplified by non-specific PCR in subsequent steps. 
 First, 10 μL of Tagment DNA Buffer (TD) Buffer was added to a 0.2 ml tube, 
then 5 μL of input DNA at 0.2 ng/μL (1 ng total) added to each tube, followed by 
5 μL of Amplicon Tagment Mix (ATM). Next, the reaction was mixed and 
centrifuged at 280g for 1 minute at 20°C.  
 Finally, the reaction was placed in a thermocycler as follows: 55°C for 5 
min, then held at 10°C. Once at 10°C, neutralization was started by adding 5 μL 
of Neutralisation Tagment Buffer (NT) to each reaction, mixed gently and 
centrifuged at 280g for 1 minute. The samples were left at room temperature 
for 5 minutes. 
 PCR Amplification: 
During this step, tagmented DNA is amplified via a limited-cycle PCR program. In 
addition to the PCR step, index 1 (i7) and index 2 (i5) and sequences required for 
cluster formation are added. After thawing the Nextera PCR Master Mix (NPM) 
and the index primers at room temperature for 30 min, 15 μL of NPM was added 
to each reaction tube containing 5μL of each index and mixed gently.  
 Next, the reaction was centrifuged at 280g at 20°C for 1 minute, PCR was 
performed in a thermocycler using the following protocol: 72°C for 3 min, 95°C 
for 30 sec, then 12 cycles of: denaturation at 95°C for 10 sec, annealing at 55°C 
for 30 sec, extension at 72°C for 30 sec, followed by 72°C for 5 min and a final 
hold at 10°C. 
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 PCR Clean-Up 
In this step, the amplified DNA was purified using AMPure XP magnetic beads as 
described in Section 2.7.2. 
2.9.3.3 Sequence library quality control  
The Agilent 2200 TapeStation® system (Agilent Technologies) automates RNA and 
DNA sample quality control (QC), including sample loading, separation, and 
imaging. Different screen tapes are available for RNA and DNA analysis 
performed on an automated gel electrophoresis system. 
 For RNA analysis (post-extraction), 1 μL of sample buffer R6K was added to 
2 μL of RNA, incubated at 72°C for 3 min, placed on ice for 2 min and loaded 
into TapeStation® microtubes. DNA quality and size were tested using a similar 
technique; 2 μL of DNA was added to 2 μL of D1K sample buffer and loaded into 
the Tapestation.  
2.9.3.4 Illumina® sequencing using the MiSeq platform 
The sequence of the DNA strands was determined using a four colour cyclic 
reversible termination technique, based on the use of dye-labelled modified 
nucleotides. The colour of the dye, and hence the type of nucleotide, is 
detected via total reflection fluorescence (TRIF) imaging using two lasers. The 
flow cell attachment sites randomly bind to complementary oligonucleotides on 
the flow cell. This random ligation with either P5 or P7 attachment sites allows 
for paired-end sequencing (i.e. both in forward and reverse direction). The 
following process of bridge amplification causes the formation of amplified 
clusters of single-stranded DNA (Figure 2-4). 
 
Chapter 2: Materials and Methods 
100 | P a g e  
Figure 2-3: Nextera XT workflow. 
 
 
A) Nextera XT transposome with adapters is combined with template DNA, 
B) Tagmentation to fragment and addition of adapters, C) Limited cycle PCR to add 
sequencing primer sequences and indices; SP: sequencing primer. D) Sequence-Ready 
Fragment. 
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  Denaturation of library 
To denature the samples, 1 ml of 0.2 N NaOH was prepared in a 1.5 ml 
eppendorf tube by mixing 800 μL of laboratory-grade water (Qiagen) and 200 μL 
from 1.0 N Stock NaOH (Sigma, UK). The tube was inverted several times to mix. 
Following that, 10 μL of 4nM sample DNA and 10 μL of 0.2 N NaOH were 
combined in a microcentrifuge tube.  
 The sample was mixed by vortexing followed by centrifugation for 1 minute 
and incubated for 5 min at room temperature to allow the denaturation of DNA 
into single strands. Next, 980 μL of pre-chilled hybridization buffer (HT1) was 
added to 20 μL denatured DNA to result in a 20 pM denatured library in 1ml of 
0.2M NaOH and placed on ice. The final DNA concentration was 12 pM, using 360 
μL of 20 pM of denatured DNA and 240 μL of HT1. The final reaction was mixed 
by inverting the tube several times followed by centrifugation. The denatured 
and diluted DNA was placed on ice until it was loaded into the MiSeq reagent 
cartridge. 
 Phi X control 
A Phi X 174 (phiX) bacteriophage genome library provided a quality control for 
cluster generation, sequencing, and alignment and a calibration control for 
cross-talk matrix generation, phasing, and prephasing. It can be rapidly aligned 
to estimate relevant sequencing by synthesis (SBS) metrics such as phasing and 
error rate. Phi X control DNA (Illumina®, UK) was diluted to 4 nM by adding 2 μL 
of a 10nM stock solution to 3 μL H2O.  
 The Phi X library was denatured by adding 5 μL of 0.2 N NaOH to 5 μL Phi X, 
then vortexed and incubated at room temperature for 5 min. This was then 
diluted to a concentration of 20 pM by adding 980 μL HT1 buffer and diluted 
again to the same loading concentration as the DNA library. 100 μL of Phi X was 
added to 90 μL DNA library to provide a final library with a 10% concentration of 
Phi X.   
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 Loading the flow cell and buffer. 
The flow cell (provided with the MiSeq reagent kit) was removed from its buffer 
and washed with distilled H2O. It was dried with a lint-free wipe, ensuring that 
the inlet and outlet ports were clear, and the surface was clean and dust-free. 
The flow cell was loaded onto the MiSeq instrument. The chiller compartment 
was opened and wash bottle removed and replaced with incorporation buffer 
(PR2). The reagent cartridge was loaded into the machine, and the run started.  
2.9.3.5 Bioinformatic analysis of Illumina® sequence data 
Sequence reads were demultiplexed using the unique dual indexes attached to 
either end of each read and checked for quality using FastQC® (Babraham 
Bioinformatics). Reads below a Phred quality score of Q20 (99% accuracy) were 
discarded and the remaining reads then trimmed to remove low-quality areas 
towards the end of the sequence, leading to a final quality score of Q30 (99.9%) 
or above using the Phred score algorithm. Remaining reads were then trimmed 
to remove low-quality areas towards the end of the sequence. 
 Sequence data were uploaded in fastq format and mapped to consensus 
reference sequences on a dedicated computer server. Full-length genomes were 
assembled using an in-house alignment program based on the BLAST algorithm 
(Tanoti) developed by Dr Sreenu Vattipally. Alignments were visualised using 
Ugene® and regions of interest including resistance mutation sites were 
annotated. Variant frequencies were calculated using an in-house script 
(Mutation report) designed by Dr Sreenu Vattipally. 
 103 | P a g e  
Figure 2-4: Workflow of Illumina sequencing. 
 
 
 
 
 
 
 
 
 
 
Cluster strands created by bridge amplification are primed and all four fluorescently labeled, 3′-OH blocked nucleotides are added to the flow cell with 
DNA polymerase. B) Optics system scans each lane of the flow cell by imaging units called tiles. Reproduced with permission from Dr Elaine Mardis 
(Mardis, 2008). 
A B 
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2.10 Full genome sequencing 
Two protocols for full genome sequencing of HCV were developed using the 
Illumina® platform; a PCR-based (Amplicon) and a metagenomic approach. 
2.10.1 Nested PCR-based full genome sequencing of HCV 
To maximize PCR sensitivity, the genome was divided into four amplicons that 
were numbered sequentially 1 to 4 starting from the 5' end of the genome. Each 
amplicon was less than 3 kb and overlapped with adjacent amplicons (Figure 
2-5).  
2.10.1.1 Primer nomenclature and design 
Primer nomenclature included the amplicon number A (1-4), polarity (F-R) and 
relative position on the H77 reference genome. Genotype 1a specific primers 
were designed that were effective for amplifying all amplicons in a reproducible 
manner; the design of nine primers was based on those published previously 
either completely matched or modified (Yao and Tavis, 2005).  
We optimized more than one combination for each amplicon. The three 
anti-sense primers must reside 3' to all three sense primers for the downstream 
amplicon to prevent gaps between the amplicons. 
All primer combinations were selected based on melting temperature and 
length of primers while avoiding sequences prone to dimer or hairpin formation 
or self-complementary primers using web-based software; 
http://www.thermoscientificbio.com/webtools /multipleprimer. Candidate 
primers of 16-20 nucleotides were designed and compared to the 1a alignment 
from which the reference sequence was generated. For positions with 
unavoidable variability within the primer, degenerate positions were introduced 
in primers with no more than 4 degenerate sites included for each primer. 
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2.10.1.2 Optimisation of PCR conditions  
Conditions with the largest impact on assay performance included the use of 
genome-specific primers in reverse transcription and the addition of a second 
nested PCR reaction to increase the sensitivity of the assay to ~1000 copies/µL 
of HCV RNA. Nested PCR reactions were assembled in two volumes; 25 µL and 50 
µL, including 5 µL of cDNA from the RT reaction as template for the first round 
PCR and different volumes (1 µL, 2 µL and 5 µL) of first round PCR product as 
template for the second PCR, for every pair of primers.  
 The PCR conditions were tested using touchdown PCR (ramping annealing 
temperatures) for increased specificity. Varying annealing temperatures were 
retested once a primer pair was optimised (42°C,48°C, 50°C, 52°C, 56°C, 60°C), 
and different extension times and number of cycles were tested. A PCR hood and 
aerosol barrier tips were used for assembly of all reactions to avoid cross-
contamination. Negative controls lacking template were included for each pair 
of primers. If any negative control was positive, all PCR reactions in that set 
were deemed to be contaminated and were discarded. Phusion® enzyme 
(Finnzymes) was used as it had the lowest error rate as described in Section 
3.2.1 and showed high sensitivity for this large-scale sequencing project.  
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Figure 2-5: PCR (Amplicon) amplification strategy. 
 
 
 
The HCV genome was covered by four overlapping amplicons (Amp 1, Amp 2, Amp 3, Amp 4). 
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Table 2-3: Primer sets and optimised conditions for amplicon 1. 
NAME SEQUENCE 
(Tm) 
Finnzymes 
(Tm)      
Allawi 
GC% Nt 
T1F20   CGACACTCCACCATGAATCAC 65.9 56.1 52.4 21 
T1F30   CCATGAATCACTYCCCTGT 61.6 53 50 19 
T1F81   AGCCATGGCGTTAGTATGAG 62.1 54 50 20 
T1F158  GGTGAGTACACCGGAATTG 61 53.4 52.6 19 
T1F198  TTGGATAAACCCGCTCAAT 62.3 51.9 42.1 19 
T1F210  GCTCAATGCCTGGAGATTT 62.3 53.3 47.4 19 
T1F463  GCCCTAGATTGGGTGTG 59.6 53 58.8 17 
T1R2354 CTGYGTGGTGGACARCAG 63.6 56.4 61.1 18 
T1R2376 GARCACGGRAGRACCTG 61 54.1 61.8 17 
T1R2555 CATCATCCACAARCAGGAG 61.1 52.4 50 19 
T1R2576 CTCYRCYTGGGATATGAG 57.2 50.4 52.8 18 
T1R2573 CGCYTGGGATATGAGTARC 60.2 52.8 52.6 19 
T1R2670 CCAYGCAAAGCAGAAGAAC 62.7 53.9 50 19 
The annealing temperature was calculated using two equations (Allawi, Finnzymes), 
primers shaded in dark grey were adapted or modified from those published by Yao et 
Tavis 2005, GC% is the GC content in each primer, Nt represent the number of 
nucleotides in each primer. 
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Table 2-4: Primer sets for amplicon 2. 
NAME SEQUENCE 
(Tm) 
Finnzymes 
(Tm) 
Allawi 
GC% Nt 
T2F2084 CCCCACTGAYTGYTTC 56.5 50.3 56.3 16 
T2F2413 CCTCCACCAGAACATYGTG 63.4 54.8 55.3 19 
T2F2471 GTCCTGGRCCATYAAGTG 60.3 53.2 55.6 18 
T2F2580 GCTTTGGARAACCTYG 55.7 28.3 50 16 
T2F2657 CTGCTTTGCRTGGTAYCTG 62.4 54.3 52.6 19 
T2R4548 GYTCGTCRCACTTYTTCT 57.2 51.5 47.2 18 
T2R4651 GTCGACACGACGACAACAT 62.9 55 52.6 19 
T2R5020 CCCTCCCAAAAYTCAAGRTG 64.7 54.2 50 20 
T2R5039 GTGAGRCCYGTRAAGACG 60.6 54.2 58.3 18 
T2R5230 GCRCCCAGTCTGTAYAGC 60.8 55.8 61.1 18 
T2R5252 CAGGGTGAYYTCATTCTG 57.7 50.4 50 18 
T2R5469 CTTCCATCTCATCGAACTC 57.8 50.2 47.4 19 
T2R5536 GCCTTCTGCTTGAACTG 57.6 51.5 52.9 17 
The annealing temperature was calculated using two equation (Allawi, Finnzymes), 
primers shaded in dark grey are adapted or modified from those published by Yao et 
Tavis in 2005, GC% is the GC content in each primer, Nt represent the number of 
nucleotides in each primer.  
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Table 2-5: Primer set for amplicon 3.   
NAME SEQUENCE 
(Tm)    
Finnzymes 
(Tm)             
Allawi 
GC% Nt 
T3F4725 GTCGAYTTYAGCCTTGACC 61 53.7 52.6 19 
T3F5067 ACAAAGCAGAGTGGGGARA 62.8 55.1 50 19 
T3F4911 GGCTGYGCTTGGTATGAG 62.5 55.2 58.3 18 
T3F4742 CCCTACCTTYACCATTGAG 58.3 51.4 50 19 
T3F5520 CAGTTCAAGCAGAAGGC 57.6 51.5 52.9 17 
T3R7109 GAARGAGTCCAGAAYCAC 54.8 50 50 18 
T3R7547 GTCGCTRAGATCCGGATC 62.1 53.7 58.3 18 
T3R7402 CTGCCAAARCTYTTGGTG 61.2 52.5 50 18 
T3R6987 GCAAGTTGCYTTGAGRG 58.8 51.7 52.9 17 
T3R7079 GACTCRACCCTGGTGATG 60.9 54 58.3 18 
The annealing temperature was calculated using two equations (Allawi, Finnzymes, GC% 
is the GC content in each primer, Nt represents the number of nucleotides in each 
primer. Primers shaded in dark grey are adapted or modified from those published by 
Yao et Tavis 2005. 
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Table 2-6: Primer sets for amplicon 4. 
NAME SEQUENCE 
(Tm)                   
Finnzymes 
(Tm)               
Allawi 
GC% Nt 
T4F6290 GATATGCGAGGTGYTGAG   58.6 51.8 52.8 18 
T4F6707 CACAGAAYTGGACGGGGT   64.2 56.1 58.3 18 
T4F7085 CAAAGTGGTGRTTCTGG 56.6 49.6 50 17 
T4F7238 GACGTGGAAAAAGCCKGAC 65 55.9 55.3 19 
T4R9214 GGAGTGAGTTTRAGCTTTGT 57.3 51.8 42.5 20 
T4R9575 CGTGACTAGGGCTAAGATGG 61.7 54.8 55 20 
T4R9638 TGCAGAGAGGCCAGTATCA 62.8 55.3 52.6 19 
The annealing temperature was calculated using two equations (Allawi, Finnzymes), 
primers shaded in dark grey are adapted or modified from those published by Yao et 
Tavis 2005, GC% is the GC content in each primer, Nt represents the number of 
nucleotides in each primer.   
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2.10.2 Metagenomic sequencing  
RNA was extracted from 400 μL of plasma using the automated easyMAG® system 
according to manufacturer’s instructions and eluted in a final volume of 60 μL of 
elution buffer. For RNA library preparation, first strand cDNA was synthesized 
from half of the RNA volume obtained during purification (concentration usually 
undetectable using Qubit®) using reverse transcriptase (SuperScript III, 
Invitrogen). Double-stranded cDNA was synthesised using a NEBNext® mRNA 
Second Strand Synthesis Module (New England Biolabs).  
 DNA samples were purified using Agencourt AMPure magnetic beads® 
(Beckmann Coulter). The dsDNA was then prepared for Illumina® sequencing 
using a Nextera XT kit®. The resulting libraries were size selected prior to 
processing on the MiSeq® platform. 
2.11 Bacterial cloning   
Bacterial cloning was used in a number of experiments including clonal analysis 
of purified PCR products and replicon assays.  For the clonal analysis of PCR 
amplicons, two different kits were used; the TOPO-TA® Cloning kit (Invitrogen) 
and CloneJet® (Thermo Scientific). A variety of Escherichia coli (E. coli) cells 
were used; One Shot® TOP10 Chemically Competent E. coli  (Invitrogen), NEB 5-
alpha Competent E. coli® and NEB 10-beta Competent E. coli®. 
2.11.1 TOPO-TA
®
 Cloning  
An aliquot (2-4 μL) of PCR product was added to 0.5-1 μL of salt solution (1.2M 
NaCl plus 0.06M MgCl2) and 1 μL of TOPO
® vector and incubated at room 
temperature for 5-30 min. Ligation of the PCR product disrupts expression of the 
lethal E. coli suicide gene ccdB permitting growth of only positive colonies upon 
transformation in One Shot® TOP10 cells (Invitrogen). 
 The cloning reaction (2 μL) was added to a vial of chemically competent 
One Shot® TOP10 E.coli cells and incubated on ice for 30 min. The cells were 
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then heat-shocked for 30 sec at 42°C in a water bath and transferred back to 
ice.  250 μL of room temperature SOC medium (2% tryptone, 0.5% yeast extract 
10 mM NaCl, 2.5 mM KCl, 10 mM MgCl2, 10 mM MgSO4, 20 mM glucose) was added 
to each vial, capped and shaken horizontally (300 rpm) at 37°C for 1 hour.  
 An aliquot of 100 μL from each transformation was spread on a pre-warmed 
agar plate containing 100 μg/ml ampicillin or 30 μg/ml tetracycline depending 
on the plasmid antibiotic selection gene and incubated overnight at 37°C. 
Incorporation of the insert into the plasmid disrupts transcription of the suicide 
gene, enabling selection of all clones containing the product. 
2.11.2  CloneJET
®
 PCR cloning  
For cloning blunt-end PCR products generated by proofreading DNA polymerases, 
the purified DNA fragment was ligated in a 3:1 molar ratio into the vector  
pJET1.2/blunt (Appendix 7.33). The ligation reaction was prepared on ice by 
adding: 10 μL of 2X Reaction Buffer, pJET1.2/blunt Cloning Vector (50 ng/μL), 
T4 DNA Ligase, purified PCR product and nuclease-free water to make the 
reaction volume up to 20 μL. The reaction mix was vortexed briefly, centrifuged 
for 5 sec and incubated at room temperature (22°C) for 5 min, then used 
directly for transformation. 
2.11.3 One shot
®
 Top 10 cells 
Two μL of the TOPO® cloning reaction was added to a vial of One Shot® 
Chemically Competent E. coli and mixed gently, followed by incubation on ice 
for 30 min. The cells were then heated for 30 sec at 42°C without shaking (heat-
shock). Immediately, the tubes were transferred to ice, and 250 μL SOC medium 
at room temperature added. After capping the tubes tightly, they were shaken 
horizontally (300 rpm) at 37°C for 1 hour. 100 μL of cells in the medium was 
then spread on a pre-warmed Agar plate and incubated overnight at 30°C. 
2.11.4  NEB 5-alpha competent  E. coli
®
  
A tube of NEB 5-alpha competent E. coli cells was thawed on ice for 10 min, 
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followed by the addition of 1-5 µL of H2O containing an average of 50 ng of 
plasmid DNA to the cell mixture. The tube was flicked 4-5 times to mix the cells 
and DNA, then placed on ice for 30 min without mixing. The mixture was 
exposed to heat shock at 42°C for 30 sec; then cells were placed on ice for 5 
min. 950 µL of room temperature SOC was next added to the mixture and 
incubated at 37°C for 60 min while shaking vigorously (300 rpm). 100 μL from 
each transformation was spread on a pre-warmed selective plate and incubated 
at 30°C for 24-36 hours.  
2.11.5  NEB 10-beta competent  E. coli
®
 
A tube of NEB 10-beta Competent E. coli cells was thawed on ice for 10 min, 
followed by the addition of 1-5 µL of H2O containing 1 pg-100 ng of plasmid DNA 
to the cell mixture. The tube was flicked 4-5 times to mix cells and DNA, then 
placed on ice for 30min, then exposed to a heat shock at 42°C for 30 sec and 
left on ice for 5 min. 950 µL of room temperature SOC was added to the mixture 
at 37°C for 60min while shaking vigorously at 300 rpm. 100 μL from each 
transformation was spread on a pre-warmed selective plate and incubated at 
30°C for 24-36 hours.  
2.12  Preparation of DNA following bacterial cloning  
Purified DNA was quantified using a Qubit® machine, and spectrophotometry 
(Nanodrop®) was carried out to assess the purity of DNA produced using the ratio 
of values obtained at A260/A280. Successful transformation was confirmed by 
restriction digest, which cuts the plasmid at two sites, generating two linear 
fragments of DNA. Digested products were run on a 1-2% agarose gel stained with 
ethidium bromide and visualised under ultraviolet light. 
2.12.1  Small scale plasmid preparation from transformed bacteria 
A single colony from a freshly streaked selective agar plate was selected and 
used to inoculate a 5 ml culture of LB with selective antibiotic (tetracycline 
30µg/ml). Following culture for 24-48 h at 30 ºC with vigorous shaking (180 rpm), 
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the bacteria were centrifuged in an Eppendorf microcentrifuge at 13,000 rpm 
and the DNA extracted from the bacterial pellet using the GeneJET® Plasmid 
Miniprep Kit (Thermo Scientific) according to the manufacturer’s instructions.  
 All purification steps were carried out at room temperature. All 
centrifugation steps were carried out in a microcentrifuge at 13,300 rpm and 
pelleted cells were resuspended in 250 µL of Resuspension Solution. To ensure 
complete suspension of bacteria, vortexing and pipetting up and down were 
carried out until no cell clumps were apparent. 250 µL of Lysis Solution was next 
added and mixed thoroughly by inverting the tube 4-6 times until the solution 
became viscous and slightly clear. This was followed by the addition of 350 µL of 
Neutralization Solution and mixed immediately and thoroughly by inverting the 
tube 4-6 times. The mixture was then centrifuged for 5 min to pellet cell debris 
and chromosomal DNA.  
 The supernatant was transferred to a supplied GeneJET® spin column by 
decanting or pipetting and centrifuged for 1 min. A wash step was carried out by 
adding 500 µL of Wash Solution to the GeneJET® spin column, then centrifuged 
for 30-60 sec and the flow-through discarded. This wash step was repeated, and 
the column was centrifuged for an additional 1 min to remove residual Wash 
Solution. The elution step was carried out by adding 50 µL of elution buffer to 
the centre of the GeneJET® spin column membrane after transferring the 
GeneJET® spin column into a fresh 1.5 ml microcentrifuge tube. The tube was 
incubated for 2 min at room temperature and then centrifuged for 2 min. The 
purified plasmid DNA was stored at -20°C. 
2.12.2  Large scale plasmid preparation from transformed bacteria 
A single colony from a freshly streaked selective agar plate was selected and 
used to inoculate a 5 ml starter culture of LB-selective antibiotic (tetracycline 
30µg/ml). Following a 24 hour incubation, the starter culture was diluted 1:1000 
into 100 ml of LB with antibiotics and cultured for 24-36 h (to an OD 600 of 2-3) 
at 30 ºC with vigorous shaking (180 rpm). The bacteria were then harvested by 
centrifugation at 5,000 g for 10 min at 4 ºC.  
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A large-scale DNA preparation was then made from the bacteria using a 
GeneJET® Plasmid Midi Prep Kit.  
 Pelleted cells were resuspended in 2 ml of resuspension solution as above 
and incubated for 3 min at room temperature 2 ml of Neutralization Solution was 
added and mixed immediately and thoroughly by inverting the tube 5-8 times, 
followed by addition of 0.5 ml of endotoxin binding reagent. The reaction was 
mixed immediately as above then incubated for 5 min at room temperature. 
After adding 3 ml of 96% ethanol, the tube was mixed by inverting the tube 5-6 
times and then centrifuged for 40 min at 4,000-5,000Xg to pellet cell debris and 
chromosomal DNA.  
 The supernatant was transferred to a 15 ml tube by decanting and 
pipetting, and 3 ml of 96% ethanol added and mixed by inverting the tube 5-6 
times. Part of the sample (~ 5.5 ml) was transferred to the supplied column pre-
assembled with a collection tube (15 ml), then centrifuged for 3 min at 2,000g in 
a swinging bucket rotor. The step was repeated after discarding the flow-
through and placing the column back into the same collection tube until all 
remaining lysate was processed through the purification column. 4ml of wash 
solution I was added to the purification column, followed by centrifugation for 2 
min at 3,000Xg in a swinging bucket rotor. A second wash step was carried out 
by adding 4 ml of wash solution II to the purification column, followed by 
centrifugation for 2 min at 3,000Xg in a swinging bucket rotor; this step was 
repeated to remove residual wash solution. 
 For elution, the column was transferred to a fresh 15 ml collection tube, 
0.35 ml of Elution Buffer added to the centre of the purification column 
membrane and incubated for 2 min at room temperature followed by 
centrifugation for 5 min at 3,000Xg to elute plasmid DNA. The purified plasmid 
DNA was stored at -20°C.    
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2.13 Mock community 
The focus of this project was to test the suitability of Illumina® sequencing for 
haplotype reconstruction by assessing coverage, error profiles, trimming/ 
filtering strategies, barcode switching and two haplotype reconstruction 
programmes; QuRe and PredictHaplo. 
2.13.1 Preparation of the mock community 
One sample from an HCV-infected patient (genotype 1a) was amplified using the 
Amp 1 primer set described earlier to produce a PCR product of an average size 
of 2.5kb. These PCR products were cloned using CloneJet® (Thermo Scientific). A 
mock community was created using 13 clones containing around 2.5 kb 
fragments of HCV viral variants (sequence divergence 0-0.9%). The 13 clones 
were mixed with log-normal abundance with a range of frequency of [3.2-
30.3%]. 
2.13.2 MiSeq sequencing 
All clones were prepared for Illumina® sequencing using Nextera XT®, and one 
dual index for the whole community. The sample was sequenced in triplicate. 
2.13.3 Haplotype reconstruction 
Quasispecies assembly was carried out with QuRe software v0.9994 
(http://sourceforge.net/projects/qure/), and PredictHaplo v0.4 software 
(http://bmda.cs.unibas.ch/HivHaploTyper). The quasispecies reconstruction 
method of QuRe employs a method based on an overlap graph constructed over 
sliding windows, selecting candidate variants using an algorithm based on 
overlap consistency and similarity of frequency distributions of variants in each 
window (Prosperi and Salemi, 2012), whilst PredictHaplo extends the sliding 
window Bayesian clustering approach to a global quasispecies inference based on 
a hidden Markov model (Schirmer et al., 2014). 
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2.14 Statistical analysis  
Statistical analysis was performed using the statistical computer package 
GraphPad prism® V6. P-values of less than or equal to 0.05 were considered to 
be statistically significant. 
2.15 Bioinformatics methods for viral sequence analysis  
2.15.1 Sequence alignment  
Sequences were aligned in fasta format in an open reading frame using MUSCLE 
(www.ebi.ac.uk/muscle) as an integrated tool in Mega 6 software. 
Chromatograms were visualised and sequences edited manually using BioEdit® or 
CLC Genomics 6®. 
2.15.2 Measures of diversity 
Viral diversity can be measured using a variety of phylogenetic and statistical 
techniques based on sequence differences (Figure 2-6). Kimura introduced the 
theory of "neutral evolution" based on the observation that many genetic 
mutations are random events and may not confer phenotypic change (Kimura, 
1980). This model may be used in the analysis of variation in HCV viral 
quasispecies, that occur largely as stochastic (random) events due to the error 
prone RNA-dependent RNA polymerase.  
 Provided the population size is large enough, some mutations may occur 
which are beneficial and increase in frequency in a population because of 
natural selection. Others may be neutral and persist due to random genetic 
drift; these changes, however, take longer to arise than adaptive mutations. 
This phenomenon can be measured by comparing genetic sequences and taking 
into account whether or not RNA sequence changes encode changes in the 
translated amino acid sequence.  
 Different measures of diversity were estimated using a script 
(FastaDiversity.sh) designed by Dr Joseph Hughes. It uses a fasta file of 
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sequences to measure i) Richness: how many different sequences are present 
within the dataset, ii) Shannon Index: When all sequences are equally abundant, 
the Shannon index takes the value of log(R). The more unequal the abundance 
e.g. with almost all abundance concentrated in one type and other very rare 
sequences, the Shannon index approaches zero when the Shannon entropy is 
zero iii) Simpson Index: the probability that two sequences taken at random 
from the dataset are the same (Figure 2-7). 
 Genetic diversity was calculated using the Hamming distance, which is 
defined as the number of amino acid differences between two sequences using 
the formula (1 - s) x 100, where s is the fraction of shared sites in two aligned 
nucleotide sequences.  
 Genetic distance was calculated as the mean percentage difference 
between all samples at any time point. Mean intra-strain corrected genetic 
distance, and Hamming distances were also calculated (separate strains were 
defined as those originating from distinct branches following phylogenetic 
analysis with >10% difference from other strains derived from the same patient) 
(Ota and Nei, 1994). 
 Intra-host sequence diversity was measured using mean pairwise diversity 
(Pi) and compared between groups using t-tests and two-sample tests controlling 
for dependency in the data structure as described previously (Gilbert et al., 
2005). The sequences from each patient were also placed on a reference 
phylogeny using the maximum-likelihood placement methods available in pplacer 
(Matsen et al., 2010). The quadratic diversity that combines abundance and 
relatedness data and phylogenetic entropy that only characterize relatedness 
were estimated from the phylogenies and compared between groups as detailed 
previously (Rao, 1982, Allen et al., 2009). 
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2.15.3 Mapping  
Recent advancements in deep sequencing technologies have resulted in the 
generation of longer sequence reads (>150 bp) providing an opportunity to map 
them using a BLAST-based approach, optimised by simultaneous searching.  
Using this approach, Dr Sreenu Vattipally has developed an in-house assembler 
named “Tanoti” (http://bioinformatics.cvr.ac.uk/Tanoti), the first fast mapping 
program to successfully map long reads using BLASTN. Batch processing and 
efficient memory management make Tanoti extremely robust, requiring minimal 
computer resource usage, without compromising speed and sensitivity (Vattipally 
B. Sreenu). 
 It was evident from viral genome mapping comparisons that Tanoti is faster 
and a more sensitive mapper than its counterparts and can reliably deal with 
data containing insertions and deletions. It achieves fast search speed by 
adopting batch processing and well-regulated simultaneous searching of reads.  
Local search algorithms, better gap handling, low consumption of computational 
resources and high speed and accuracy make Tanoti an efficient program for 
mapping divergent reads from small genomes. 
2.15.4 Construction of phylogenetic trees  
Phylogenetic trees may be produced using exhaustive search methodology or 
stepwise clustering. Exhaustive search methods evaluate all possible tree 
topologies and apply criteria to select the most likely candidate. However, with 
increasing numbers of sequences, increasingly large numbers of possible trees 
may be produced, resulting in a lengthy analysis. Stepwise clustering methods 
overcome this problem by grouping sequence data together to form clusters with 
each new sequence compared to a cluster, thereby reducing computing time 
(e.g. Neighbour-Joining (NJ) tree).  
 Examples of exhaustive search methods are maximum parsimony (selects a 
tree with the smallest number of mutations required to generate internal nodes 
for each sequence) and maximum likelihood (ML) trees.  
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As Maximum likelihood outperforms neighbour joining under comparable 
conditions, ML trees were used in the construction of phylogenetic tree in this 
study (Huelsenbeck, 1995). 
 Sequences were aligned using MUSCLE. Phylogenetic trees were constructed 
with MEGA 6.0 using the maximum likelihood method, and each data set was 
tested for best-fit substitution model, Kimura two-parameter distance for all 
substitutions was the best model in all of our data sets, and the inferred 
phylogenies were tested with 1,000 bootstrap replications.  
2.16  Resistance mutation database 
A systematic review was performed jointly with Weronika Witkowska and Yangie 
Pinanga. Published articles were retrieved from Pubmed, OvidSP, Embase, and 
The Web of Knowledge website without date restriction. The following keywords 
were used: Simeprevir, Paritaprevir, Ledipasvir, Ombitasvir, Daclatasvir, 
Dasabuvir, or Sofosbuvir and 'resistance'. The former names of these drugs were 
also used as keywords: TMC 435, ABT-450, GS-5885, ABT-267, BMS-790052, ABT-
333, or GS-7977. Oral and poster presentations from recent scientific 
conferences/ symposiums related to HCV such as AASLD, EASL, CROI, the 
International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy, 
International Symposium on Viral Hepatitis and Liver Diseases (ISVHLD) were also 
reviewed. 
 Resistance-associated mutations (RAMs) obtained from the literature were 
listed in mutation tables. The tables contain RAMs with reference to the relevant 
DAAs, along with the change in fold-resistance compared to wild type variant 
and the methods used to detect the RAMs. Tables were later utilized to create 
mutation reports for HCV-infected patients in this study. 
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Figure 2-6: Examples of measures of diversity. 
 
Measures of diversity are based on different parameters including richness, evenness, 
and relatedness.  
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Figure 2-7: Relationship between diversity measures. 
 
Measures of diversity according to their sensitivity to abundance and relatedness, 
Modified from (Allen et al., 2009). 
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2.17 Human Hepatoma Cells (Huh7.5) 
Human hepatoma Huh7.5 cells (Huh7 cells cured of the HCV replicon with 
interferon) (Blight et al., 2002), were propagated at 37 °C in an atmosphere of 
5% CO2 in Dulbecco’s modified Eagle’s medium (DMEM
®) supplemented with 10% 
fetal calf serum (FCS) and 1% penicillin/streptomycin.  
 Cell lines were grown in 80 cm2 or 175 cm2 tissue culture flasks (Nunc®). 
Passage of cells (twice weekly) was carried out when cells reached 80% 
confluency by first gently washing cells with 5 ml of ice-cold PBS to the flask and 
pass over the cell surface by gently rotating the flask. This is a wash step to 
remove dead cells and any residual fetal bovine serum. Removal of cells was 
achieved by the addition of 3ml of 0.05% Trypsin /EDTA to the T150 flask 
(Sigma®). Cells were then resuspended in 10 ml of complete DMEM before re-
seeding or use in experiments.  
2.18 In vitro replication assays 
A bicistronic, subgenomic replicon system has been developed to examine the 
RNA synthesis of hepatitis C virus (HCV) genotype 1a (Blight et al., 2000). This 
replicon contains an HCV IRES that directs expression of the neomycin resistance 
gene in the first cistron and an encephalomyocarditis virus (EMCV) IRES to direct 
production of the HCV non-structural proteins NS3–NS5B in the second cistron as 
shown in (Figure 2-8). This replicon was used as a template for the construction 
of a genotype 1a transient replication system as described in Section 2.18.2. 
2.18.1 Site-Directed Mutagenesis 
Mutagenesis reactions were performed using the QuickChange XL® Site-Directed 
Mutagenesis kit (Stratagene). Forward and reverse primers for mutagenesis 
(Table 2-7) were designed to incorporate the desired mutation in the middle of 
the primer sequence and were between 25 and 45 bases in length, according to 
manufacturer’s instructions (Figure 2-9).  
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A Quick-Change PCR reaction was prepared by mixing 5 µL of 10X reaction 
buffer, DNA Plasmid (10 ng),  1.25 µL Forward primer (10µM), 1.25 µL Reverse 
primer (10µM), 1 µL of dNTP mix, 3 µL of QuickSolution reagent, 1 µL of PfuUltra 
HF DNA polymerase and nuclease-free water added to complete a final volume 
of 50 µL. Cycling conditions in the thermocycler were as follows: 1 min at 95°C, 
18X (50 sec at 95°C, 50 sec at 60°C, 1min/kb at 68°C), 7min at 68°C. 
 Following the PCR reaction using QuickChange II XL®, each reaction was 
chilled on ice for 2 min followed by the addition of DpnI (10 U) to digest the non-
mutated dam-methylated parental DNA. Reactions were mixed by pipetting, 
then centrifuged in an Eppendorf microcentrifuge at 13,000 rpm for 1min, 
followed by incubation at 37 ºC for 1 h. DpnI-treated DNA was transformed into 
50 μL NEB 10-beta cells as described in Section 2.11.  
2.18.2 Introduction of mutations into the HCV-1a subgenomic replicon 
All mutations were individually introduced into the TA/SG/Luc/HCV-1a replicon 
by site-directed mutagenesis. Six colonies from each agar plate were selected 
and used to prepare plasmid mini-preps as described in Section 2.12.2. Plasmids 
were sequenced using the appropriate sequencing primers (Table 2-8). Positive 
clones were then restriction digested with ClaI and Bsu36I to remove the 
fragment containing the mutated NS5B sequence, which was subsequently 
ligated back into the parental TA/SG/Luc/HCV-1a vector backbone.  
 The ligation mixture was then transformed into bacteria and used to 
prepare a plasmid maxi-prep. A diagnostic digest was performed on the plasmid 
using ClaI and Bsu36I to confirm the ligation of the desired sequence.  In 
addition, the same sequencing primers; for adaptation mutations (Adaptation-
F645), for NS5B mutations (Robin-F3047, Robin-F4239, Robin-F3502), and Lucy-
Forward were used to verify that no mutation occured accidently during the 
subcloning process. 
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2.18.3 Restriction enzyme digestion of DNA 
All restriction enzyme digests of plasmid DNA were carried out at 37°C for at 
least 1h unless otherwise specified by the manufacturer. Typically, 10U of each 
enzyme per µg DNA were used in a total volume of 50µL. All reactions were 
performed using the appropriate enzyme buffers and BSA if necessary. 
2.18.4 DNA ligation 
A Rapid DNA Ligation Kit® (Thermo Scientific) was used for DNA ligation 
reactions. It was used to introduce an insert into a plasmid vector in the 
subcloning process to insert mutant fragments into the TA/SG/Luc/HCV-1a 
backbone (Table 2-9 and Table 2-10).  
2.18.5 In vitro transcription 
In vitro transcription was carried out using RiboMAX® Large Scale RNA Production 
Systems (Promega) following manufacturer's instructions. 
2.18.5.1 DNA linearization 
ClaI enzyme digestion linearised plasmids in a 100 μL reaction in 1.5  ml RNase-
free tube (Ambion) followed by treatment with Mung Bean nuclease® (Promega) 
treatment to digest the sticky ends (30°C for 30 min). The concentration of 
linear DNA template was then determined using Qubit®. 
2.18.5.2 Transcription Procedure 
The reaction components were assembled at room temperature in a 1.5 ml 
microcentrifuge tube by adding 1 μg of linear DNA template, 20μL of T7 
Transcription 5X Buffer, 30μL of rNTPs (25mM ATP, CTP, GTP, UTP, 10μL of 
Enzyme Mix (T7) plus nuclease-free water up to 100μL final volume. After all the 
components were added and mixed by pipetting gently, the reaction was 
incubated at 37°C for 2 hours. RNA was visualized by gel electrophoresis on a 1% 
agarose gel; finally, the amount of RNA was measured by Qubit®. 
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Figure 2-8: Genotype 1a HCV subgenomic replicon APP238 pH/SG-Neo (L+I) 
 
The plasmid encoding the genotype 1a HCV subgenomic was supplied by Apath; USA. 
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Table 2-7: Mutagenesis primers. 
Primer Sequence 
qc H77GNDfor caccatgctcgtgtgtggcAacgacttagtcgttatctg 
qc H77GNDrev cagataacgactaagtcgtTgccacacacgagcatggtg 
qc H77 K1691R fore  caggattgtcttgtccgggaGgccggcaattatacctg 
qc H77 K1691R rev  caggtataattgccggcCtcccggacaagacaatcctg 
qc H77 E1726G fore  gagcaagggatgatgctcgctgggcagttcaagcagaaggcc 
qc H77 E1726G rev ggccttctgcttgaactgcccagcgagcatcatcccttgctc 
qc S96T Foreward gcctgacgcccccacatacagccaaatc 
qc S96T Reverse gatttggctgtatgtgggggcgtcaggc 
qc S282T Foreward caggtgccgcgcgAccggcgtac 
qc S282T Reverse gtacgccggtcgcgcggcacctg 
qc R32A Foreward actgagcaactcgttgctagcccatcacaatctggtg 
qc R32A Reverse tgactcgttgagcaacgatcgggtagtgttagaccac 
qc G493A Foreward gcctcagaaaacttgcggtcccgccctt 
qc G493A Reverse aagggcgggaccgcaagttttctgaggc 
qc P495A Reverse gctcgcaagggcgcgaccccaagtttt 
qc P495A Foreward aaaacttggggtcgcgcccttgcgagc 
qc P496A Foreward cttggggtcccgGccttgcgagctt 
qc P496A Reverse aagctcgcaaggccgggaccccaag 
qc R32H Forward gagcaactcgttgctacaccatcacaatctggtgt 
qc R32H Reverse acaccagattgtgatggtgtagcaacgagttgctc 
qc R32A Forward actgagcaactcgttgctagcccatcacaatctggtg 
qc R32A Reverse caccagattgtgatgggctagcaacgagttgctcagt 
Eleven residues were targeted, representing reported SOF-resistance associated 
mutations and predicted resistance mutations. 
Table 2-8: Sequencing primers. 
Robin -F3047 CAATGTCTTATTCCTGGAC 
Robin-F4239 GACAGCAAGACACACTCC 
Robin-F3502 GGTCGTAAGCCAGCTCGTC 
Lucy- Forward CATG GAA GAC GCC AAA AAC 
Adaptation- F645 CCAACACCCCTGCTATAC 
These primers were used for verification of the introduction of desired mutations in the 
replicon. Sanger sequencing was carried out by Beckman Coulter Genomics. 
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Figure 2-9: Schematic representation of mutations introduced into the 
replicon. 
 
WT residues are shown in green and mutated residues in red. (M) represent mutated 
sites introduced with the Quickchange XL protocol. 
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2.18.6 Electroporation of RNA 
Huh7.5 cells (80% confluent) in a T75 flask were trypsinised and transferred into 
a 50ml Falcon tube for counting. 3x106 cells were transferred into a 15 ml falcon 
tube and centrifuge at 1000 rpm for 5 min. After discarding the supernatant, the 
cells were washed twice by adding 10 ml of PBS to resuspend the pellet and 
centrifuge at 1000 rpm for 5 min, then resuspend the cell pellet in 1 ml of fresh 
PBS. For electroporation, cells were transferred to 4 mm electroporation cuvette 
and ~5 µg of RNA was added per electroporation.  
 The electroporation apparatus was set at 270v and 950 capacitance setting 
the resistance to ∞. Treated cells were then added to 20 ml of medium and 
distributed into 12 wells of a 24-well plate (1ml per well). Extracts from cells 
were made at 24 hourly time interval up to 120h to measure luciferase activity 
in triplicates. 
2.18.7 Firefly luciferase activity assay 
D-luciferin is the substrate for firefly luciferase (Photinus pyralis). Luciferase 
catalyzes the oxidation of luciferin to oxyluciferin in the presence of ATP and 
magnesium, resulting in bioluminescence. After removal of culture medium and 
washing the cells twice with 1 ml of PBS buffer, cells were lysed by adding 80 µL 
of cell culture lysis reagent® (Promega) for 2 min. After scraping the bottom of 
the plate to ensure complete lysis, 40µL cell lysate was transferred per well into 
an Eppendorf tube containing 80µL luciferin (Promega). The sample was mixed 
by vortexing, and the resulting luminescence analysed using a GloMax® Single 
Tube Luminometer (Promega). All luciferase assays were carried out in 
triplicate, and representative data are given for each experiment. All 
calculations and graphical conversions were performed using GraphPad Prism 6®. 
2.18.8 Prediction model for detecting resistance mutations for SOF 
The HCV RNA polymerase crystal structure in complex with UTP crystal structure 
(PDB ID: 1GX6) from the protein databank (http://www.rcsb.org). Residues 
interacting with UTP were obtained using an in-house C program. 
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It uses spatial coordinates of each atom and measures van der Waals forces with 
all other atoms that are within 5 angstroms radius from the atomic centre. With 
this information, it is possible to predict key residues in the protein with their 
high contact interactions.  
 Since SOF acts as a nucleotide analogue, it is likely that residues 
interacting with UTP will also interact with SOF. From the RNA polymerase and 
UTP complex crystal structure, residues that interact with UTP and have low 
contact interactions with other residues for the detection of possible resistance 
mutations were identified. The model was designed by Dr Sreenu Vattipally.  
2.18.8.1 Transcription Procedure 
The reaction components were assembled at room temperature in a 1.5 ml 
microcentrifuge tube by adding 1 μg of linear DNA template, 20μL of T7 
Transcription 5X Buffer, 30μL of rNTPs (25mM ATP, CTP, GTP, UTP, 10μL of 
Enzyme Mix (T7) plus nuclease-free water up to 100μL final volume. After all the 
components were added and mixed by pipetting gently, the reaction was 
incubated at 37°C for 2 hours. RNA was visualized by gel electrophoresis on a 1% 
agarose gel; finally, the amount of RNA was measured by Qubit®. 
2.18.9 Electroporation of RNA 
Huh7.5 cells (80% confluent) in a T75 flask were trypsinised and transferred into 
a 50ml Falcon tube for counting. 3x106 cells were transferred into a 15 ml falcon 
tube and centrifuge at 1000 rpm for 5 min. After discarding the supernatant, the 
cells were washed twice by adding 10 ml of PBS to resuspend the pellet and 
centrifuge at 1000 rpm for 5 min, then resuspend the cell pellet in 1 ml of fresh 
PBS. For electroporation, cells were transferred to 4 mm electroporation cuvette 
and ~5 µg of RNA was added per electroporation.  
 The electroporation  apparatus was set at 270v and 950 capacitance setting 
the resistance to ∞. Treated cells were then added to 20 ml of medium and 
distributed into 12 wells of a 24-well plate (1ml per well). 
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Extracts from cells were made at 24 hourly time interval up to 120h to measure 
luciferase activity in triplicates. 
2.18.10 Firefly luciferase activity assay 
D-luciferin is the substrate for firefly luciferase (Photinus pyralis). Luciferase 
catalyzes the oxidation of luciferin to oxyluciferin in the presence of ATP and 
magnesium, resulting in bioluminescence. After removal of culture medium and 
washing the cells twice with 1 ml of PBS buffer, cells were lysed by adding 80 µL 
of cell culture lysis reagent® (Promega) for 2 min. After scraping the bottom of 
the plate to ensure complete lysis, 40µL cell lysate was transferred per well into 
an Eppendorf tube containing 80µL luciferin (Promega).  
 The sample was mixed by vortexing, and the resulting luminescence 
analysed using a GloMax® Single Tube Luminometer (Promega). All luciferase 
assays were carried out in triplicate, and representative data are given for each 
experiment. All calculations and graphical conversions were performed using 
GraphPad Prism 6®. 
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Table 2-9: Ligation of insert DNA into plasmid vector DNA. 
Linearized vector DNA 10-100 ng 
Insert DNA (at 3:1 molar excess over vector) variable 
5X Rapid Ligation Buffer 4 μL 
T4 DNA Ligase, 5 U/μL 1 μL 
Water, nuclease-free to 20 μL 
Total volume 20 μL 
The reaction was carried out in a 1.5 ml microcentrifuge tube and incubated at 22°C for 
5 min. 
 
Table 2-10: Recircularization of linear DNA using Rapid DNA Ligation Kit. 
Linearized vector DNA 10-50 ng 
5X Rapid Ligation Buffer 10 μL 
T4 DNA Ligase, 5 U/μL 1 μL 
Water, nuclease-free to 50 μL 
Total volume 50 μL 
The reaction was carried out in a 1.5 ml microcentrifuge tube and incubated at 22°C for 
5 min. 
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Chapter 3: Intra-host viral population structures 
3.1 Background 
The viral load of HCV may reach 107 copies/ml in immunocompetent patients, 
with the production and clearance of 1010–1012 genomes per day (Gregori et al., 
2014). The HCV error-prone RdRP leads to a  high viral mutation rate that is 
estimated to be 2.5x10-5 mutations per nucleotide per genome replication cycle 
(range 1.6–6.2x10-5) (Ribeiro et al., 2012). This high mutation rate is consistent 
with the high degree of intra-host genetic diversity observed in HCV-infected 
patients (Cruz-Rivera et al., 2013).  
 Studies of intra-host viral diversity may explain the evolutionary dynamics 
of HCV infection including, replication rate, natural selection and random 
genetic events (Gray et al., 2012). Heterogeneity at the nucleotide sequence 
level is not distributed evenly across the HCV genome. The most variable part of 
the HCV genome is the hypervariable region 1 (HVR1) (Moreau et al., 2008). 
HVR1 has been investigated in many HCV quasispecies studies, given that a high 
degree of diversity increases the likelihood of distinguishing one HCV variant 
from another.  
 The targeted region was amplified using multiplexed genotype-specific 
primers to compare different sequencing techniques (direct Sanger sequencing, 
bacterial clonal analysis, and deep sequencing) for the detection of quasispecies 
heterogeneity as described in Section 2.5.2.  In addition, for more detailed and 
accurate information about population structure, two methods of sequencing the 
whole genome were developed using two approaches; PCR-based amplicon 
sequencing and metagenomic sequencing. The optimisation of these approaches 
is discussed in detail in this chapter. 
 Viral complexity and diversity indices may be measured in sequential 
samples in one patient (intra-host diversity) or groups of patients. It is important 
that a consistent and non-biased framework be used to estimate the measure of 
diversity thus a number of techniques for measuring viral diversity and 
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reconstructing haplotypes were assessed. In the new era of direct-acting 
antivirals (DAAs), studying the HCV viral population before and after treatment 
is of great value, as viral complexity within infected individuals may result in 
treatment failure due to either mixed infection or the de novo evolution of 
resistance during therapy.  
 The prevalence of mixed genotype infection in HCV-infected subjects 
ranges from 5% in a cohort of patients co-infected with HCV/HIV to 39% in a 
cohort of PWID (Pham et al., 2010, McNaughton et al., 2013). There may be an 
increased need for improved screening, by applying sequencing techniques at 
baseline to ensure the detection of multiple variants infection of low frequency 
in the viral population which are missed by current diagnostic methods 
(Abdelrahman et al., 2015, McNaughton et al., 2013). 
 A potential candidate is the use of next generation sequencing (NGS) 
(Barzon et al., 2011). Further work is required to assess whether the detection 
of low-frequency variants is associated with treatment failure – at present, it is 
not clear how relevant the detection of such variants is, but the evolution of 
new sequencing technologies will allow a clearer view of viral population 
structures and their evolution during treatment.  
 The development of NGS technologies opens up significant challenges; a 
major challenge is to reconstruct circulating viral haplotypes from NGS data. 
Two of the currently available haplotype reconstruction programmes 
(PredictHaplo and QuRe) are assessed using a variety of artificially constructed 
mock communities as described in Section 2.13.  
 In this chapter, different methods of assessing HCV population structures 
are compared using direct sequencing, clonal sequencing, and deep sequencing 
approaches. The development of whole genome sequencing approaches using 
PCR and metagenomic deep sequencing are detailed. Finally, a variety of 
bioinformatic approaches for the reconstruction of viral populations is assessed 
(Table 3-1). 
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3.2 Results 
3.2.1 PCR error rate estimation 
Three different enzymes were tested using clonal sequence analysis of a single 
DNA insert in the pJET1.2/blunt vector as a template for sequencing. The 
produced clones were directly sequenced, and error rate was calculated 
according to the formula; Error rate = number of errors/ (target size × number of 
clones).  
 Error rate estimates were determined to be as follows; Phusion® High-
Fidelity DNA Polymerase (<7.1x10-6 error/bp), KOD Hot Start DNA Polymerase® 
(5.2x10-6 error/bp), AccuStar® DNA polymerase (1.32x10-5 error/bp). These error 
rates were lower than that of MegaMix® Blue PCR Taq polymerase (1.9x10-5 
error/bp). The proofreading enzyme Phusion® High-Fidelity DNA Polymerase 
(<7.1x10-6 error/bp) was selected for use in all further PCR reactions (Figure 
3-1).  
3.2.2 454 pyrosequencing error rate estimation 
An alignment of control HVR1 plasmid sequences resulted in a mean depth of 
16,918 at each nucleotide site. The most frequently found sequence was the 
original sequence in the plasmid. Based on the polymorphisms detected, the 
calculated error rate was 0.002 per base pair. Either these errors could arise 
during sequencing, during reverse transcription step or during PCR amplification 
that may affect the interpretation of the presence of polymorphism; hence, an 
abundance cut-off was instated above the error rate value to avoid any false 
results. 
3.2.3 Measuring viral diversity using HVR1 region   
A 183 base pair region of the E1/E2 gene including the HVR1 region was 
amplified from samples obtained from 16 patients with early HCV and chronic 
HIV infection using indexed fusion primers as described in Section 2.5.2.  
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We analysed viral diversity in paired samples using three different techniques; 
direct Sanger sequencing, bacterial cloning followed by Sanger sequencing, and 
454 pyrosequencing. An additional three samples were used to compare two 
deep sequencing platforms; 454 pyrosequencing and Illumina® sequencing. 
3.2.4 Viral complexity 
We used two criteria for differentiating viral variants, a pairwise distance of 
>10% and phylogenetic signal (Abdelrahman et al., 2015).  
3.2.5 Comparison of sequencing techniques  
After sequencing 16 samples using Sanger sequencing, visual inspection of 
chromatograms generated using Bio-Edit v.7.1.3 software revealed that 8/16 
patients had evidence of miscalling due to double peaks suggestive of mixed 
strain infection (Figure 3-2). 
 Using deep sequencing, multiple variants were detected in all patients, 
with two or more variants found in every sample. These were undetected by 
direct sequencing and partially detected using clonal analysis (Table 3-2). Mixed 
genotype or subgenotype infection was detected in 37.5% of samples (6/16) 
using deep sequencing, two of which were undetected by clonal analysis. An 
example of multiple variant infections is illustrated in Figure 3-3. 
 Clonal analysis and deep sequencing only partially correlated with LiPA 
genotyping, as the latter did not result in detection of mixed-genotype 
infections. In all patients, the variant identified by either LiPA or direct 
sequencing was detected by both clonal analysis and deep sequencing (Figure 
3-4).  
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Table 3-1: Overview of experiments discussed in chapter 3.  
Experiment Samples Method Results 
PCR error rate estimation One sample from (P13) 
E1/E2 amplified using four different 
polymerase enzymes as details in Section 
2.5.1 
Section 3.2.1 
Comparison of different 
methods to study viral 
diversity 
16 samples from patients 
(P21,P31,P38,P55,P57,P63, P67, 
P112,P118, P131,P141) 
Amplified region of E1/E2 (183 bp) is 
sequenced using different techniques; Direct 
sequencing, Clonal analysis, Illumina 
sequencing and 454 Pyrosequencing 
Section 3.2.5 
Full genome sequencing 
(Amplicon approach) 
14 samples from patients  
(P2,P3,P6,P8,P9,P11,P12,P13,P14,
P22,P55,P63,P101,P105) 
The optimisation of the full genome 
sequencing using amplicon approach as 
described in Section 2.10.1 
Section 3.2.6 
Full genome sequencing 
(Metagenomic approach) 
11 samples from patients 
(P10,P12,P13,P22,P17,P22,P34,P4
5,P52,P55,P75,P113) 
Using Metagenomic approach as described 
in Section 2.10.2 
Section 3.3.3 
Mock community One sample from (P13) 
2.5kb region was amplified using Amp 1 
primer then clonal analysis followed by NGS 
sequencing as described in section 2.13.1 
Section 3.3.5 
Patients were anonymised and attributed a (P) number. Samples used were either serum or plasma. 
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Figure 3-1: Estimation of the error rate of different polymerase enzymes. 
 
Alignment of sequences following direct sequencing of the HVR1 region amplified by different polymerase enzymes. Three PCR enzymes 
were assessed using a plasmid template for amplification. The alignment shown in the second column was carried out using Clustal W 
embedded within MEGA 6.0 software; this represents an average of 15 clones studied for each enzyme. The third column is showing the 
estimated error rate of each enzyme. 
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Figure 3-2: A chromatogram showing an example of miscalling. 
 
A region of a chromatogram generated by Sanger sequences A) Direct Sanger sequencing 
of one sample with grey arrows point to double peaks, B) Sanger sequencing after 
bacterial cloning demonstrating the purity of the sequence. Sequencing was carried out 
by Beckman Coulter Genomics, UK. 
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Table 3-2: Viral complexity and viral diversity using different sequencing 
techniques. 
 
Viral complexity (number of variants detected), viral diversity (overall mean pairwise 
distance), Direct sequencing (DS), Clonal analysis (CS), and 454 pyrosequencing (NGS).    
(*) Genotyping carried out by (INNO-LiPA II®; Innogenetics) and was not able to identify 
a subtype. The genotypes are highlighted in red 
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Figure 3-3: Illustrative example of multiple variants detected by CS and NGS. 
 
Maximum likelihood tree showing all variants from different sequencing platforms; 
Clonal analysis (CS) in blue, 454 pyrosequencing (NGS) in red, with the frequency of 
each variant in the total population. The analysis included; 13 clonal sequences, 23,788 
reads derived from 454 pyrosequencing and selected HCV references from the Los 
Alamos HCV database. The values on the branches represent bootstrap support. 
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Figure 3-4: Illustrative example of the superiority of NGS compared to Sanger 
sequencing in detecting viral variants. 
 
Maximum likelihood tree showing all sequence variants from different sequencing 
platforms; the direct sequence (DS) is shown in purple, clonal analysis sequences (CS) in 
blue, and 454 pyrosequences (NGS) in red, with the frequency of each variant shown in 
brackets. The analysis included 18 clonal sequences, 19739 reads derived from 454 
pyrosequencing and selected HCV references from the Los Alamos HCV database. The 
values on the branches represent bootstrap support. 
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We noted a disparity however in the representation of minority variants using 
clonal sequencing, with some variants over-represented and others under-
represented.  In one patient, for example, a variant present at a prevalence of 
0.06% using pyrosequencing was detected by clonal analysis (Figure 3-5), while 
another variant present at a level of 25% using pyrosequencing was undetected 
(Figure 3-6). Deep sequencing resulted in the detection of at least one additional 
quasispecies variant in 93.7% of samples when compared with clonal analysis 
(Figure 3-7). 
 We next used three samples to compare two different deep sequencing 
technologies; 454 pyrosequencing as described in Section 2.9.2, and Illumina® 
sequencing as described in Section 2.9.3. Both technologies detected almost 
identical variants in these samples (Figure 3-8). 
3.2.6 Full genome sequencing of HCV 
We next aimed to develop and refine methods to amplify and sequence the 
whole HCV ORF of genotype 1 for further analysis of population structure within 
infected individuals. We used two approaches, a PCR-based approach, and a 
metagenomic approach. The aim was to optimise several steps in the process, 
including extraction of HCV RNA from patient plasma or serum, reverse 
transcription, PCR primer sequences, PCR cycling conditions, template 
preparation, library preparation, and finally sequencing and assembly.  
 We were able to amplify the HCV ORF of genotype 1a from 93% (13/14) of 
samples using RT-PCR amplification to generate four amplicons (Amp 1-4) and 
successfully obtained viral sequences from all 13 samples that could be 
amplified. Samples used had a mean viral load of 25813 copies/ml, with a range 
of [1,512-13,163] copies/ml, the failed sample had a viral load of 13620 
copies/ml; it was possible to amplify Amp 3 and Amp 4 from this sample, but not 
Amp1 and Amp 2.  
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Figure 3-5: Illustrative example of clonal analysis detecting a minority variant 
(0.06%). 
 
Maximum likelihood tree showing all sequences from different sequencing platforms; 
the direct sequence (DS) is shown in purple, clonal sequences (CS) in blue, 454 
pyrosequences (NGS) in red, with the frequency of each variant in the total population 
shown in brackets. The analysis included 14 clonal sequences, 46155 reads derived from 
454 pyrosequencing and selected HCV references from the Los Alamos HCV database. 
Values on the branches represent bootstrap support. 
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Figure 3-6: Clonal analysis may not detect variants detected by deep 
sequencing. 
 
Maximum likelihood tree showing all sequences from different sequencing platforms; 
the direct sequence (DS) is shown in purple, clonal sequences (CS) in blue, 454 
pyrosequences (NGS) in red, with the frequency of each variant in the total population 
shown in brackets. The analysis included; 16 clonal sequences, 587 reads derived from 
454 pyrosequencing and selected HCV references from the Los Alamos HCV database. 
Values on the branches represent the bootstrap support. 
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Figure 3-7: Distribution of the number of variants detected by clonal analysis 
(CS) versus 454 pyrosequencing (NGS). 
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The comparison included 16 samples; NGS detected more variants than CS. 
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Figure 3-8: Comparison of variants detected using different NGS platforms. 
  
Maximum likelihood tree showing sequences derived from different sequencing 
platforms; Illumina sequencing (Illumina) in blue, 454 pyrosequencing (454) in red and 
the frequency of each variant within the total viral population. The analysis includes; 
695856 reads derived from Illumina sequencing, 16500 reads derived from 454 
pyrosequencing, and selected HCV references from the Los Alamos HCV database. 
Values on the branches represent the bootstrap support. 
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In order to account for differences in circulating variants between US and UK 
isolates, we adapted primers and designed a selection of new primers using 
genotype 1a full genome sequences from the NCBI database as shown in Section 
2.10.1.1.  
3.2.6.1 Optimization of RNA extraction for PCR-based amplification of 
the HCV genome 
We evaluated two RNA extraction methods prior to PCR amplification of HCV 
sequences; the QIAamp® Viral RNA Mini Kit (Qiagen) and the automated 
NucliSENS® easyMAG® (BioMérieux). Extractions were performed according to the 
manufacturer’s recommendations as described in Section 2.2. Each sample was 
extracted, and amplification of the 5’UTR region carried out in triplicate using 
real-time PCR. The mean threshold cycle (Ct value) was calculated as the mean 
Ct value of the triplicate of each sample, and it was compared using each 
technique. Both methods resulted in similar results (p value=0.75) (Figure 3-9).  
3.2.6.2 Optimisation of cDNA synthesis  
We tested several conditions and concentrations of the reverse transcriptase 
enzyme SuperScript® III (Invitrogen) and subsequently Maxima RT with a view to 
optimising the synthesis of long strands of cDNA in order to facilitate reverse 
transcription of the entire HCV genome (9.6 kb).  
 Choice of annealing/elongation temperature 
The manufacturer’s recommendation of 55°C for the elongation step was tested 
using a temperature gradient of 37°C, 42°C, 50°C, 52°C and 55oC as well as 
different elongation times. The highest yield of cDNA was detected by 
quantitative PCR when using a temperature of 37°C (Figure 3-10). 
 Primer selection for cDNA synthesis 
We next compared cDNA synthesis using random hexamers versus HCV-specific 
primers as detailed in Section 2.3.  
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Different oligonucleotide primers which were tested included random hexamers 
and primers that annealed to the NS5B or 3’ untranslated region (UTR).  
 Random hexamers generated shorter fragment lengths of 500-800 base 
pairs while two specific primers T4R9214 that anneals to NS5B and T4R9575 that 
anneals to the 3’ UTR of HCV RNA, both resulted in the production of cDNA 
encompassing the entire HCV ORF. Using eight samples for a direct comparison, 
both primers resulted in similar levels of amplified PCR product as quantified by 
RT-PCR (Figure 3-11). 
 Choice of reverse transcriptase enzyme 
Nine samples were tested for cDNA synthesis using SuperScript III versus Maxima® 
reverse transcriptase (RT) (Thermo Scientific). Ct values generated following 
real-time qPCR suggested that the enzymes were comparable with no significant 
difference between mean Ct values (Figure 3-12). 
3.3 PCR Amplification strategy  
In order to maximize PCR sensitivity, we divided the genome into four 
overlapping amplicons that were numbered sequentially as amplicons 1 to 4 
starting from the 5' end of the genome. Each amplicon was less than 3 kb (Figure 
2-5).  
3.3.1 Optimization of nested PCR  
Nested PCR was used for all PCR reactions, and PCR cycling conditions were 
optimised for each amplicon. Negative controls lacking template were included 
for every primer set. If any negative control was positive, all PCR reactions in 
that set were deemed to be contaminated and discarded. 
 We optimized nested PCR conditions for each amplicon independently. 
Initially, we tested the primer sets and cycling conditions for nested PCR 
reported by Yao and Tavis (Yao and Tavis, 2005); in their study, primer design 
was based on sequences from US isolates.  
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In an initial optimisation with four samples, we were only able to amplify the 
Amp 4 region in two samples, while failing to amplify other amplicons 
consistently in these samples (Figure 3-13).  
 We aimed to incorporate viral genetic heterogeneity into our primer 
design. Primers targeted conserved regions of the genome to facilitate annealing 
to a maximal number of isolates. 
3.3.1.1 Amplicon 1  
The nested PCR was optimised with the following protocol;  first run, in a 50 µL 
volume reaction, 25 µL High Fidelity Phusion buffer 2X, 2.5 µL reverse primer 
(T1R2576) 10µM, 2.5 µL forward primer (T1F20) 10µM, 10000 copies minimum 
cDNA, adding water up to total volume of 50 µL, cycling conditions; 98°C for 2 
min, followed by 40 cycles [98°C (10 sec), 62°C (30 sec), 72°C (2:30 min)], then 
72°C for 10min, finally hold at 4°C for ∞. 
 For the second run, 1 µL was added of first run product to 25 µL of High 
Fidelity Phusion buffer 2X, 19 µL water, 2.5 µL reverse primer 10µM, 2.5 µL 
forward primer 10 µM, cycling conditions; 98°C 2 min, followed by 35 cycles 
[98°C (10 sec), 60°C (30 sec), 72°C (2 min)], then 72°C for 10min, finally hold at 
4°C for ∞. The resulting amplicon was 2345 base pairs; Figure 3-14 shows an 
illustrative example of the optimisation process.  
3.3.1.2 Amplicon 2  
The nested PCR was optimised with the following protocol; first run, in a 50 µL 
volume reaction, 25 µL High Fidelity Phusion buffer 2X, 2.5 µL reverse primer 
(T2R5536) 10 µM, 2.5 µL forward primer (T21275, T2F1305, T2F1397, or 
T2F2084) 10 µM, 10000 copies minimum cDNA, adding water up to total volume 
of 50 µL, cycling conditions; 98°C for 2 min, followed by 35 cycles [98°C (10 
sec), 58°C (30 sec), 72°C (4 min)], then 72°C for 10 min, finally hold at 4°C for 
∞. 
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Figure 3-9: Comparison of the performance of different RNA extraction 
methods. 
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Performace was compared using the yield of RT-PCR carried out using Three samples 
extracted by both methods; QIAamp® Viral RNA Mini Kit (Qiagen) and easyMAG® 
(BioMérieux) were used, with extracts processed in triplicate. 
Figure 3-10: Optimisation of incubation temperature for cDNA synthesis. 
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Performace was compared using the yield of RT-PCR carried out using the same sample 
processed for cDNA synthesis using the reverse transcriptase enzyme SuperScript® III 
(Invitrogen) at 37°C versus 52°C. Four samples were used, and each cDNA product was 
processed in triplicate. 
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Figure 3-11: Comparison of the yield of cDNA synthesized using different 
HCV-specific primers. 
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Performace was compared using the yield of RT-PCR carried out using eight samples in 
triplicates. The compared primers are reverse primers (TR 9412 located in NS5B and TR 
9575 in 3’UTR region). 
Figure 3-12: Comparison of cDNA synthesis using Maxima® versus SuperScript 
III®.   
1 2 3 4 5 6 7 8 9
0
1 0
2 0
3 0
S a m p le
C
t 
V
a
lu
e
M a x im a
S S  II I
 
Performace was compared using the yield of RT-PCR carried out using nine samples in 
triplicates. 
Chapter 3: Intra-host viral population structures 
153 | P a g e  
For the second run, 1 µL of first run product was added to 25 µL of High Fidelity 
Phusion buffer 2X, 19 µL water, 2.5 µL reverse primer (T2R5469, T2R5020, or 
T2R5230) 10 µM, 2.5 µL forward primer (T2F2662) 10 µM, cycling conditions; 
98°C 2 min, followed by 35 cycles [98°C (10 sec), 58°C (30 sec), 72°C (2:30 
min)], then 72°C for 10 min, finally hold at 4°C for ∞. The resulting amplicon 
was 2817 base pairs. Figure 3-15 shows an illustrative example of the 
optimisation process.  
3.3.1.3 Amplicon 3 
The nested PCR was optimised with the following protocol; first run, in a 50µL 
volume reaction, 25 µL High Fidelity  Phusion buffer 2X, 2.5 µL Reverse primer 
(T3R7987)10µM, 2.5 µL Forward primer (T3F4725) 10µM, 10000 copies minimum 
cDNA, adding water up to total volume of 50 µL, cycling conditions; 98°C for 2 
min, followed by 35 cycles [98°C (10 sec), 50/60°C (30 sec), 72°C (3 min)], then 
72°C for 10 min, finally hold at 4°C for ∞.  
 For the nested PCR, 1 µL of first run product was added to 25 µL of High 
Fidelity  Phusion buffer 2X, 19 µL water, 2.5 µL reverse primer (T3R7109) 10 µM, 
2.5 µL forward primer (T3F5001) 10 µM, cycling conditions; 98°C for 2 min, 
followed by 35 cycles [98°C (10 sec), 60°C (30 sec), 72°C (2 min then 72°C for 
10 min, finally hold at 4°C for ∞, or 2.5 µL Reverse primer(T3R7987) 10µM, 2.5 
µL Forward primer (T3F5001) 10µM, cycling conditions; 98°C 2 min, followed by 
35 cycles [98°C 10s, 60 °C 30s, 3:00  72°C], then 72°C for 10 min, finally hold at 
4°C for ∞. The resulting amplicon was 2986 base pairs. Figure 3-16 shows an 
illustrative example of the optimisation process. 
3.3.1.4 Amplicon 4 
The nested PCR was optimised with the following protocol; first run, in a 50 µL 
volume reaction, 25 µL High Fidelity  Phusion buffer 2X, 2.5 µL Reverse primer 
(T4R9575 or T4R9214) 10µM, 2.5 µL Forward primer (T4F6290) 10µM, 10000 
copies minimum cDNA, adding water up to total volume of 50µL, cycling 
conditions; 98°C for 2 min, followed by 35 cycles [98°C 10s, 60 °C 30s, 3:00  
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72°C], then 72°C for 10 min, finally hold at 4°C for ∞. For the nested PCR, 1 µL 
of first run product was added to 25 µL of High Fidelity  Phusion buffer, 19 µL 
water,2.5 µL reverse primer (T3R7109) 10µM, 2.5 µL forward primer (T3F5001) 
10µM, cycling conditions; 98°C 2 min, followed by 35 cycles [98°C (10 sec), 60°C 
(30 sec), 72°C (2 min)], then 72°C for 10 min, finally hold at 4°C for ∞, or adding 
1 µL of first run product to 25 µL of High Fidelity Phusion buffer 2X, 19 µL Water, 
2.5 µL reverse primer (T4R9214) 10µM, 2.5 µL forward primer 
(T4F6707/T4F7085) 10 µM, cycling conditions; 98°C for 2 min, [98°C (10 sec), 
55°C (30 sec), 72°C (2:30 min)], then 72°C for 10 min, finally hold at 4°C for ∞. 
The resulting amplicon was 2507 base pairs. Figure 3-17 shows an illustrative 
example of the optimisation process. 
3.3.2 The PCR amplification process 
Despite the high sequence diversity of HCV, successful amplification of a near 
full-length (~9 kb) HCV genotype 1 genome by assembling sequences from Amp 
1-4, was completed in 93% of patient plasma samples with viral RNA levels 
greater than or equal to 1000 copies/ml (Figure 3-18).  
3.3.2.1 Sequencing  
Each set of sequencing primers contained three primers; including both sense 
and anti-sense primers to allow complete coverage of each amplicon. Using 
Sanger sequencing, mean read length was approximately 1kb (Figure 3-19). 
 Beckman Coulter Genomics UK carried out sequencing using the ABI 
automated dye-terminator system. Consensus sequences were assembled and 
edited using CLC Genomics 6. This program automatically assembles overlapping 
sequence reads and identifies nucleotide positions with discrepancies between 
overlapping regions. Computer base-calling errors were corrected following 
visual inspection of the corresponding sequence chromatograms. Mixed-base 
positions within the HCV quasispecies were resolved by identifying the 
predominant base manually at each position.  
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Figure 3-13: Optimisation of modified primer sets for whole genome 
amplification of HCV genotype 1a. 
 
PCR amplification of Amp 4 was carried out using two sets of primers; those described 
by Yao and Tavis, 2005: Y and a set of modified primers: T. Primer set Y consisted of 
outer primers A4xF3 and Out7KbR, and inner primers A4xF3 andF7R. Primer set T 
(Modified primers) consisted of outer primers T4F7085 and Out7KbR, and inner primers 
T4F7085 and F7R, both sets were compared at different annealing temperature (50, 55, 
60°C). 
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Figure 3-14: Optimisation of PCR amplification of Amp1. 
 
Amplicon length is 2345 bp, optimisation was carried out using seven sera samples to 
estimate the amplification efficiency of the primers. 
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Figure 3-15: Optimisation of PCR amplification of Amp 2. 
 
Optimisation was performed using different primer sets; Illustrated are two different 
outer primer sets (F2413 and R5469), and (F2413 and R5230) with the second run 
performed using the one reverse primer (R5536) and five different forward primers 
(F852, F1275, F1305, F2084, and F2413).  
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Figure 3-16: Optimisation of PCR amplification of Amp 3. 
 
Amplicon length is 2108 bp, optimisation was carried out using five sera samples, Primer 
set consisted of outer primers (R7987 and F4725), and inner primers (R7109 and F5001), 
the set was tested using two different annealing temperature in the first run (50°C and 
60°C). 
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Figure 3-17: Optimisation of PCR amplification of Amp 4. 
 
Optimisation was carried out using five samples; different Primer sets were tested. Two 
sets were able to amplify Amp 4; outer primer set (R9575 and F6290) with two inner 
sets (F6707 and R9214) or (F7085 and R9214). 
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Figure 3-18 : PCR Amplification process. 
   
The cut-off for successful sequencing of clinical samples using amplicon sequencing was 
estimated to be 1000 copies/ml. 
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Where necessary, additional sequencing reactions were performed to confirm 
the identity of a base or its predominance in the quasispecies population. For 
accuracy, we stipulated that each nucleotide was present in at least two 
unambiguous sequencing reactions.  
3.3.3 Metagenomic sequencing 
 We next assessed the possibility of sequencing whole HCV genomes using a 
metagenomic sequencing approach utilising an in-house Illumina® MiSeq 
platform. The central aim was to provide a detailed method for the construction 
of unbiased metagenomic libraries from sera and to develop bioinformatics 
pipelines for the assembly of sequencing data.  
3.3.3.1 Construction of Metagenomic Sequencing Libraries 
 Quantitative RT-PCR on HCV RNA was carried out prior to library 
preparation. If the viral load was above 1000 copies/ml, double-stranded cDNA 
was synthesised as described in Section 2.4. This was fragmented and tagged 
using Nextera XT® (Illumina) as described in 2.9.3.2. 
 Evaluation of library size 
The quality and fragment size of each library was measured using a TapeStation 
platform as described in Section 2.9.3.3. Following AmpureXP® bead 
purification, purified products were visualised. Fragment lengths were 
dependent on the concentration of input DNA used in the Nextera XT® reaction. 
We initially used 1ng DNA as recommended by the manufacturer but noted a 
shift towards longer fragment length with increased DNA concentration, reaching 
saturation at 10 ng (Figure 3-20). 
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Figure 3-19: Example of chromatograms derived from Sanger sequencing of 
HCV amplicons. 
 
The sequencing was performed by Beckman Coulter Genomics. Results were received in 
fasta files associated with their chromatograms. 
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The DNA input quantity was therefore varied in order to achieve the fragment 
length required for Illumina® sequencing. For 300X MiSeq cartridges, (optimal 
fragment length 300-400 base pairs), we used 1ng input DNA while for the 600X 
kit, a higher amount of DNA input (5 ng) was used (optimal fragment length 500 
base pairs).  
 Samples and Preparation of Nucleic Acids  
 Optimisation of RNA extraction  for metagenomic sequencing 
As for PCR-based sequencing, we assessed two RNA extraction methods; column-
based extraction using the QIAamp Viral RNA Mini Kit® (Qiagen) and magnetic 
bead extraction using the easyMag® (Biomerieux) platform.   
 Following sequencing of samples extracted using each method, 
metagenomic sequencing was carried out. In samples extracted using column 
based extraction (based on the use of carrier RNA), we found that while larger 
concentrations of RNA were eluted, greater quantities of carrier RNA were 
present in the sample as indicated by a very marked AT bias. This was 
particularly evident when random hexamers were used for cDNA synthesis rather 
than HCV-specific primers.  The quality and size of RNA extracted by each 
method were assessed using the TapeStation system as described in Section 
2.9.3.3; the Tapestation-RNA screen tape demonstrated a peak in keeping with 
that of carrier RNA whereas lower concentrations of RNA were found following 
easyMAG® extraction. EasyMAG® was subsequently adopted as the RNA extraction 
method of choice for metagenomic sequencing as it does not use carrier RNA 
that may interfere with downstream sequencing. 
 Optimisation of cDNA synthesis  
 Superscript III versus Maxima Reverse Transcriptase 
Two reverse transcription systems Maxima®RT (Thermo Scientific) and 
SuperScript® III RT (Invitrogen) were compared for metagenomic sequencing. Ten 
10 samples were processed using both systems. The results were analysed using 
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bioinformatics pipeline described in Section 3.3.4.1. The results were 
comparable with no evidence of inhibition of downstream sequencing. Both 
systems generated similar ratios of viral reads to total reads with ranges of 0.05-
2% for SuperScript III® RT and 0.07-3.1% for Maxima® RT; this difference was not 
statistically significant with a p value of 0.08 as illustrated in Table 3-3, Table 
3-4, and Figure 3-22. 
 Primer choice for reverse transcription 
As described above, 0.05%-3.1% of total reads generated by metagenomic 
sequencing was found to map to the HCV genome. We next investigated whether 
the use of random hexamers versus HCV-specific primers resulted in a difference 
in the number of HCV reads generated following metagenomic sequencing. There 
was a trend for the generation of more HCV reads using random hexamers. 
However, there was no statistical difference observed between the percentages 
of HCV viral reads detected when using random hexamers compared to HCV 
genome-specific primers (Table 3-5 and Figure 3-23).  
 In conclusion, a process for metagenomic sequencing of the HCV genome 
was developed incorporating RNA extraction using easyMAG®, cDNA synthesis 
using random hexamers, quantification of input HCV using RT-PCR with a cut off 
of 1000 copies/ml and quality assessment using Tapestation DNA D1K® screen 
tape (Figure 3-24). 
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Figure 3-20: Effect of input DNA concentration in Nextera XT® on final library 
size. 
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Nextera library size was measured using the D1K DNA screen tape (TapeStation 
platform), A) DNA Ladder, B) DNA input 10ng, C) DNA input 1 ng.  
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3.3.4 Illumina
®
 sequencing of HCV full genome 
We next compared nested PCR amplification and metagenomic sequencing for 
sample processing using the MiSeq® NGS platform (Illumina®). We compared 
three samples using both approaches. In the PCR approach arm, the four 
amplicons were mixed in equimolar concentrations prior to library preparation 
using Nextera XT® while in the metagenomic arm the library covered the whole 
HCV genome. 
3.3.4.1 Bioinformatics analysis Pipeline 
Sequences were mapped to a reference genome using an in-house bioinformatics 
pipeline.  
 Quality analysis of deep sequencing raw data.  
Quality screening of the raw sequence data generated in Fastq format was 
carried out using FastQC® (Babrahman Bioinformatics) software. Low quality 
regions present at the ends of the sequences were filtered and then trimmed to 
reach a final overall Phred quality score of Q30 or above; during paired-end 
Illumina® sequencing, the second read was always of lower quality than the first 
read especially toward the end of each sequence. 
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Figure 3-21: RNA yield following extraction by different nucleic acid 
extraction methods. 
A
B
 
RNA yield following extraction measured using Tapestation RNA screen tape.A) easyMag 
extract, B) QIAamp Viral RNA Mini Kit extract, the peak demonstrating large quantities 
of carrier RNA. 
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Table 3-3: The distribution of reads generated following Superscript III® cDNA 
synthesis. 
ID 
Total 
Reads 
1
 
Cleaned 
Reads 2 
Unmapped 
reads 
3
 
HCV reads              
(%Total )
4
 
1 1135885 941592 107654 8534 (0.75) 
2 1371825 720036 116090 3158 (0.23) 
3 978041 1069190 39596 6091 (0.62) 
4 1092475 886308 65776 1013 (0.09) 
5 987171 556186 131272 4477(0.45) 
6 1267607 837250 48950 1976 (0.16) 
7 711142 505972 36940 1192(0.17) 
8 1189758 542722 47301 654(0.05) 
9 1111914 621997 170456 22373(2) 
10 923149 665188 89664 6829(0.74) 
1-Number of sequence reads in the raw Fastq file following sequencing on the MiSeq 
platform, 2 -Number of reads retained after data clean up, 3-Number of reads not 
mapped to the human genome or cDNA, 4-Number of reads mapped to HCV reference 
from the total and its percentage. 
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Table 3-4: The distribution of reads generated following Maxima®RT. 
ID 
Total 
Reads 1 
Cleaned 
Reads 2 
Unmapped 
reads 3 
HCV             
(%Total )4  
1 1857873 941592 143939 34483 (1.86) 
2 1280247 720036 73644 935 (0.07) 
3 1812403 1069190 65235 9714 (0.54) 
4 1519185 886308 102685 1607 (0.11) 
5 1301716 556186 64086 1524 (0.12) 
6 1353311 837250 115174 6750 (0.5) 
7 1180880 505972 99801 4320 (0.37) 
8 740678 542722 47814 904 (0.12) 
9 1227695 621997 200667 38004 (3.1) 
10 1168174 665188 141110 13909 (1.19) 
1-Number of sequence reads in the raw Fastq file following sequencing on the MiSeq 
platform, 2 -Number of reads retained after trimming of adapters and discarding 
unpaired reads using the in-house Weecleaner script, 3-Number of reads not mapped to 
the human genome or cDNA, 4-Number of reads mapped to HCV reference using Tanoti 
from the total and its percentage. 
Figure 3-22: Number of mapped HCV reads generated using different cDNA 
synthesis systems. 
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The number of reads generated from each sample was not dependent on the method of 
cDNA synthesis.  
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Figure 3-23: Comparison of primer choice for reverse transcription. 
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 The comparison was carried out using 6 samples (1-6), then detecting the yield using 
qPCR targeting 5’UTR region. 
 
Table 3-5: Comparison between random hexamers and HCV specific primer 
based cDNA synthesis. 
  
HCV specific primer 
(T4R9412) 
Random Hexamers 
1 2 3 1 2 3 
Total reads 1 1225095 439532 2195446 1332924 1814619 2377050 
Clean reads 2 630519 152950 794551 405985 918920 732326 
Unmapped 
reads (%) 3 
158900 
(13%) 
71943 
(16.3%) 
180631 
(8.2%) 
127074 
(9.5%) 
111189 
(6.1%) 
144247 
(6%) 
HCV reads (%) 
4 
17896 
(1.46%) 
14347 
(3.26%) 
12335 
(0.56%) 
24172 
(1.8%) 
19979 
(1.1%) 
23024 
(0.97%) 
1-Number of sequence reads in the raw Fastq file following sequencing on the MiSeq 
platform, 2-Number of reads retained after trimming of adapters and discarding 
unpaired reads using the in-house Weecleaner script, 3-Number of reads not mapped to 
the human genome or cDNA, 4-Number of reads mapped to HCV genome using Tanoti 
and % of total reads. 
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Figure 3-24: Metagenomic approach process. 
 
The cut-off for successful sequencing of clinical samples using metagenomic sequencing 
was estimated to be 1000 copies/ml. 
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 Adapter Removal  
Different adapters were used during the library preparation prior to sequencing. 
We removed the standard Nextera® adapter CTGTCTCTTATACACATCT using 
Trim_galore (http://www.bioinformatics.babraham.ac.uk/projects/trim_galore). 
Cleaned reads are shown in Figure 3-26, the trimming led to shortening of the 
median sequence length from 150 to 131 base pairs, and improvement of the 
Phred quality score to Q30. 
 Next generation sequencing alignments 
Using the reads generated by three samples P13, P22, P55, mapping with Tanoti 
yielded better coverage using the metagenomic approach (99.2%) than the 
nested PCR approach (97%). This was mainly attributable to mapping to the 
5’UTR (the primers used annealed at site 210 on the reference HCV genome 
(H77)) (Table 3-6). However, the depth of coverage was higher using the PCR 
based approach (mean=17133) than the metagenomic approach (mean=172). 
 We next used an in-house script (SAM_Coverage) to calculate the coverage 
and depth of reads in each sample (Figure 3-27, Figure 3-28). The coverage in 
the samples processed by amplicon sequencing was bounded by the 5' and 3' 
locations of the primers used; both approaches covered the complete ORF, while 
amplicon sequencing presented a higher depth than metagenomic approach.  
 Quasispecies complexity 
The analysis of samples processed using the metagenomic and amplicon-based 
approaches revealed that both generated very similar (but not identical) 
consensus sequences. The genetic distance between consensus sequences is 
illustrated in (Table 3-7). We created a maximum likelihood tree based on these 
consensus sequences and 10 genotype 1a reference variants from the NCBI 
database (Figure 3-29). It revealed that both approaches identified similar 
consensus sequence in the studied samples.   
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Figure 3-25: Data analysis pipeline. 
 
Different programmes and scripts were used in the pipeline, examples are presented in 
brackets. 
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Figure 3-26: Quality of reads generated using the amplicon sequencing 
approach. 
 
 
A) Raw reads (first read) generated by MiSeq run, B) cleaned reads (first read) cleaned 
by weeCleaner. 
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Figure 3-27: An example of read coverage using the amplicon sequencing 
approach. 
 
This was carried out using Sam_coverage script, showing coverage across HCV genome. 
Figure 3-28: An example of read coverage using the metagenomic approach. 
 
This was carried out using Sam_coverage script, showing coverage across HCV genome. 
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Table 3-6: Analysis of reads generated by metagenomic and nested PCR-based 
sequencing. 
  
Metagenomic approach Nested PCR approach 
Mapped 
area 
Coverage 
Average 
depth 
Mapped 
area 
Coverage 
Average 
depth 
P13 9303 98.80% 226 9120 96.86% 16980 
P22 9384 99.66% 242 9129 96.95% 11615 
P55 9261 98.35% 50 9185 97.55% 22805 
The comparison was carried out using 3 samples; The amplicon approach has limited 
coverage due to location of the inner primers used. 
 
Table 3-7: Genetic distance between consensus sequences. 
 
P13 P22 P55 
Genetic distance (Nucleotides) 0.50% 2.60% 1.90% 
Genetic distance (Amino acids) 1.10% 5.90% 4.40% 
All positions containing gaps and missing data were eliminated. There was a total of 
9120 positions in the final dataset. The genetic distance between consensus sequences 
generated by metagenomic and nested PCR approaches was calculated using MEGA 6. 
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Figure 3-29: Comparison between consensus sequences generated by 
metagenomic and amplicon approaches. 
 
Maximum likelihood tree illustrating consensus sequences derived using different 
approaches and selected genotype 1a HCV references from the Los Alamos. 
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3.3.5 Mock community experiment 
We next studied two of the currently available haplotype reconstruction 
programmes (PredictHaplo and QuRe) and assessed their performance using an 
artificial mock community that we designed as described in Section 2.13.1. The 
mock community was created using 13 clones containing around 2.5 kb 
fragments of HCV viral variants which simulate the quasispecies in a clinical 
sample. The 13 clones were mixed with log-normal abundance with a range of 
frequency of [3.2-30.3%] in order to attempt to link sequences to identify whole 
viral genomes present within each sample.  
 The clones were each 2,225 - 2,377 base pairs in length. The pairwise 
genetic distance between the clones was 0- 0.9% as described in Table 3-8. The 
pJET1.2/blunt cloning vector containing the insert was fragmented using 
Nextera XT® kit, the library’s average fragment length was 500 base pairs. The 
quality of reads was high with read quality per base over Q30, only deteriorating 
as expected towards the end of the second read. 
3.3.5.1 Haplotype reconstruction programmes 
Quasispecies assembly and evaluation of reconstruction performance of QuRe 
and PredictHaplo were applied to the mock community data set. QuRe 
calculated homopolymeric and non-homopolymeric error rates as estimated from 
mapping the reads to the plasmid reference (default parameters for the rest). 
PredictHaplo was run with default parameters. 
 QuRe and PredictHaplo reconstructed 16 and 3 distinct variants 
respectively for the mock data set in two samples (3B and 3C) of the triplicate 
while the third sample (3A) revealed 16 and 5 distinct variants when using QuRe 
and PredictHaplo respectively . All variants were true variants with a precision 
of 100% for both algorithms. Reconstructed variants were classified as ‘correct’ 
when clustering with original Sanger clones in a phylogenetic tree at 75% 
bootstrap support. The analysis was done in collaboration with Dr Melanie 
Schrimer.  
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Table 3-8: Mock community; pairwise distance among 13 clones. 
1 2 3 4 5 6 7 8 9 10 11 12
1 M36 (3.2%)
2 M37 (2.8%) 0
3 M38 (5.3%) 0.003 0.002
4 M39 (2.2%) 0.005 0.005 0.006
5 M46 (2%) 0.007 0.007 0.009 0.009
6 M47 (17%) 0.006 0.006 0.006 0.007 0.003
7 M49 (6.6%) 0.008 0.008 0.009 0.009 0.004 0.003
8 M51 (4.4%) 0.008 0.007 0.008 0.009 0.003 0.002 0.004
9 M52 (2.5%) 0.004 0.004 0.005 0.006 0.008 0.006 0.008 0.008
10 M53 (3.7%) 0.004 0.004 0.005 0.005 0.007 0.006 0.008 0.008 0.004
11 M54 (30.3%) 0.004 0.004 0.005 0.006 0.008 0.006 0.008 0.008 0.004 0.004
12 M55 (11.5%) 0.007 0.007 0.009 0.009 0.004 0.004 0.006 0.004 0.009 0.008 0.009
13 M56 (8.5%) 0.004 0.004 0.005 0.005 0.006 0.005 0.007 0.007 0.004 0.004 0.004 0.007
 Sequence
 
Pairwise distance calculated using Mega 6 software. The frequency of each clone in the 
mock community is shown in brackets. 
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Figure 3-30: Performance of different quasispecies assembler using the mock 
community 
 
Maximum likelihood tree showing known sequences from mock community, and 
reconstructed haplotypes from QuRe in red, and PredictHaplo in blue. The frequency of 
each variant is shown in brackets. The values on the branches represent bootstrap 
support. 
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Figure 3-31: Reconstructed haplotypes using PredictHaplo in one of the 
triplicate (3A).  
 
 
 
Maximum likelihood tree showing known sequences from Mock community (M3A), and 
reconstructed haplotypes from PredictHaplo (20119 reads); the frequency of each 
haplotype depicted in brackets. The values on the branches represent bootstrap 
support. 
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QuRe identified more variants and at least one variant clustered with each node 
on the phylogenetic tree from the original artificial set. All variant frequency 
estimation methods correlated significantly with the original distributions 
(Figure 3-30).  
 The haplotypes reconstructed using PredictHaplo (20119 reads), the 
reconstructed haplotypes matched the clones with the highest frequency in Mock 
community as shown in Figure 3-31. 
3.4 Discussion 
3.4.1 The role of NGS in understanding HCV viral population 
structure 
Viral complexity is defined as the number of viral variants within the HCV 
quasispecies. A genetic distance of 15% between HCV genomes is the cut-off for 
the assignment of subgenotypes; a new class of subgenotype requires 
identification of three strains within that group (Smith et al., 2014). Genomic 
sequences of independent HCV isolates were reported to differ by approximately 
10% (Nattermann and Tacke, 2009). However, there is no consensus on the cut-
off of genetic distance to assign two isolates as different variants within a 
subgenotype.   
 In our cohort, multiple variant infections were detected in all patients, as 
two or more variants were detected in every sample. These were undetected by 
direct Sanger sequencing  as it yields only a single consensus sequence. Smith et 
al. reported similar results in another cohort of 10 patients with acute HCV 
infection, where 80% of patients harboured more than 1 HCV subtype (Smith et 
al., 2010). 
 Clonal analysis is the standard method for studying viral quasispecies. 
However, this strategy lacks the sensitivity to detect minority variants. Minority 
variants present in viral populations may be critically relevant to the disease 
progression and response to treatment (Barzon et al., 2011). 
Chapter 3: Intra-host viral population structures 
183 | P a g e  
Accurate genotyping of HCV is important for tailoring antiviral therapy, as well 
as for predicting the likelihood of response. As current diagnostic techniques fail 
to detect mixed infections (McNaughton et al., 2013, Abdelrahman et al., 2015), 
NGS methods may be increasingly adopted in the clinical setting if the 
emergence of minority variants is shown to occur following the larger scale use 
of DAAs. The first diagnostic assay likely to be performed using NGS will be those 
currently based on Sanger sequencing because of limited sensitivity. In the case 
of HCV, genotyping and antiviral resistance testing would be relevant future 
applications that may be developed using NGS. 
 Among currently used diagnostic techniques, the Abbott m2000 RealTime 
HCV Genotype II assay is able to resolve most HCV genotypes (∼90%), but further 
sequencing is required to fully resolve the genotype in the remaining cases 
(Benedet et al., 2014). Importantly, commercial HCV genotyping assays, such as 
LiPA®, underestimate the true prevalence of mixed HCV infection (Blackard and 
Sherman, 2007), and have error rates of HCV subtyping of 10-15.6%, with an 
intrinsic bias towards HCV genotype 1b (Sarrazin et al., 2007, Fan et al., 2009). 
 Sanger sequencing is the reference laboratory method for genotyping; 
while direct Sanger sequencing suffices for simple mutation patterns, it does not 
detect variants present at levels lower than 20% (Kwong et al., 2011). In 
multiple variant infections, Sanger sequencing often results in “miscalling” 
where the software is not able to assign a base due to the presence of double 
peaks. This was the case in 50% of samples in this study, where we were unable 
to identify the genotype in these samples using this technique. 
 Clonal analysis may provide a better understanding of the true viral 
population by avoiding miscalling and increasing numbers of clones sequenced. It 
is possible to sample any variant with equal chance, but the detection limit will 
always be more than 1/N, where N is the number of sequenced clones (Gregori 
et al., 2014).  
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The reported consensus in the literature has been between 15-20 clones 
sequenced, but this limits detection of drug-resistant variants to around 20–25% 
of the viral population in an individual sample (Barzon et al., 2011). Several 
studies in HIV have shown that minor RAVs are often responsible for the 
virological failure of a new antiretroviral treatment regimen (Barzon et al., 
2011, Roquebert et al., 2006).  
  In our study cohort, we noticed that detection of variants by clonal 
analysis could be a very random process and having a cut-off is not accurate as a 
variant that has a frequency of 0.06% was detected by clonal analysis, while it 
missed another variant that had a variant frequency of 25% as reported by 454 
pyrosequencing. 
 In this study, it was possible to detect multiple infections in all samples 
including, variants at low frequencies, which would go undetected by 
conventional methods. NGS detected mixed subtype/genotype infection in 37.5% 
of samples (6/16), two of which were missed by clonal analysis. The estimated 
frequency cut-off for detectability by different techniques is shown in Figure 
3-32. Nevertheless, in order to reliably reconstruct the viral quasispecies from 
raw data obtained by NGS, thorough data analysis is required (Caraballo Cortes 
et al., 2013). 
 Nucleotide sequencing is subject to some notable artefacts. Firstly, 
sequence errors may be introduced by use of non-proofreading DNA polymerases 
to assess viral diversity; hence, DNA polymerases with proofreading activity 
should always be used when performing PCR for quasispecies analysis to 
minimize such errors.  
 Another issue is the primer bias where primers may not bind to 
heterologous template-binding sites leading to selective amplification of a 
portion of the sequences in the target population. The primer bias could be 
quantified and minimized through careful primer design and control experiments 
(Yao and Tavis, 2005, Mullan et al., 2001).  
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In the case of low viral load, the viral complexity may be lower than the true 
value due to template re-sampling during PCR (Cruz-Rivera et al., 2013). 
3.4.2 HCV full genome sequencing 
The detection of HCV sequence variation has important implications in 
understanding HCV biology. Significant sequence variation is present within the 
HCV ORF at both the nucleotide and the amino acid levels, especially in hyper-
variable regions (HVR1, HVR2 and HVR3) (Kato et al., 1992).  
 Amplification of the HCV genome must overcome not only high quasispecies 
diversity, but also low viral load concentration. This is why whole genome 
sequencing of HCV has traditionally been very challenging, especially from 
heterogeneous clinical isolates. Different PCR-based strategies have been 
designed, usually based on multiple amplicon amplification using nested PCR to 
increase the sensitivity and specificity. Yao and Tavis reported an amplification 
strategy using five amplicons, but employed a Taq DNA polymerase that lacked 
the proofreading activity, which is insufficiently accurate for diversity studies 
(Yao and Tavis, 2005). 
 Following the introduction of DAAs, there is a need to develop a method to 
analyse the NS3, NS5A, and NS5B regions of HCV. Zhang et al. recently described 
an efficient RT-PCR method that allows viral sequencing of all regions targeted 
by the most common DAAs, this assay  was used in clinical trials to amplify a 
nearly full-length HCV genotype 1 genome with a success rate of 97% including 
samples with low viral load (Zhang et al., 2013). However, the method used a 
mixture of Taq polymerase and high fidelity enzyme and is therefore likely to 
have been subject to both primer bias and PCR amplification error. 
 RNA isolation must be efficient to yield adequate amounts of pure template 
due to the limited amount of patient plasma or serum and the relatively low 
viral load. Automated extraction presented a better option to avoid 
contamination and decrease variability in the clinical laboratory. 
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Figure 3-32: Estimated frequency cut-off for detectability by different 
techniques. 
 
The sensitivity of different techniques was variable in our study. The clonal analysis is a 
random process and only once was able to detect a variant with a frequency of <1% of 
the total population. 
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There is a consensus that the nucleic acid extracted by easyMAG® is of better 
quality for amplification than manual methods (Dundas et al., 2008). The 
extracted RNA using easyMAG® was superior in our downstream deep sequencing 
analysis as it lacked the carrier RNA incorporated in the RNA extraction process 
using Qiagen® that caused artefactual reads.  
 Two full-genome sequencing methods were developed using Illumina® 
technology, with two different approaches; the first was PCR-based amplicon 
sequencing using four amplicons covering the whole genome and the second 
employed a metagenomic approach. The consensus sequences generated by both 
approaches were similar but not identical suggestive of primer bias. However, 
the metagenomic approach was limited by a low number of reads in one region 
of HCV genome (only two reads), which highlights the importance of low 
coverage of the metagenomic approach. Depth of coverage can be improved by 
increasing the amount of sequencing, but this has resource implications. 
 In this study, we demonstrated two methods of successfully amplifying the 
whole HCV genome. The PCR-based approach was limited to genotype 1a while 
the metagenomic approach allowed the reconstruction of any HCV genotype. We 
assessed the complexity of HCV viral populations in the plasma of an acute 
HCV/HIV co-infected cohort.  
 The identification of viruses in NGS libraries relied on alignments to 
reference genomes although de novo assembly methods not covered here would 
also allow the identification of novel viruses using a metagenomic sequencing 
approach. NGS detected viruses that were diagnosed by traditional diagnostic 
methods; additionally, other genotypes were detected in several samples. 
Finally, we defined a threshold of abundance of viral reads to serve as a cut-off 
to discards false reads.  
 Metagenomic sequencing is a potential tool that could be extensively 
implemented in clinical research and diagnostics in the near future due to its 
high sensitivity and the ability to simultaneously detect a broad spectrum of 
viruses and new variants. 
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3.4.3 Bioinformatics framework 
The raw NGS data analysis presents several challenges; efficient mapping to an 
appropriate reference sequence, error detection/correction, SNP identification, 
and genome assembly methods (Bao et al., 2011). 
 The reverse transcription (RT) and PCR steps create a noise level that lead 
to sequencing errors. A cut-off to differentiate true from erroneous mutations is 
required, but a major issue is where to estimate an abundance filter to exclude 
artefactual haplotypes and point mutations. Any data processing of amplicon 
sequencing requires such a threshold that is vital for studying complexity and the 
intrinsic diversity of the sample. In this study, we elected to exclude single 
sequences only.  
 This problem was investigated by Carballo et al. using three different 
strategies; firstly, they considered variants detected at a frequency higher than 
1%; which retained only eight variants. A second strategy was to include 
sequences covered bi-directionally in both a forward and reverse reads; this 
method identified 40 variants. In the third strategy, they used ShoRAH software 
that had a variable outcome depending on the implemented cut-off value; “low 
cut-off value may result in low precision (fraction of true haplotypes among all 
called haplotypes) and conversely, high cut off may significantly lower recall 
(fraction of called haplotypes among all true haplotypes)” (Caraballo Cortes et 
al., 2013). 
 NGS has higher sensitivity than conventional methods in detecting low 
variants carrying SNPs. The NGS reads from any sequencing technology may 
contain noise from PCR amplification and platform specific noise, which must be 
distinguished from real diversity to be able to reconstruct the haplotypes 
accurately; however, the short read lengths render it difficult to determine 
which SNPs reside on the same haplotype.  
 In the near future, NGS will overcome Sanger’s limitations. A key step will 
be achieved when available SNP detection and assembly algorithms are 
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sufficiently reliable. Two approaches were implemented in this study; 
metagenomic and amplicon sequencing. Two possible factors can cause a 
difference in the viral complexity detected by both approaches, either through 
selection bias in the amplicon approach or underrepresentation in the 
metagenomic approach. 
 The main limitation of such analysis in the metagenomic arm is that our in-
house script (Sam Variation) has a limited length (read length= 150bp), and it 
gathers only the reads covering the region under investigation completely. 
Hence, despite a depth of more than 200 reads in certain regions, the analysed 
reads could be only 20-30 reads and even in this group, many singletons were 
found. Whether these are artefacts or true reads remains a major doubt. As 
singletons were excluded in such analysis, only few reads (8-12) were compared 
with the amplicon arm in some regions. 
 An abundance filter cut-off (1%) was used for the amplicon reads, which is 
suggested by Illumina® to discard any false reads due to cross talk between 
indices, whether lower reads have been true ones and represent a minority 
variant is to be considered. Until an accurate analysis tool is available, we will 
not be able to address the comparison between both approaches (metagenomic 
and amplicon) except at SNP level, which could be of value in the case of 
assessing the presence of antiviral resistance mutations as discussed later in 
chapter 5. 
 Different quasispecies assembly methods have performed robustly in 
simulations and empirical experiments (Zagordi et al., 2010b, Prosperi et al., 
2011, Astrovskaya et al., 2011) This study is the first to consider HCV intra-host 
quasispecies, by creating an artificial viral population (mock community) by 
sequencing amplicon products from a clinical sample from a known HCV patient. 
After clonal analysis, the clones were mixed at controlled proportions and then 
processed using Illumina® sequencing.  
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Using our Mock data set, two assemblers, Qure and PredictHaplo, were able to 
reconstruct the most frequent variants as demonstrated by phylogenetic 
analysis. PredictHaplo was found to be a conservative algorithm, with only three 
variants detected (23%) of the reported variants, which was similar to 25% 
recalled when validated using a 454 dataset (Prosperi et al., 2013).  
 QuRe showed the best precision/recall trade-off, although we were not 
able to determine a recall rate due to the low diversity of the artificial mock 
community data set but we would not predict it to be far from the 50% value 
reported by Prosperi et al, in a similar validation using a 454 pyrosequencing 
HCV dataset (Prosperi et al., 2013). In both assemblers, the estimated variant 
frequencies correlated with the original values stated in the mock community 
design.  
 Various factors can influence the performance of any haplotype 
reconstruction programme such as the instrumental sequencing error of NGS 
platform, read length, coverage, depth, the variant prevalence and the average 
diversity (Prosperi et al., 2013). Evaluation of these assemblers in different 
settings, using artificial data sets along with biological materials will be an 
important step in validating bioinformatics pipelines for studying viral 
populations in infected individuals. 
 None of the programmes that we tested was specifically designed for 
Illumina® reads. Hence, the higher coverage provided with Illumina® may present 
a challenge when using these assemblers. For example, QuRe was designed to 
deal with an average 20,000 reads produced by pyrosequencing. We had 
technical difficulties using this assembler for samples with 60,000-100,000 reads 
produced by Illumina® platform. 
 We tested the programmes on the Illumina® reads to examine their 
potential for viral haplotype reconstruction as Illumina® sequencing has become 
the most popular deep sequencing platform across all applications (Li et al., 
2014). However, the lack of validated viral sequence analysis tools for the 
Illumina® platform remains a hurdle to the widespread adoption of Illumina® 
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sequencing in clinical laboratories. Viral haplotype reconstruction from a set of 
observed reads is one of the most challenging bioinformatics problems that 
requires further improvement. Further experiments are still needed to address 
this problem as explained in Section 6.2.3.  
3.5 Conclusions 
NGS is a powerful technique that has a potential role in HCV diagnostic 
algorithms for the detection of mixed infection currently underdiagnosed by 
standard methods (e.g. PCR-based hybridization assays and direct Sanger 
sequencing) and in screening for known antiviral resistance mutations. NGS is 
superior to both direct Sanger sequencing and clonal analysis in the detection of 
minority variants. The recent advances in NGS technology are associated with 
the parallel development of a large number of software and algorithms capable 
of handling the massive amount of data generated by NGS platforms. This will 
lead to faster implementation in a variety of settings (e.g. field of molecular 
epidemiology) (Escobar-Gutierrez et al., 2012).  
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Chapter 4: Hepatitis C virus diversity 
4.1 Background 
HCV displays high intra-host diversity, forming a pool of closely related but 
distinct genetic variants, the viral quasispecies (Martell et al., 1992). The 
immune system promotes a high degree of diversity in viral progeny and 
contributes to the ongoing evolution of HCV. This is confirmed by the fact that a 
low degree of HVR1 genomic variability has been observed in immunosuppressed 
patients, suggesting that the variability in HVR1 is directed by random 
substitutions induced by host immune pressure (de Amorim et al., 2014). 
  Studies of the treatment outcome in HCV-infected patients identified 
various viral factors as predictors of treatment response, such as genotype, viral 
load,  and viral diversity (Wohnsland et al., 2007). Moreover, host factors were 
reported to affect response rates, such as age, weight, sex, race, liver function, 
and extent of fibrosis. IL28B genotype and clinical variables were integrated into 
a clinical prediction model that produced a useful individualized prediction of 
treatment response (O'Brien et al., 2011). 
 Characterization of the natural history of HCV infection has been hindered 
by a lack of studies due to the asymptomatic nature of early infection. Infection 
with the virus is often unknown until liver cirrhosis develops, usually after many 
years of silent infection. Acute HCV infection is conventionally defined as the 
initial six months of infection that induces virus-host interactions that influence 
the outcome of the disease. 
 In the last decade, an emerging epidemic of acute HCV infection among 
HIV-infected MSM has provided the opportunity to prospectively study the 
progression of early disease as patients are identified early in infection, due to 
the detection of abnormal liver function tests at routine follow-up visits for their 
HIV infection (Dominguez et al., 2006, Gilleece et al., 2005, Vogel et al., 2005, 
Matthews et al., 2009, Fierer et al., 2008).  
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In the pre-DAAs era, SVR rates were lower in the HIV/HCV co-infection group 
(59–71%) than in HCV mono-infected patients (98%) (Gilleece et al., 2005, 
Serpaggi et al., 2006). Studies in this group of patients are likely to increase 
understanding of the determinants of spontaneous clearance versus evolving 
progression to chronicity.  
 Viral complexity in HCV/HIV co-infected patients prior to treatment has 
been a controversial topic, with various studies showing either greater 
complexity compared to those with HCV mono-infection, no difference from 
those with mono-infection or even less complexity (Sherman et al., 2010). 
 Several studies have investigated the composition and the evolution of HCV 
quasispecies to determine their role in predicting the outcome of antiviral 
therapy. Many studies have suggested a correlation between a high level of 
heterogeneity within HVR1 and a poor response to PegIFNα/RBV therapy (Farci 
et al., 2002, Chambers et al., 2005, Sandres et al., 2000). 
 The accurate evaluation of viral complexity may play a major role in the 
prediction of the outcome of antiviral treatment (Gregori et al., 2014). Current 
diagnostic methods vary in their sensitivity; most are likely to underestimate the 
complexity of viral populations due to lack of detection of low-frequency 
variants. The development of NGS platforms provided a new tool for detailed 
analysis of intra-host viral populations as shown in chapter 3 and reported 
previously (Cruz-Rivera et al., 2013). In this chapter, we revisited some 
questions about the role of viral diversity in understanding and predicting 
treatment outcome in a unique acute HCV/HIV cohort using an NGS-based 
approach. We compared this with more conventional Sanger sequencing and 
cloning-based approaches. 
 Different diversity measures were employed in this study. Shannon entropy 
and the Simpson’s index both measure diversity based on the number of variants 
present (species richness) and the distribution of the number of organisms per 
species (species evenness). Simpson's index estimates the probability that two 
isolates randomly selected from a sample will be the same variant, the index 
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value ranges from 0 to 1, with a value of “1” indicating no diversity. However, 
both measures of diversity are not sensitive to variant frequency; hence, they 
may not reflect the presence of rare variants.  
 Other measures of diversity such as pairwise diversity (Pi) determines how 
different all variants within the population are, while considering the genetic 
distance between each pair of individuals in the viral population. Hamming 
distance, (the mean number of amino acid differences between variants) may 
also be used to quantify the composition of the quasispecies population 
(Thomson et al., 2011).  
 Meanwhile, phylogenetic entropy and quadratic diversity are sensitive to 
relatedness, using phylogeny in determining the viral diversity in the population. 
Phylogenetic entropy places a high value on distinctive species but also retains 
the rare variants (Allen et al., 2009).  
 We hypothesized that high viral diversity would be expected in patients 
who do not respond to treatment while treatment response might be predicted 
by low viral diversity. We further hypothesized that diversity analyzed using NGS 
might be a better predictor than the use of less sensitive techniques such as 
bacterial cloning. 
 Descriptions of HCV re-infection in acute HCV/HIV-infected MSM have been 
widely reported without detailed phylogenetic analysis (Lambers et al., Martin 
et al., 2013). Multiple HCV variants are commonly present in individual infected 
patients in this group (Thomson et al., 2011). Such variation could occur because 
of transmission of multiple HCV strains either around the time of initial infection 
or sequentially over time.  
  We hypothesised that re-infection rates following treatment would be 
over-estimated by standard Sanger sequencing due to lack of detection of 
varying dominance of minority variant strains present at the onset of infection 
and aimed to investigate this in a group of HCV/HIV co-infected patients who 
failed HCV treatment. 
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In order to test the above hypotheses, pyrosequencing was used to characterize 
the complexity of HVR1 as described in Section 2.9.2, to determine whether 
intra-patient viral diversity of HCV in HIV-positive patients during early infection 
determines the likelihood of SVR following treatment with PegIFNα/RBV. 
 The same NGS platform was used to dissect the different causes of 
treatment failure using pre- and post-treatment plasma samples taken from 
patients who failed standard of care therapy with 24-48 weeks of PegIFNα/RBV. 
NGS data were analysed using phylogenetic analysis of pre- and post- treatment 
variants obtained using clonal analysis and pyrosequencing to differentiate 
relapse from reinfection. 
4.2  Results 
The study outlined here is the first to evaluate viral complexity and diversity in 
an acutely infected HCV cohort using deep sequencing. To determine whether 
viral diversity affects treatment response, pre-treatment viral diversity was 
analysed using a segment of 183 nucleotides from the E1/E2 region including the 
HVR1 region. 
4.2.1 Viral diversity as a predictor of treatment outcome 
4.2.1.1  Characterization of the study group 
Twenty patients were selected who had completed treatment with 48 weeks of 
PegIFNα/RBV. Ten patients achieved SVR following treatment, and ten failed to 
clear the virus (four null responders, three partial responders, and three 
relapsers). The groups were matched for different variables including peak ALT, 
pre-treatment viral load and duration of HCV infection (an estimate calculated 
by the difference between the date of the RNA-positive study sample and date 
of last negative HCV RNA PCR). All of the patients were reported by the clinical 
virus laboratory to be infected with genotype 1a (Table 4-1).  
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4.2.1.2 Diversity of viral quasispecies. 
After sequencing the 20 samples using pyrosequencing, the data generated by 
NGS of the study group were analysed as described in 2.15.2. The genetic 
diversity of quasispecies sequences from patients in each group was calculated 
using pairwise diversity (Pi), Simpson’s index, Shannon index, phylogenetic 
diversity and quadratic diversity. Diversity at baseline and within 150 days from 
infection was significantly lower in those who achieved SVR compared to the TF 
group as summarized in (Table 4-2). 
 Similar results were obtained comparing only the HVR1 region between the 
two groups and using a normalized set of 10,000 sequences per sample (data not 
shown). The measures of viral diversity in individual patients in each group are 
shown below (Table 4-3 and  
Table 4-4); the two groups are compared in (Figure 4-1). 
4.2.1.3 Entropy  
The amino acid sequence variability at each position of HVR1 was evaluated 
using the Shannon Entropy program at the Los Alamos National Security Website 
(http://hcv.lanl.gov/content/sequence/ENTROPY/entropy.html). A detailed 
analysis of entropy per site of the sequences provided evidence that higher 
variability was observed in HVR1 in the non-responder group than in the 
responder group; an example comparing a patient from each group is illustrated 
in Figure 4-2.  
 Graphical representations of the patterns within a multiple sequence 
alignment called sequence logos provide a richer and more precise description of 
sequence similarity than consensus sequences and revealed the higher variability 
per site in the HVR1 region. The logos in Figure 4-3 were created using WebLogo 
software (Crooks et al., 2004). 
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Table 4-1: Characteristics of the study groups of subjects. 
Variable 
TF group           
Mean ± SEM  
SVR group  
Mean ± SEM 
P-value 
Peak ALT 917.6 ± 330.8 1039 ± 236.6  0.7633 
Days of infection 91.93 ± 21.2 121.3 ± 31.9 0.1339 
Days of infection is an estimate of the time between last HCV RNA sample and the study 
sample. 
 
 Table 4-2: Comparison of quasispecies diversity in TF group versus SVR 
group. 
 
 SVR group                        
Mean ± SEM 
TF group                         
Mean ± SEM 
P-value 
Shannon’s index 0.8 ± 0.07 1.66 ± 0.19 0.0005 
Simpson’s index 0.73 ± 0.03 0.44 ± 0.04 0.0001 
Pairwise diversity 1.33 ± 0.39 10.66 ± 4.08 0.0356 
Phylogenetic entropy 0.009 ± 0.003 0.12 ± 0.056 0.05 
Quadratic diversity 0.003 ± 0.001 0.08 ± 0.04 0.05 
P-value calculated using paired t-test. 
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Table 4-3: Measures of diversity in the treatment failure group (TF). 
ID 
Numbers 
of reads 
Shannon 
index 
Simpson 
index 
Phylogenetic 
entropy 
Quadratic 
diversity 
Pairwise 
diversity  
1 23042 1.2 0.599 0.092 0.045 0.663 
2 21702 1.629 0.504 0.001 0.001 0.077 
3 10742 1.368 0.43 0.005 0.002 1.54 
4 23639 0.974 0.606 0.002 0.001 0.482 
5 19165 1.594 0.455 0.399 0.271 1.898 
6 21246 1.739 0.337 0.483 0.321 1.774 
7 19739 1.972 0.439 0.037 0.023 0.89 
8 20659 1.043 0.65 0.032 0.019 0.705 
9 20453 2.191 0.281 0.004 0.002 0.795 
10 16500 2.969 0.158 0.188 0.129 0.622 
Measures of diversity were calculated using a Perl script designed by Dr Joseph Hughes.  
 
Table 4-4: Measures of diversity in responder group (SVR). 
ID 
Number 
of  reads 
Shannon 
index 
Simpson 
index 
Phylogenetic  
entropy 
Quadratic 
diversity 
Pairwise 
diversity  
1 28238 0.964 0.623 0.007 0.002 0.71 
2 26719 0.97 0.616 0.009 0.002 0.903 
3 38968 1.06 0.641 0.027 0.011 1.225 
4 26292 0.537 0.866 0.003 0.001 0.741 
5 52970 0.958 0.73 0.002 0.001 0.862 
6 21424 0.801 0.715 0.004 0.001 1.042 
7 41729 0.611 0.84 0.026 0.011 0.959 
8 15054 0.916 0.645 0.004 0.001 0.922 
9 63048 0.836 0.755 0.003 0.001 1.258 
10 31036 0.432 0.897 0.005 0.002 1.014 
Measures of diversity were calculated using a Perl script designed by Dr Joseph Hughes.  
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Figure 4-1: Comparison of diversity measures between non-responders (TF) 
and responders (SVR) groups. 
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Figure 4-2: Illustrative example of the difference in Shannon entropy 
between SVR group (P6) and TF group (P81). 
The compared region is 183 nt covering HVR1 region. Shannon entropy of P6 
represented above (0) and P81 below (0), significantly different sites (p-value<0.05) are 
plotted in red.  
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Figure 4-3: HVR1 amino acid diversity. 
A 
 
B 
 
Viral diversity A) in a patient (P6) who responded to treatment, B) in a patient (P81) 
who failed treatment. 
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4.2.1.4 Viral complexity  
Phylogenetic analysis was performed using HVR1 nucleotide sequences from all 
patients. The phylogenetic trees suggested a pattern of higher viral complexity 
in the TF group compared to the SVR group, with multiple variants detected in 
the TF group; an illustrative example of the difference is shown in (Figure 4-4). 
The viral variants detected in each group are detailed in a maximum likelihood 
phylogenetic tree in Appendix 7.1 and Appendix 7.2. 
4.2.1.5  Star Phylogeny  
Star phylogeny in a phylogenetic tree represents the occurrence of multiple 
short branches originating from an internal node. It is indicative that the viral 
population evolved from a common ancestor. In order to distinguish infections 
initiated by a single variant (homogenous infection) from those where multiple 
variants entered the host, we employed a tool used extensively in the HIV field 
for this purpose (Poisson Fitter).  
 Poisson Fitter analyses Hamming distance (HD) frequencies by computing 
the best fitting Poisson distribution and evaluating results of the Goodness of Fit 
test (GOF). P-values of less than 0.05 indicate divergence from a Poisson 
distribution and can be interpreted as transmission of multiple viral variants or 
the presence of positive selection. The analysis was performed using the online 
tool http://www.hiv.lanl.gov/content/sequence/POISSON_FITTER/ (Giorgi et 
al., 2010).  
 The analysis revealed that patients in the TF group were more likely to be 
infected with multiple founder strains than those in the SVR group. For example, 
the SVR group P6 sample followed a star-like phylogeny suggesting the infection 
originated from a single founder virion, while P81, a sample from the TF group, 
did not follow a star phylogeny and was suggestive of multiple variant infection 
as shown in Figure 4-5. The results of individual samples are detailed in 
Appendix 7.3 to Appendix 7.18.  
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Figure 4-4: Illustrative example of the difference in viral complexity in SVR 
(P6) and TF (P81) groups. 
 
Maximum likelihood tree showing the variants in P6 (SVR group) and P81 (TF group). The 
bootstrap values are shown next to the branch points (1,000 replicates); only values 
higher than 70% are shown. 
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Figure 4-5: Illustrative example of Poisson Fitter from both groups. 
 
P6 follows star phylogeny with one founder virus while P81 does not follow star 
phylogeny with possibly 5 clusters of sequences representing multiple infection at the 
outset. The convolution estimates are used as an internal check for star-phylogeny, the 
observed values represent the hamming distance calculated among circulating variants. 
Figures (A and C) show the histogram of  observed hamming distance, Plots (B and D) 
demonstrate the observed pairwise HD (in black) and the theoretical (convolution) 
pairwise HD frequency counts (in red) if the sample were to follow a star-phylogeny, 
and finally the best fitting Poisson by the blue line. 
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4.2.2 Superinfection versus relapse 
4.2.2.1 Cohort characteristics 
A group of 15 patients failed to respond to treatment (which includes the 
patients included in the TF versus SVR study group); six null responders, three 
partial responders, and six relapsers. Paired samples from each patient pre- and 
post-treatment were analysed. Demographic and clinical parameters are shown 
in Table 4-5. 
4.2.2.2 Viral dynamics in pre- and post- treatment paired serum 
samples.  
The pairwise distance between variants (for deep sequencing and clonal 
analysis, this was calculated between the most similar pre-treatment and post-
treatment strains) was significantly higher using direct rather than 
pyrosequencing (mean 0.221 versus 0.026 respectively; p=0.0002).  
 Using direct sequencing, evidence of a new variant was detected in 10/15 
(66%) of patients post-treatment as illustrated in Figure 4-6. In contrast, 
comparison of pre-treatment sequences determined by pyrosequencing with 
clonal sequences from post-treatment samples revealed that 100% of patients 
had evidence of a similar variant present in pre- and post-treatment samples. A 
new variant (in addition to a pre-existing variant) was detected in post-
treatment samples in 6/15 (40%) patients as shown in Table 4-6. The new variant 
was a minority variant in three patients and a majority variant in three patients. 
4.2.2.3 Mixed strain infections  
Multiple strains infection was detected in all 15 patients who failed treatment, 
the number of detected variants was 2-6 variants of genotype 1a. Seven patients 
had evidence of mixed subtype or genotype infection at baseline; six patients 
had two subtypes (1a and 1b), and one patient had a mixed genotype infection 
(1a and 4d). The frequency of minority strains that emerged following therapy 
ranged from 3% to 13% of the viral population in pre-treatment samples and 
reached up to 75-100% of the total viral population in post–treatment samples. 
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4.2.2.4 Patient groups 
In null responders [six patients - P38 (Figure 4-7), P63 (Figure 4-8), P67 (Figure 
4-9), P81 (Figure 4-10), P112 (Figure 4-11) and P118 (Figure 4-12)], mixed 
subtype infection (1a/1b) at the outset was detected in 5/6 patients and the 
sixth patient had multiple variants of genotype 1a. All six patients had evidence 
of a similar strain present pre- and post-infection. Three patients (P63, P67, 
P112) had persistent infection with the same pre-treatment dominant strain, one 
patient (P118) had new dominance of a pre-existing minority variant, and two 
patients (P81, P38) had evidence of a new variant in addition to pre-existing 
strains (minority and majority post-treatment variant respectively). 
 In all partial responders [P31 (Figure 4-13), P21 (Figure 4-14), P105 (Figure 
4-15)], multiple variants were present (3, 4 and 5 variants respectively). One 
patient had persistent infection with the same pre-treatment variant (P31), and 
two patients (P21, P105) had persistent infection with evidence of a new 
previously unidentified strain in the post-treatment sample (minority and 
majority variants respectively). 
 In relapsers [6 patients- P57 (Figure 4-16), P141 (Figure 4-17), P76 (Figure 
4-18), P75 (Figure 4-19), P101 (Figure 4-20), P131 (Figure 4-21), all patients had 
evidence of persisting variants and four of them (P101, P57, P76, P141) showed 
new dominance of pre-existing minority strains. Two patients had evidence of 
new previously undetected strains; in one case the previously undetected variant 
became dominant in the post-treatment sample (P131) while in another patient 
(P75), the undetected variant was a minority strain (29%) on top of a pre-
existing variant (71%). 
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Table 4-5: Clinical characteristics of the treatment failure cohort. 
 
ID: study ID number, UAI: Unprotected Anal Intercourse, PWID – People Who Inject 
Drugs, INDU – Intranasal Drug Use, RVR – Rapid Virological Response, (-) unknown data. 
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Figure 4-6: Phylogenetic tree of direct Sanger sequences. 
 
A maximum likelihood tree was constructed using nucleotide sequences determined 
using Sanger sequencing from paired samples and selected HCV reference sequences 
downloaded from the Los Alamos HCV database (Red- Relapsers, Blue-Null responders, 
and Green-Partial responders). 
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Table 4-6: Characteristics of viral population dynamics and treatment 
response in patients with treatment failure. 
 
Outcome is determined by comparing consensus sequence of pre- and post-treatment 
samples using Sanger sequencing, 2- Pairwise distance is the pairwise distance between 
the similar variants in paired samples where a new dominance of pre-existing minority 
strain was noticed, 3- New dominance is the frequency of the new dominant variant of 
the post-treatment sample detected in the pre-treatment sample. 4- Number of new 
variants detected in the post-treatment sample, 5- Number of variants that cleared 
under treatment pressure. 
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Figure 4-7: Comparison of viral complexity in paired serum samples in P38. 
 
(A) ML tree was constructed using sequences from pre- and post-treatment samples in 
P38 (Null response, Persistent infection with new post-treatment variant detected), and 
selected HCV reference sequences for the Los Alamos HCV database. A total of 4(A-D) 
HCV variants detected. The analysis included; 25 clonal sequences (post-treatment) and 
46755 reads derived from 454 pyrosequencing (pre-treatment). There was a total of 183 
positions in the final dataset. (B) Bubble chart of the frequency of each variant (A-D) in 
pre- and post-treatment samples. (C) The pairwise distance between the most similar 
variants in the pre- and post-treatment samples (p-distance). 
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Figure 4-8: Comparison of viral complexity in paired serum samples in P63. 
       
(A) ML tree was constructed using sequences from Pre- and post-treatment samples in 
P63 (Null response, Persistent infection) and selected HCV reference sequences for the 
Los Alamos HCV database. A total of 4 (A-D) HCV variants detected. The analysis 
included; 25 clonal sequences (post-treatment) and 46156 reads derived from 454 
pyrosequencing (pre-treatment). There was a total of 183 positions in the final dataset. 
(B) Bubble chart of the frequency of each variant (A-D) in paired samples. (C) The 
pairwise distance between the most similar variants in the paired samples (p-distance). 
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Figure 4-9: Comparison of viral complexity in paired serum in P67. 
 
 (A) ML tree was constructed using sequences from paired samples- P67 (Null response, 
Persistent infection), and selected HCV reference sequences for the Los Alamos HCV 
database. A total of 3 (A-C) HCV variants detected. The analysis included; 8 clonal 
sequences (post-treatment) and 10742 reads derived from 454 pyrosequencing (pre-
treatment). There was a total of 183 positions in the final dataset. (B) Bubble chart of 
the frequency of each variant (A-C) in pre- and post-treatment samples. (C) The 
pairwise distance between the most similar variants in the pre- and post-treatment 
samples (p-distance). 
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Figure 4-10: Comparison of viral complexity in paired serum samples in P81 
 
 (A) ML tree was constructed using sequences from paired samples- P81 (Null response, 
Persistent infection with a new post-treatment variant detected), and selected HCV 
reference sequences for the Los Alamos HCV database. A total of 6 (A-F) HCV variants 
detected. The analysis included; 12 clonal sequences (post-treatment) and 19610 reads 
derived from 454 pyrosequencing (pre-treatment). There was a total of 183 positions in 
the final dataset. (B) Bubble chart of the frequency of each variant (A-F) in pre- and 
post-treatment samples. (C) The pairwise distance between the most similar variants in 
the pre- and post-treatment samples (p-distance). 
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Figure 4-11: Comparison of viral complexity in paired serum samples in P112.  
 
(A) ML tree was constructed using nucleotide sequences from paired samples from P112 
(Null response, Persistent infection), and selected HCV reference sequences for the Los 
Alamos HCV database. A total of 6 (A-F) HCV variants detected. The analysis included; 
25 clonal sequences (post-treatment) and 21246 reads derived from 454 pyrosequencing 
(pre-treatment). There was a total of 183 positions in the final dataset. (B) Bubble chart 
of the frequency of each variant (A-F) in pre- and post-treatment samples. (C) The 
pairwise distance between the most similar variants in the pre- and post-treatment 
samples (p-distance). 
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Figure 4-12: Comparison of viral complexity in paired serum samples in P118.  
 
 (A) A maximum likelihood tree was constructed using sequences from paired samples- 
P118 (Null response, Persistent infection with new dominance of a pre-existing minority 
variant), and selected HCV reference sequences for the Los Alamos HCV database. A 
total of 6 (A-F) HCV variants detected. The analysis included; 20 clonal sequences (post-
treatment) and 28131 reads derived from 454 pyrosequencing (pre-treatment). There 
was a total of 183 positions in the final dataset. (B) Bubble chart of the frequency of 
each variant (A-F) in pre- and post-treatment samples. (C) The pairwise distance 
between the most similar variants in the pre- and post-treatment samples (p-distance). 
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Figure 4-13: Comparison of viral complexity in paired serum samples in P31. 
 
  (A) ML tree was constructed using sequences from paired samples-P31 (Partial 
response, Persistent infection), and selected HCV reference sequences for the Los 
Alamos HCV database. A total of 4 (A-D) HCV variants detected. The analysis included; 
35 clonal sequences (post-treatment) and 36422 reads derived from 454 pyrosequencing 
(pre-treatment). There was a total of 183 positions in the final dataset. (B) Bubble chart 
of the frequency of each variant (A-D) in pre- and post-treatment samples. (C) The 
pairwise distance between the most similar variants in the pre- and post-treatment 
samples (p-distance). 
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Figure 4-14: Comparison of viral complexity in paired serum samples in P21.  
 
A) ML tree was constructed using sequences from paired samples-P21 (Partial response, 
Persistent infection with new post-treatment variant detected) and selected HCV 
reference sequences for the Los Alamos HCV database. A total of 5 (A-E) HCV variants 
detected. The analysis included; 29 clonal sequences (post-treatment) and 46755 reads 
derived from 454 pyrosequencing (pre-treatment). There was a total of 183 positions in 
the final dataset. (B) Bubble chart of the frequency of each variant (A-E) in pre- and 
post-treatment samples. (C) The pairwise distance between the most similar variants in 
the pre- and post-treatment samples (p-distance). 
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Figure 4-15: Comparison of viral complexity in paired serum samples in P105.  
 
A)ML tree was constructed using sequences from paired samples-P105 (Partial response, 
Persistent infection with expansion of a pre-existing minority variant with a new post-
treatment variant detected) and selected HCV reference sequences for the Los Alamos 
HCV database. A total of 4 (A-D) HCV variants detected. The analysis included; 26 clonal 
sequences (post-treatment) and 44296 reads derived from 454 pyrosequencing (pre-
treatment). There was a total of 183 positions in the final dataset. (B) Bubble chart of 
the frequency of each variant (A-D) in pre- and post-treatment samples. (C) The 
pairwise distance between the most similar variants in the pre- and post-treatment 
samples (p-distance). 
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Figure 4-16: Comparison of viral complexity in paired serum samples in P57.  
 
ML tree was constructed using sequences from paired samples-P57 (Relapse, Persistent 
infection with new dominance of pre-existing minority variant), and selected HCV 
reference sequences for the Los Alamos HCV database. A total of 3(A-C) HCV variants 
detected. The analysis included; 20 clonal sequences (post-treatment) and 23042 reads 
derived from 454 pyrosequencing (pre-treatment). There was a total of 183 positions in 
the final dataset. (B) Bubble chart of the frequency of each variant (A-C) in pre- and 
post-treatment samples. (C) The pairwise distance between the most similar variants in 
the pre- and post-treatment samples (p-distance). 
Chapter 4: Hepatitis C virus diversity 
220 | P a g e  
Figure 4-17: Comparison of viral complexity in paired serum samples in P141.  
 
 (A) ML tree was constructed using sequences from paired samples-P141 (Relapse, 
Persistent infection with new dominance of pre-existing minority variant) and selected 
HCV reference sequences for the Los Alamos HCV database. A total of 5 (A-E) HCV 
variants detected. The analysis included; 18 clonal sequences (post-treatment) and 
23588 reads derived from 454 pyrosequencing (pre-treatment). There was a total of 183 
positions in the final dataset. (B) Bubble chart of the frequency of each variant (A-E) in 
pre- and post-treatment samples. (C) The pairwise distance between the most similar 
variants in the pre- and post-treatment samples (p-distance). 
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Figure 4-18: Comparison of viral complexity in paired serum samples in P76.  
 
(A) ML tree was constructed using sequences from paired samples-P76 (Relapse, 
Persistent infection with new dominance of pre-existing minority variant) and selected 
HCV reference sequences for the Los Alamos HCV database. A total of 4(A-E) HCV 
variants detected. The analysis included; 20 clonal sequences (post-treatment) and 587 
reads derived from 454 pyrosequencing (pre-treatment). There was a total of 183 
positions in the final dataset. (B) Bubble chart of the frequency of each variant (A-E) in 
pre- and post-treatment samples. (C) The pairwise distance between the most similar 
variants in the pre- and post-treatment samples (p-distance).      
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Figure 4-19: Comparison of viral complexity in paired serum samples in P75.  
 
(A) A Maximum likelihood tree was constructed using sequences from paired samples-
P75 (Relapse, Persistent infection with new post-treatment variant detected) and 
selected HCV reference sequences for the Los Alamos HCV database. A total of 3(A-C) 
HCV variants detected. The analysis included; 17 clonal sequences (post-treatment) and 
23639 reads derived from 454 pyrosequencing (pre-treatment). There was a total of 183 
positions in the final dataset. (B) Bubble chart of the frequency of each variant (A-C) in 
pre- and post-treatment samples. (C) The pairwise distance between the most similar 
variants in the pre- and post-treatment samples (p-distance). 
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Figure 4-20: Comparison of viral complexity in paired serum samples in P101.  
 
(A) ML tree was constructed using sequences from paired samples-P101 (Relapse, 
Persistent infection) and selected HCV reference sequences for the Los Alamos HCV 
database. A total of 4(A-D) HCV variants detected. The analysis included; 24 clonal 
sequences (post-treatment) and 21265 reads derived from 454 pyrosequencing (pre-
treatment). There was a total of 183 positions in the final dataset. (B) Bubble chart of 
the frequency of each variant (A-D) in pre- and post-treatment samples. (C) The 
pairwise distance between the most similar variants in the pre- and post-treatment 
samples (p-distance). 
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Figure 4-21: Comparison of viral complexity in paired serum samples in P131.  
 
(A) ML tree was constructed using sequences from paired samples-P131 (Relapse, 
Persistent infection with new post-treatment variant detected) and selected HCV 
reference sequences for the Los Alamos HCV database. A total of 6 (A-F) HCV variants 
detected. The analysis included; 26 clonal sequences (post-treatment), and 19739 reads 
derived from 454 pyrosequencing (pre-treatment). There was a total of 183 positions in 
the final dataset. (B) Bubble chart of the frequency of each variant (A-F) in pre- and 
post-treatment samples. (C) The pairwise distance between the most similar variants in 
the pre- and post-treatment samples (p-distance). 
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4.3 Discussion 
We hypothesized that high quasispecies diversity is a predictive factor of 
negative treatment outcome while treatment response might be predicted by 
low viral diversity. We further hypothesized that deep sequencing will give an 
accurate estimate of diversity providing a better predictor than the use of less 
sensitive techniques such as Sanger sequencing.  
4.3.1 Predictors of outcome in patients treated with PegIFNα/RBV.  
The response to antiviral therapy is influenced by several viral and host factors. 
Several viral factors have been reported to play a role in the response to 
treatment in HCV-infected patients including viral load and molecular profile of 
quasispecies at baseline. 
 Although patients with low baseline viral load have a favourable treatment 
response,  with an arbitrary value to differentiate between high and low HC viral 
load commonly defined at 800,000 IU/ml, the influence of baseline viral load on 
response to treatment is unlikely to be only due to a high absolute number of 
copies of the RNA (Sallie, 2007). 
 Several studies have been carried out to assess variation within the HCV 
quasispecies and its effect on the response to treatment of chronic HCV 
infection, mainly in HIV-negative populations, but more recently in HIV-positive 
patients.   
 Payan et al. proposed an algorithm for prediction of treatment response in 
HIV/HCV co-infected patients using rapid virological response (RVR; at week 2 
and week 4 after starting treatment) and HCV RNA level. The algorithm allowed 
the prediction of non-SVR as early as week 4 (Payan et al., 2007). Another model 
integrated both host and viral variables including viral complexity as the main 
variable. It had a high positive predictive value in predicting the outcome of 
therapy in HCV-genotype 1b treatment-naïve patients (Saludes et al., 2013). 
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Pre-treatment quasispecies complexity within the HVR1 region is negatively 
associated with SVR during chronic HCV infection using heteroduplex and clonal 
sequence analysis in both HIV-positive and negative patients (Shire et al., 2006, 
Ueda et al., 2004) (Yeh et al., 2002, Moreau et al., 2008). However, Abbate et 
al. did not find any significant difference in Shannon entropy between the 
patients who failed treatment and those who achieved SVR in a homogeneous 
genotype population (Abbate et al., 2004).  
 Another study in HCV genotype 1a and 1b infected patients by Chambers et 
al., concluded that viral diversity could not significantly predict treatment 
responders from non-responders (Chambers et al., 2005). Meanwhile, Fan et al. 
reported that early viral response is correlated with a high genetic diversity at 
base line, although the end point was at 12 weeks of treatment, so a direct 
comparison is not possible as SVR was not investigated in that study. Moreover, 
The difference between two groups did not reach statistical significance (Fan et 
al., 2009). 
 These contradictory results could be attributed to techniques used to 
assess HCV quasispecies diversity which may be another source of data 
discrepancy (Fan et al., 2009). Clonal analysis bias towards missing low- 
frequency variants could affect the analysis of viral complexity. Furthermore, 
until now, the presence or absence of low-frequency variants that may 
contribute to quasispecies complexity may have been undetected; the 
introduction of NGS as a sensitive tool will shed more light on the viral 
complexity due to its ability to detect minor variants. 
 In the present study, we retrospectively investigated the diversity profile of 
two groups of acute HCV/HIV co-infected patients using NGS; a group of ten 
patients who failed to respond to treatment (TF group), and another group of 
ten patients who achieved SVR after standard treatment (SVR group).  
 When we compared the genetic diversity between the two groups, we 
observed that the patients in the TF group had a high degree of intrapatient viral 
diversity in addition to a higher frequency of variable sites in the HVR1 when 
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compared to the SVR group. Consistent with these observations, the entropy 
analysis between the two groups also showed statistically significant differences 
in the variability of amino acids in the TF group (p<0.05) when compared with 
the SVR group.  
 Our data suggest that it may be possible to predict treatment outcome 
using viral diversity measurement at baseline. This is in keeping with previous 
studies that have investigated viral diversity as a potential predictor of the 
treatment outcome (Farci et al., 2002, Chambers et al., 2005, Abbate et al., 
2004, Yeh et al., 2002).  
 The two groups of our study are well defined and matched (e.g., treatment 
naïve, all infected with genotype 1, concomitant infections rigorously excluded), 
and quality genetic data were obtained. However, the small sample size of our 
study makes it difficult to draw conclusions on the correlation between viral 
diversity and response to treatment in HCV. Therefore, larger studies are 
needed to confirm the present findings.  
4.3.2 Transmission diversity 
In order to distinguish infections initiated by a single variant from those where 
multiple variants entered the host, we used Poisson Fitter to estimate Hamming 
distance (HD) frequencies. Although the correlation between high viral diversity 
and low SVR rate has been reported, the time at which viral diversity reaches a 
threshold that causes failure of treatment is unknown. 
 It remains to be determined whether the diversity level at transmission 
defines the outcome, or if there is a gradual expansion of the quasispecies over 
time offering higher possibility of achieving SVR if treatment is initiated during 
acute disease. If transmission diversity is a factor, it might be expected that 
patients with haemophilia as a route of transmission would have greater 
diversity and lower SVR rates than intravenous drug users due to the larger 
inocula introduced; further studies is needed to explore this hypothesis. 
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In our study, the samples in the TF group did not follow star phylogeny, with 
different variants detected, compared to samples following star phylogeny in the 
responder group where one or two variants only were identified as founder 
variants. This may be attributed to higher transmission diversity in the TF group, 
but this study was not set up to investigate this hypothesis. Another possibility is 
that the quasispecies changed after transmission because of adaptation to 
immune pressure. 
 If the time at which the quasispecies diversity reaches a threshold level 
defines the time of treatment, this could potentially be used to target treatment 
appropriately in individual patients. 
4.3.3 Definition of relapse and re-infection in HCV 
In the setting of antiviral treatment in HCV/HIV co-infected MSM, the 
reappearance of viral RNA after treatment is often assumed secondary to re-
infection. This assumption was based on behavioural studies that have shown 
that HIV-infected patients with acute HCV are likely to be at high risk of re-
exposure (Grebely et al., Danta et al., 2007).  
 Multiple variant infections in HCV/HIV co-infected individuals have been 
reported in up to 40% of those infected (Thomson et al., 2011). However, the 
screening methods may lack sensitivity for the detection of low-frequency 
variants. Thus this prevalence may be underestimated. Moreover, the frequency 
of sampling may affect estimates as infrequent sampling may miss transient 
infections. In this study, pre- and post-treatment samples were sequenced to 
investigate whether treatment failure occurred due to viral relapse or re-
infection.  
 Our findings indicate that multiple infections are common in early HCV 
infection, reaching 100% in our cohort, with a mean of 3.8 variants present prior 
to treatment. Other studies may not have detected multiple strains because of 
limited sampling,  primer selection bias, or reduced sensitivity of the method 
used (Wang et al., 2010).  
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The samples used in this study were collected early in the infection timeline. 
Hence, the presence of multiple viral strains at a single time-point is attributed 
mainly to simultaneous transmission or superinfection within a short timeframe 
as the time required for strain, sub-genotype or genotype evolution would be 
longer than the length of infection in each individual.  
 Mixed HCV infection is known to be transient due to immune selective 
pressure or competitive growth between variants leading to the outgrowth of the 
fitter variants (Pham et al., 2010). In contrast, we found that mixed infection 
was present at both time points examined in the majority of our patients; 
variation in quasispecies composition was common suggesting that certain strains 
may have been positively selected during treatment. The presence of multiple 
variants in all post-treatment samples in this cohort suggests that re-infection is 
not the only mechanism of treatment failure in this cohort. The presence of 
previously undetected variants in 40% of post-treatment samples could represent 
superinfection, but could also represent variants present below the detectability 
limit of NGS analysis. 
 In null responders, all patients had a persistent strain pre- and post-
treatment and 50% of patients had a persistent variant that remained dominant 
throughout. Emerging dominance of a pre-existing minority variant occurred in 
two patients, one of whom had evidence of a previously undetected minority 
variant following treatment. In the remaining patient, a new majority variant 
emerged after treatment in addition to a persistent minority variant. This could 
represent superinfection or emergence of a strain below the limit of detection of 
pyrosequencing (in this case, 46,755 sequence reads were analysed pre-
treatment). 
 In partial responders, we found evidence of persistent variants in all three 
patients. In two patients (P21 and P105), the dominant variant cleared following 
treatment while the third patient (P31) cleared a variant representing 44% of the 
pre-treatment viral population. In all cases, clearance was concurrent with a fall 
in viral load during treatment. A previously undetected variant was present in 
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two of three patients in post-treatment samples. Such variants may have been 
positively selected from minority variants undetected in the pre-treatment 
sample or could represent superinfection during treatment. 
 In those with viral relapse, all patients had evidence of a pre-existing 
variant present in post-treatment samples. Three patients (P57, P76, and P141) 
had evidence of emerging dominance of pre-existing minority strains (rising from 
3-9% of in pre-treatment samples to 100% in post-treatment samples). Two 
patients (P101 and P75) had the same majority variant present pre- and post-
treatment. In P75, a previously undetected minority variant was also detected 
post-treatment. One patient (P131) is the most likely case of superinfection in 
the cohort as he had evidence of a persisting minority variant and in addition, 
two new variants were detected.   
 In this study, NGS revealed that all patients who failed to respond to 
treatment had at least one persistent variant. If Sanger sequencing had been 
used alone, persisting variants would have been detected in only 34% of cases. 
The new variants detected by direct Sanger sequencing were found to be due to 
the emergence of a minority variant already present in the pre-treatment 
sample. It is likely that such emergent variants represent viral strains with 
reduced sensitivity to antiviral medications.  
 There is no evidence of re-infection in this cohort. However, view the 
ongoing behavioural risk of this group, we cannot rule out the possibility of re-
infection from the same source.  A new variant has been detected in as many as 
6/15 (40%) of the patient cohort in whom a previously undetected (new) variant 
was found. In three of these cases (20%), the new variant represented the 
majority variant and in three cases (20%), the new variant was a minority 
variant. The presence of new variants in post-treatment samples could be due to 
superinfection, but it also may represent previously undetected minority 
variants selected by treatment or compartmentalised variants within different 
regions of the liver, lymphocytes or the central nervous system (Sobesky et al., 
2007, Forton et al., 2004a, Thomson et al., 2011, Blackard et al., 2007). 
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Several studies of HCV re-infection have been limited by the lack of sensitivity of 
detection method or even the absence of phylogenetic support. Lambers et al. 
reported a high incidence rate of HCV re-infection (15.2 per 100 person years) 
among HIV-infected MSM, who previously cleared HCV after treatment (Lambers 
et al., 2011). Martin et al. also described a high risk of HCV re-infection among 
HIV-positive MSM who were either treated for or who spontaneously cleared 
initial HCV infection (Martin et al., 2013). In German PWID cohort, a re-infection 
rate of 0–4.1/100 person-years has been reported (Grady et al., 2012). These 
studies were not designed to identify multiple variant infections prior to 
treatment, nor the emergence of minority variants following treatment. We 
propose therefore that the definition of re-infection, persisting infection or 
superinfection should always be based on rigorous viral sequencing techniques 
(Figure 4-22). 
4.3.4 HCV compartmentalisation 
Detection of HCV RNA in extrahepatic compartments is reported. However, the 
role of compartmentalised virus acting as a reservoir for future recrudescence is, 
as yet, relatively unexplored (Sobesky et al., 2007, Forton et al., 2004a, Forton 
et al., 2004b, Thomson et al., 2011, Blackard et al., 2007). It has been 
considered an independent predictor of treatment outcome (Di Liberto et al., 
2006). Hara et al. demonstrated that in late relapsers, HCV variants could be 
detected in liver biopsies during the aviraemic phase highlighting the possibility 
of compartmentalisation in patients with viral relapse (Hara et al., 2013). 
  HCV compartmentalization is relatively common among patients with 
HCV/HIV co-infection. Hence, measuring viral diversity in the serum/plasma 
alone may not represent virus replicating within the liver or extrahepatic 
compartments. Therefore, the higher sensitivity offered by NGS in the detection 
of minority variant may not resolve the complexity of intra-host viral population 
in other compartments. This issue needs to be considered in future studies 
(Blackard et al., 2014).  
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Figure 4-22: Viral dynamics during treatment failure. 
 
Four different outcomes are expected after applying drug-selective pressure.   
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4.4 Conclusion 
Deep sequencing has a potential role in laboratory diagnosis of HCV as it offers a 
better understanding of viral populations than current techniques; however, 
further clinical studies are required to validate this technology in the clinical 
setting.  
 The complexity of HCV evolution affects our understanding of the natural 
history of disease. Hence, a phylogenetic analysis is required to understand the 
viral diversity in any clinical samples, while considering that variants detected in 
peripheral blood may not entirely reflect the viral dynamics due to lack of 
representation from other sites (e.g. liver biopsies).  
 Using NGS we were able to address two important questions in the field of 
HCV; SVR of acute HCV infection can be predicted by low viral diversity within 
the quasispecies population, and the emergence of new viral strains following 
treatment failure is most commonly associated with emerging dominance of pre-
existing minority variants rather than re-infection. Super-infection may occur in 
this cohort, but re-infection is overestimated by current diagnostic techniques. 
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Chapter 5: HCV antiviral drug resistance 
5.1 Background 
As discussed in Chapter 1, HCV DAAs target several proteins and functions, 
namely the NS3 protease, NS5A and the NS5B RNA-dependent polymerase (Heim, 
2013, Schneider and Sarrazin, 2014). IFN-free regimens are now recommended as 
first-line therapies in the latest HCV treatment guidelines issued by the 
European Association for the Study of the Liver (EASL) and the American 
Association for the Study of the Liver (AASLD) and will also be recommended in 
the forthcoming WHO guidelines in 2015/2016  (EASL, 2015, AASLD/IDSA, 2015). 
The question of whether the successful launch of DAAs will be limited by the 
emergence of drug resistance is a subject of intense debate. 
 The introduction of the first generation of protease inhibitors (PI) in 
combination with PegIFNα/RBV provided the first evidence of an increased 
likelihood of achieving SVR in both HCV mono-infected and HCV/HIV co-infected 
populations by directly targeting viral function. In genotype 1-infected patients, 
triple therapy with PegIFNα/RBV and the NS3 PIs, TVR or BOC, showed 
significantly improved SVR rates compared to PegIFNα/RBV alone (Poordad et 
al., 2011, Bacon and Khalid, Zeuzem et al., 2011, Enomoto et al., 2013). 
However, TVR and BOC have limited efficacy against non-genotype 1 NS3 
proteases and so were restricted for use to genotype 1–infected patients.  
 Since 2011, additional PIs including SMV and PTV have demonstrated pan-
genotypic activity. Newer DAAs now include inhibitors of the NS5B polymerase 
(SOF and DSV) and NS5A (DCV, LDV, and OBV). The efficacy profiles of the 
different DAAs are described in detail in Section 1.12.  
 Drug resistance information on DAAs used to treat HCV infection is 
accumulating rapidly (Sarrazin and Zeuzem, 2010, Welsch et al., 2012). Strains 
within the HCV quasispecies may carry mutations that confer resistance to DAAs 
by either preventing elongation of RNA synthesis or blocking other functions 
required for replication.  
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Naturally occurring RAVs are selected early in monotherapy (Sarrazin et al., 
2007, Susser et al., 2009), and natural polymorphisms are prevalent in treatment 
naïve populations (Kuntzen et al., 2008).  
 The prevalence of RAVs is variable and depends on the domain involved in 
binding the DAAs, the exposure to a drug, the genetic barrier to resistance, and 
HCV genotype. Moreover, host immune responses exert powerful selection 
pressure that influence HCV genetic diversity and replication dynamics, thereby 
affecting the development of RAVs (Gaudieri et al., 2009). The ability of RAVs to 
persist and induce treatment failure is related to their fitness compared to the 
wild-type virus (Welsch et al., 2012). 
 As described in Chapter 3, the detection of RAVs depends primarily on the 
sensitivity of the method that is used. The impact of RAVs present at very low 
frequencies is not well understood, and further studies are needed. It is very 
likely, however, that most drug resistance variants are present at a low level 
before subsequent selection under treatment pressure rather than arising de 
novo following the start of treatment.  
 RAVs must be able to replicate efficiently in order to occupy replication 
space left by susceptible WT virus during drug exposure. Thus, a low-level 
resistant RAV that can propagate efficiently in the presence of the drug has 
more clinical significance than a highly resistant RAV with low replication 
fitness. The fitness of a resistant variant may be restored with compensatory 
mutations that allow it to replicate efficiently in the presence of the drug, and 
even to persist after drug withdrawal.  
 In the following sections, an exhaustive literature review was carried out to 
create a database of all reported in vitro and in vivo RAVs that confer resistance 
against current DAAs (SMV, PTV, LDV, OBV, DCV, DSV, or SOF). A total of 1070 
journal hits were retrieved from a literature search and 140 reports fulfilled the 
inclusion criteria for our review. 
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5.1.1.1 NS3/4A protease inhibitors. 
Currently, there are two types of NS3 PI. The first generation PIs; TVR and BOC, 
were designed to form covalent bonds within the active site of the viral 
protease, whereas second generation PIs, including SMV and PTV, are both non-
covalent inhibitors of NS3. NS3 PIs act by inhibiting protease-mediated cleavage 
at boundaries between non-structural proteins encoded by the viral genome (Lin 
et al., 2006). This is described further in Section 1.12 (Romano et al., 2010). 
 In vivo RAMs are shown in Figure 5-1 and in vitro mutations conferring 
resistance to SMV are listed in the Appendix (7.21). The natural Q80K resistance 
polymorphism has a prevalence that varies geographically - in South America, it 
occurs in 9.1% of genotype 1a isolates, in Europe 19.4%, and in North America 
48.1% but is rarely detected in genotype 1b (0.5%) (Schneider and Sarrazin, 
2014). It can also emerge on therapy; the median time until loss of the Q80K 
mutation is between 24 and 36 months after stopping treatment (Schneider and 
Sarrazin, 2014).  
 PTV shows a mean viral load decline of 4 log10 when administered for three 
days as monotherapy. In order to increase its bioavailability and prolong its half-
life, it is boosted with ritonavir leading to a reduced dosage regimen 
requirement (Gentile et al., 2014a, Pilot-Matias et al., 2015). Ritonavir-boosted 
PTV/ OBV/ DSV (PrOD) ± RBV for 12 weeks is associated with SVR rates of 90-
97.5% in naïve and treatment-experienced non-cirrhotic patients with HCV 
genotype 1 (Ferenci et al., 2014) (Zeuzem et al., 2014b).  
 Mutations that present the highest level of resistance to PTV are 
D168A/H/Y and R155K, which result in a x59-219 and x37-43 fold increase in 
resistance compared to wild-type respectively. RAMs reported in vivo are shown 
in Figure 5-1 and in vitro in the Appendix (7.19). Overlapping cross-resistance 
profiles for SMV and PTV as shown in Figure 5-1. 
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Figure 5-1: Schematic representation of Protease inhibitors resistance associated 
mutations detected in vivo. 
 
Reported RAMs to SIM and PTV occur at nine residues. The color code indicates the 
agent against which the residue confers resistance. 
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5.1.1.2 NS5A inhibitors 
Inhibitors of NS5A interfere with viral replication and assembly, but their 
mechanisms of action are unclear. A single dose of DCV, OBV or LDV results in a 
substantial reduction in viremia in patients with genotype 1 HCV (Nettles et al., 
2011), but they have a low genetic barrier to resistance (Pawlotsky, 2013a, 
Nakamoto et al., 2014). RAVs reported with DCV, LDV, and OBV treatment are 
summarised in Figure 5-2. 
5.1.1.3 NS5B inhibitors 
NS5B inhibitors can be divided into two different groups; non-nucleoside 
inhibitor and nucleoside analogues (Asselah and Marcellin, 2011). SOF is a 
nucleoside analogue that serves as a chain terminator; hence, it hampers the 
elongation of RNA transcripts.  In contrast, DSV is a non-nucleoside inhibitor that 
binds to a distinct site on the HCV RdRp leading to disruption of viral replication 
(Asselah and Marcellin, 2011). 
 Mutations that confer resistance to SOF and DSV are presented in Figure 
5-3. RAVs reported in vitro are detailed in the Appendix (7.29 and 7.31). The 
first in vitro RAV reported against SOF was the substitution of serine 282 with 
threonine (S282T) (Wohnsland et al., 2007). However, as this mutation results in 
a large reduction in replicative capacity (up to 20%) compared with WT replicon, 
it is not prevalent as a natural polymorphism (Ludmerer et al., 2005). None of 
the 1292 patients reported in phase 3 studies harboured the S282T mutation 
(Schneider and Sarrazin, 2014).  
 Compensatory mutations may enhance replication capacity without altering 
the level of resistance conferred by the S282T substitution (Ali et al., 2008). SOF 
maintains activity against HCV variants harbouring mutations conferring 
resistance to other classes of DAAs, which present it as a potent option for 
retreatment in case of treatment failure (Abraham and Spooner, 2014). Residues 
associated with resistance to the non-nucleoside inhibitor DSV have been 
reported more frequently in vitro rather than in vivo. 
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The mutation with the highest level of resistance is C316Y, which results in 
1472-fold resistance compared to wild-type in vitro. 
5.1.2 Replicative fitness  
Viral fitness is defined as the replication capacity of mutated variants in 
proportion to the replication capacity of the WT virus. It is a major determinant 
of the frequency of RAVs within the viral quasispecies, as the persistence of 
RAVs depends on their viral replication fitness (Welsch et al., 2012). 
 The HCV replicon system is extensively used to assess the replicative fitness 
of HCV variants in vitro (Bartenschlager and Lohmann, 2000). Viral fitness may 
also be estimated in vivo using viral load and clonal analysis at different time 
points after the end of therapy to assess the growth rate of RAVs compared to 
WT virus after the withdrawal of drug-selective pressure (Susser et al., 2009). 
RAVs regularly emerge, but they do not persist in the absence of selective 
pressure due to the intrinsic fitness cost of resistance mutations (Rong and 
Perelson, 2010, Adiwijaya et al., 2010). 
 In this chapter, we describe the construction of an HCV genotype 1a 
subgenomic transient replication system to evaluate the replication fitness of 
mutations in this genotype, and we describe a bioinformatics approach to 
predict putative SOF resistance mutations (designed in collaboration with Dr 
Sreenu Vattipally). 
5.1.3 Importance of resistance testing  
Several studies have identified mutations that confer resistance to DAAs (Welsch 
et al., 2012). Understanding resistance patterns is important to enable the use 
of optimum therapies. The emergence of RAVs under drug selection pressure 
leads to reduced DAA efficacy resulting in treatment failure (Pawlotsky, 2011, 
Schneider and Sarrazin, 2014). Almost all individuals that have failed DAA 
treatment have had a resistant mutation present in their sample (Kuntzen et al., 
2008). 
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Figure 5-2: Schematic representation of NS5A inhibitors resistance associated 
mutations detected in vivo. 
 
Reported RAMs to NS5A inhibitors occur at ten residues. The color code indicates the 
agent against which the residue confers resistance. 
 
 
 
 
 
Chapter 5: HCV Antiviral drug resistance 
241 | P a g e  
Figure 5-3: Schematic representation of NS5B inhibitors resistance associated 
mutations detected in vivo. 
 
Reported RAMs to NS5B inhibitors occur at 11 residues. The color code indicates the 
agent against which the residue confers resistance. 
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The clinical significance of pre-existing minority RAVs at baseline and the impact 
of their presence on treatment outcome are still partially described (Thomson et 
al., 2009). A simple model explaining the emergence of HCV resistance to DAA 
drugs is shown in Figure 5-4.  
 The rapid emergence of RAVs in patients who received TVR or BOC 
monotherapy (after <15 days) may be attributed to HCV high replication rate or 
the pre-existence of minority RAVs. The majority of PI RAVs are rarely detected 
by Sanger sequencing as they circulate at low frequency (0.1–3%) and typically 
their fitness is impaired (Schneider and Sarrazin, 2014). However, if their fitness 
reached that of WT virus, they would likely circulate as dominant variants and 
are detected more frequently (Halfon and Sarrazin, 2012). 
 The introduction of NGS enables the detection of minority variants and has 
other advantages; faster processing and larger scale sequencing (Hiraga et al., 
2011, Nasu et al., 2011, Ninomiya et al., 2012). However, challenges of this 
technology include the need for sophisticated bioinformatic tools to enable 
reliable data analysis and exclude possible cross-contamination (NGS is highly 
prone to cross-contamination) (Gregori et al., 2013). 
 The overall aims of this series of experiments were:  
1. To sequence the HCV genome from serum samples of acutely infected, 
treatment-naïve patients using Illumina deep sequencing, and to identify 
baseline polymorphisms associated with known resistance to DAAs.  
2. To construct a genotype 1a subgenomic replicon to quantify viral fitness in 
vitro of selected resistance mutations introduced into the NS5B gene. These 
mutations included four mutations predicted in silico and two control mutations 
reported in the literature.  
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Figure 5-4: Model of HCV resistance in case of pre-existing minority RAV. 
 
 
 
The figure illustrates the minority RAV that has poorly fitness before treatment. During 
treatment with DAAs, these pre-existing RAVs have a fitness advantage and can outgrow 
the dominant variant in the viral quasispecies, while the sensitive viral variants fail to 
replicate. After the end of therapy, the viral fitness returns to pre-treatment condition 
and the viral population revert to WT variant. Modified from (Pawlotsky, 2006). 
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5.2 Results 
Sixteen samples from treatment-naïve acute HCV/HIV co-infected individuals 
were analysed in the following section; all patients were genotype 1a. Samples 
were processed using the metagenomic approach for HCV full genome 
sequencing as described in Section 2.10.2. Sequences were screened for 
substitutions at amino acid residues reported to confer resistance against 
currently recommended DAAs; PIs (SMV and PDV), NS5A inhibitors (DCV, LDV, and  
OBV) and NS5B inhibitors (SOF and DSV). A comparison group of sequences from  
18 HCV mono-infected, genotype 1a treatment-naïve patients was used from the 
HCV Research UK cohort.  
5.2.1 Natural polymorphisms in the NS3 protease region 
A natural polymorphism at Q80 was the most prevalent RAM in the HCV/HIV 
cohort (56.25%). Other polymorphisms were present in approximately 25% of 
patients at residues V36, D168, and I/V170. As many as 12.5% of patients were 
identified to have a polymorphism at residues F43, T54, V55, A156, or F169 
(Figure 5-5). 
In the 18 HCV mono-infected patients, polymorphisms at baseline were 
found in fewer residues other than Q80; Q80 (83.33%), R155 (11%), D168 (11%), 
and F169 (5.6%). Unlike HIV/HCV co-infected patients, polymorphisms at V36, 
Q41, F43, T54, V55, A156, V163, and I/V170 were not detected in patients with 
mono-infection. 
5.2.1.1  Resistance associated variants in the NS3 protease region. 
In the HCV/HIV cohort, the prevalence of RAVs was calculated within each 
mutation site. All detected mutations were associated with PI resistance except 
two residues (V55 and V/I 170) (Figure 5-6). In the HCV mono-infection cohort, 
all detected mutations were known RAMs. 
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5.2.1.2  Distribution of resistance-associated variants in NS3 protein at 
intra-host Level 
In the HCV/HIV cohort, RAVs that were identified in the NS3 region represented 
a minority variant except Q80 variants. Q80K was distributed as an intermediate 
(20-50%) and major variant (>50%), in three patients and one patient 
respectively (Figure 5-7). A list of individual mutations detected is shown in 
(Table 5-1). 
 For HCV mono-infected patients, RAVs were detected as minor variants at 
Q80, R155, D168, and F169 at low prevalence, which ranged from 6%-20% out of 
18 samples and only 1 patient had Q80K as a dominant resistance variant. Only 
3/18 subjects did not have natural occurring RAVs (Figure 5-8). 
5.2.2 Natural polymorphism in the NS5A gene 
Baseline polymorphisms within NS5A were found at residues M28 and M62 in half 
of the study cohort. In other reported residues, the percentage of mutated 
residues was Q30 (43.75%), H58 (37.5%), Y93 (37.5%), K24 (31.25%), A92 
(18.75%), L31 (12.5%), S38 (12.5%) and mutations in P32 were the lowest 
detected at only 6.25% of total population (Figure 5-9). Amongst mono-infected 
samples, two residues, H58 and E62 were detected in 55% and 66% of total 
samples respectively. K24 and Y93 were detected in as many as 50%, whereas 
M28 and Q30 were slightly lower at 28%. P32 and A92 had a low prevalence level 
at 5.56%. Variants at residues L31 and S38 were not detected in any sample. 
5.2.2.1 Resistance associated variants in NS5A 
In the HCV/HIV cohort, the mutations detected in NS5A residues were not 
exclusively RAVs. All mutations detected at S38 and H58 were not reported in 
the literature to confer resistance. Only 37.5%, 40%, and 62% of detected 
mutation at residues E62, K24, and M28 respectively were known RAVs. 
However, all mutations detected in residues Q30, L31, P32, A92, Y93 were 
known RAVs (Figure 5-10). 
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Figure 5-5: Prevalence of natural polymorphisms in NS3 of HIV/HCV co-
infected patients and HCV mono-infected patients. 
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Samples were sequenced using the Illumina MiSeq. The prevalence of RAVs was 
measured as a percentage (%) of the total number of variants present at baseline in 
each cohort. 
 
 
 
 
 
 
 
Chapter 5: HCV Antiviral drug resistance 
247 | P a g e  
Figure 5-6: Frequency of RAVs within NS3 in HIV/HCV co-infected patients. 
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Baseline polymorphisms were stratified into resistance associated (RAV) and non-
resistance associated variants (Non-RAV). Prevalence is shown as the percentage (%) of 
total HIV/HCV co-infected samples (N=16). 
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Figure 5-7: Distribution of baseline RAVs within NS3 of HIV/HCV co-infected 
patients. 
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The frequency of RAVs within the HCV intra-host quasispecies was categorized as minor 
(<20%), intermediate (20-50%) and dominant (>50%) variants. Prevalence is the 
percentage (%) of the total number of RAVs in all HIV/HCV co-infected patients. 
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Figure 5-8: Distribution of baseline RAVs in NS3 region of HCV mono-infected 
patients. 
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The frequency of RAVs within HCV intra-host quasispecies was categorized as minor 
(<20%), intermediate (20-50%) and dominant (>50%) variants. Prevalence was shown as 
the percentage (%) of total number RAVs in all HCV mono-infected patients. 
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Table 5-1: Prevalence of resistance-associated variants within the NS3 gene 
in HIV/HCV co-infected patients and distribution at the intra-host level. 
NS3 Protein 
residues 
Mutation 
Prevalence in total 
population (%)           
N=16 
Prevalence within 
individual                 
 (% range) 
V36 A 12.5% 1.00% 
 
G 12.5% 3% (1-5%) 
 
L 18.75% 1.3% (1-2%) 
T54 A 6.25% 2.00% 
 
S 12.5% 1.5% (1-2%) 
V55 A 6.25% 4.00% 
Q80 K 50% 29% (1-85%) 
 
L 6.25% 1% 
 
H 6.25% 1% 
 
R 6.25% 4% 
R155 K 6.25% 1% 
 
T 6.25% 1% 
 
S 6.25% 3% 
A156 S 12.5% 1% 
D168 Y 12.5% 1% 
 
A 6.25% 1% 
 
V 6.25% 1% 
 
G 12.5% 1% 
 
E 6.25% 4% 
 
N 6.25% 2% 
F169 L 12.5% 1.5% (1-2%) 
V/I 170 L 12.5% 3% 
 
T 6.25% 1% 
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Meanwhile, in samples with HCV mono-infection, all variants at position Q30 and 
Y93 are associated with resistance. Furthermore, as many as 80% of patients 
with mutations at M28 were reported RAVs, while only 11% of detected 
mutations at K24 were RAVs. No HCV mono-infected patient was harbouring RAVs 
at P32, H58, E62 and A92 (Figure 5-11). 
5.2.2.2 Distribution of RAVs in NS5A at the intra-host level 
In the HCV/HIV cohort, only one patient harboured the M28V RAV as a dominant 
variant (90%), while other minor RAVs were distributed at residues K24, L31, 
P32, Q54, H58, E62, A92, and Y93 by prevalence from 6.25% up to 50% out of 16 
patients. Intermediate RAVs were found in only one patient at Q30 (Figure 5-12). 
A detailed distribution of individual mutations detected is listed in Table 5-2. 
 In the NS5A region of HCV mono-infected patients, Y93H was a dominant 
variant in only one sample. In addition, minor variants were identified at 
residues K24, M28, Q30, and Y93 (Figure 5-13).  
5.2.3 Natural polymorphisms in the NS5B gene 
In the HCV/HIV cohort, polymorphisms were found mostly in the NS5B region 
compared to the other non-structural genes. The most prevalent mutation sites 
were L159, C316, A553, and S556 with a mutation detected in 37.5% of total 
samples and 31.25% at residue E446. The prevalence of baseline polymorphisms 
at other sites was as follows, M414 (18.75%), S282 (12.5%), L320 (12.5%), V321 
(12.5%), Y448 (6.25%), and D559 (6.25%) (Figure 5-14). 
 Polymorphisms were fewer in HCV mono-infected patients. The most 
prevalent amino acid substitution was at C316 and detected in up to 61% of 
samples, (C316N was not reported as an RAV for genotype 1a). Natural 
polymorphisms were detected at residues E446 (55.5%), L159 (50%), A553 
(44.4%), and S556 (44.4%).  
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Substitutions at S282 and Y448 (11.1%), L320 and V321 (5.5%), and M414 (11.1%) 
had lower prevalences. No mutations were identified at the D559 site. 
5.2.3.1 Resistance associated variants within NS5B 
In the HCV/HIV cohort, all substitutions detected at residues L159, S282, M414, 
A553, S556, and D559 have previously been reported as RAVs. The frequency of 
resistance polymorphisms at position E446 was 80% while 50% of the mutations at 
L320 and V321 were reported RAVs. Amino acid substitutions at C316 have also 
been identified as RAVs and were present at a frequency of 16.6%. Finally, none 
of the mutations detected at Y448 were identified to be RAVs (Figure 5-15). 
 The NS5B S282T mutation was detected in one patient with a frequency of 
3% while two other substitutions were detected in the same patient, S282R and 
S282G at frequencies of 12% and 5% respectively. 
 In the HCV mono-infected cohort, all substitutions detected at residues 
L320, M414, E446, A553, and S556 were known to confer resistance. Half of the 
mutations at S282, compared to 33.3% of mutations detected at L159 were found 
to be RAVs. Meanwhile, none of the mutations detected at residues C316, V321, 
Y448 was identified as an RAV (Figure 5-16). 
5.2.3.2 Distribution of RAVs in NS5B at the intra-host level 
In the HCV/HIV cohort, all RAVs were detected as minority variants. In the NS5B 
region, apart from the mutations reported in vivo that are shown above, many 
mutations are reported to confer resistance to SOF and DSV in vitro as listed in 
the appendix (7.29 and 7.31). Below is a detailed list of all mutations detected 
in this cohort including RAVs reported both in vivo and in-vitro  
 Dominant resistance-associated variants were detected in the HCV mono-
infected cohort at residues L159 and E446Q. Intermediate variants were 
detected in 37.5% of samples at two residues, A553 and S556. Other detected 
RAVs at other residues were minority variants (Figure 5-17). 
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Figure 5-9: Prevalence of natural polymorphisms within NS5A in HIV/HCV 
coinfected and HCV mono-infected patients. 
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Samples were sequenced using the Illumina MiSeq. The prevalence of RAVs was 
measured as a percentage (%) of the total number of variants present at baseline in 
each cohort. 
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Figure 5-10: Frequencies of resistant and non-resistant variants within NS5A 
in HIV/HCV Co-infected Patients. 
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Baseline polymorphisms were stratified into resistance associated (RAV) and non-
resistance associated variants (Non-RAV). Prevalence is shown as the percentage (%) of 
total HIV/HCV co-infected samples (N=16). 
 
 
 
 
 
 
 
 
Chapter 5: HCV Antiviral drug resistance 
255 | P a g e  
Figure 5-11: Frequencies of resistant and non-resistant variants within NS5A 
region in HCV mono-infected patients. 
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Baseline polymorphisms were stratified into resistance associated (RAV) and non-
resistance associated variants (Non-RAV). Prevalence is shown as the percentage (%) of 
total HCV mono-infected samples (N=18).  
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Figure 5-12: Distribution of baseline RAVs in NS5A of HIV/HCV co-infected 
patients. 
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The frequency of RAVs within the HCV intra-host quasispecies was categorized as minor 
(<20%), intermediate (20-50%) and dominant (>50%) variants. Prevalence is the 
percentage (%) of the total number of RAVs in all HIV/HCV co-infected patients. 
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Figure 5-13: Distribution of baseline RAVs in NS5A of HCV mono-infected 
patients. 
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The frequency of RAVs within HCV intra-host quasispecies was categorized as minor 
(<20%), intermediate (20-50%) and dominant (>50%) variants. Prevalence was shown as 
the percentage (%) of total number RAVs in all HCV mono-infected patients. 
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Table 5-2: Prevalence of RAVs within NS5A in HIV/HCV co-infected patients 
and distribution at the intra-host level. 
NS5A Protein 
residues 
Mutation 
Prevalence in total 
population (%)           
N=16 
Prevalence within 
individual                 
(% range) 
K24 N 12.50% 3% (2-4%) 
M28 I 18.75% 3% (1-5%) 
 
T 6.25% 1% 
 
V 6.25% 90% 
Q30 H 25.00% 5.25% (1-13%) 
 
R 18.75% 1% 
 
K 6.25% 4% 
 
P 6.25% 4% 
L31 M 12.5% 2.5% (2-3%) 
 
R 12.5% 2.5%(1-4%) 
P32 L 6.25% 1% 
E62 D 18.75% 2% (1-3%) 
A92 T 18.75% 1% 
Y93 C 6.25% 1% 
 
H 25.00% 2% (1-4%) 
 
S 12.50% 2.5% (2-3%) 
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Figure 5-14: Prevalence of Natural Polymorphisms in NS5B Region of HIV/HCV 
Co-infected Patients (HIV/HCV) and HCV mono-infected patients (HCV). 
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Samples were sequenced using Illumina MiSeq. Prevalence was measured as a 
percentage (%) of the total number variants at baseline at a particular site in all 
samples. 
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Figure 5-15: Frequencies of resistant and non-resistant variants within NS5B 
in HIV/HCV Co-infected Patients. 
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Baseline polymorphisms were stratified into resistance associated (RAV) and non-
resistance associated variants (Non-RAV). Prevalence is shown as the percentage (%) of 
total HIV/HCV co-infected samples (N=16). 
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Figure 5-16: Frequencies of Resistant and Non-resistant Variants Within NS5A 
Region in HCV mono-infected Patients 
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Baseline polymorphisms were stratified into resistance associated (RAV) and non-
resistance associated variants (Non-RAV). Prevalence is shown as the percentage (%) of 
total HCV mono-infected samples.  
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Figure 5-17: Distribution of baseline RAVs in NS3 region of HCV mono-
infected patients. 
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The frequency of RAVs within HCV intra-host quasispecies was categorized as minor 
(<20%), intermediate (20-50%) and dominant (>50%) variants. Prevalence was shown as 
the percentage (%) of total number RAVs in all HCV mono-infected patients. 
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Table 5-3: Prevalence of resistance-associated variants within NS5B protein 
in HIV/HCV co-infected patients and distribution at intra-host level. 
NS5B Protein 
residues 
Mutation 
Prevalence in total 
population (%)            
N=16 
Prevalence             
within individual                 
(% range) 
C110 S 37.50% 21.7% (2-35%) 
N117 S 12.50% 2.00% 
L159 F 25.00% 1.25% (1-2%) 
S282 G 6.25% 5.00% 
  R 6.25% 1.00% 
  T 6.25% 3.00% 
C316 W 12.50% 4% (3-5%) 
  N 25.00% 7.5% (4-18%) 
  K 6.25% 1.00% 
L320 F 6.25% 4.00% 
V321 A 6.25% 2.00% 
  I 6.25% 2.00% 
A376 C 12.50% 1.5% (1-2%) 
T390 I 6.25% 1.00% 
A395 G 6.25% 1.00% 
V405 I 43.75% 24.7% (1-99%) 
N411 S 6.25% 1.00% 
M414 I 18.75% 3% (1-7%) 
  L 12.50% 3.5% (2-5%) 
  V 6.25% 1.00% 
F415 Y 31.25% 29.2% (1-39%) 
S431 G     
I434 M 62.50% 27.1% (1-99%) 
C445 F 6.25% 4.00% 
E446 Q 25.00% 1.00% 
C451 G 12.50% 3% (2-4%) 
  S 12.50% 1.5% (1-2%) 
A553 T 6.25% 2% 
S556 G 37.50% 4.5% (1-12%) 
  R 6.25% 6.00% 
D559 G 6.25% 1.00% 
  N 6.25% 1.00% 
I585 V 6.25% 89.00% 
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5.2.3.3 Prevalence of predicted mutations in the HCV/HIV cohort  
A prediction model of mutations that confer resistance to SOF was designed as 
described in Section 2.18.8. It predicts key residues that could interact with the 
SOF binding site at R32, G493, P495, and P496 (Figure 5-18). The cohort used 
above was analysed for the presence of any of these residues. Minority variants 
only were detected in only two samples as listed in Table 5-4. 
5.2.4 Design of a genotype 1a replicon-based luciferase assay  
5.2.4.1 Strategy for the construction of a replication-competent 
genotype 1a subgenomic replicon.  
The genotype 1a HCV replicon APP238 pH/SG-Neo (L+I) was modified by 
introducing a luciferase firefly cassette and two adaptive mutations; NS4A-
K1691R and NS4B-E1726G through a cloning strategy involving an intermediate 
cloning vector pGFP-C1 (Figure 5-19). This replicon was used as a backbone for 
mutations within the NS5B region, introduced to assess replicative fitness. 
5.2.4.2 Introduction of the luciferase reporter gene 
To construct subgenomic TA/SG/Luc/HCV-1a  replicons containing the luciferase 
gene, a fragment composed of the firefly luciferase gene was amplified from 
pSGR-JFH1 using forward and reverse primers (Kato et al., 2003). The luciferase 
gene was amplified with primers flanked by restriction sites for ApaLI and AscI 
enzymes to produce a DNA fragment with ApaLI and AscI sites at the 5` and 
3`termini, respectively with an expected product size of 1650 bp. The primers 
were designed using CLC genomics®:  5`-ApaLI-luc: Gtgcac c ATG GAA GAC GCC 
AAA AAC, 3- luc(stop)-AscI:  “ GGC GGA AAG ATC GCC GTG TAA gGcgcgcc“.  
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Figure 5-18: Predicted NS5B resistance associated mutations based on HCV 
structure and interaction sites. 
 
Residues interacting with the SOF active site on NS5B within 5 Å are shown. Halos 
around residues represent the degree of interaction, four residues (R32, G493, P495, 
and P496) are predicted as potential resistance mutations (Reproduced with permission 
from Dr Sreenu Vatipally). 
Table 5-4:  List of mutations detected in predicted residues. 
 
Sample 1 Sample 2 
R32 P (2%), L (2%), G (2%), S (3%) C (1%), L(2%),P(1%),S(3%) 
G493 E (1%), L(1%) E(1%),R(2%), V(6%),W(3%) 
P495 Q(2%) T(5%), Q(4%), L(2%) 
P496 T(3%) L(2%),H(4%),T(5%) 
The four residues harboured minority variants in 12.5% of the study cohort. 
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The genotype 1a HCV replicon APP238 pH/SG-Neo (L+I) was digested using AgeI 
and KpnI as illustrated in (Figure 5-20), the schematic representation of this 
process is shown in (Figure 5-21). The resulting fragment was ligated into the 
pGFP-C1 plasmid as shown in (Figure 5-22), to allow the introduction of the 
luciferase cassette.  
 After introducing the luciferase cassette into the AgeI-KpnI fragment, 
another digest was carried out to re-introduce the fragment back into the 
subgenomic replicon backbone (shown in the red circle, 1 Figure 5-20). The 
ligation product (TA/SG/Luc/HCV-1a) was then transformed into E. coli followed 
by selection and culturing of tetracycline-resistant colonies. The resulting 
constructs were then sequenced to confirm the presence and correct orientation 
of the fragment carrying the luciferase cassette. 
 The two adaptive mutations, NS4A (K1691R) and NS4B (E1726G) were 
introduced into TA/SG/Interim/HCV-1a replicon using site-directed mutagenesis. 
Subcloning of the digested red fragment shown in Figure 5-23 using NsiI and 
Bsu36I in the TA/SG/Luc/HCV-1a backbone, the resulting replicon was 
sequenced using Sanger sequencing to confirm the orientation of the fragment 
and the presence of mutations as shown in Figure 5-24 and Figure 5-25. 
 Meanwhile, an intermediate plasmid TA/SG/Interim/HCV-1a was produced 
(Figure 5-23) by digesting TA/SG/Luc/HCV-1a using AgeI and PmlI to create a 
shorter plasmid of 8417 bp as shown in Figure 5-20 (green square). A  shorter 
replicon was used to decrease the error rate in future subcloning. 
 The predicted resistance mutation in our model was introduced to the 
intermediate replicon via site-directed mutagenesis. Both TA/SG/Interim/HCV-
1a and wild-type TA/SG/Luc/HCV-1a were digested using the restriction 
enzymes ClaI and Bsu36I, to produce a final mutated subgenomic replicon as 
shown in Figure 5-26. 
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Figure 5-19 Cloning strategy.  
 
 
 
 
 
 
 
 
 
 
The cloning strategy involved 3 different replicons and 3 steps; 1) Replacing the neomycin gene with a luciferase cassette (pGFP-C1), 2) Creating an 
interim replicon with shorter length to introduce the mutations (TA/SG/Interim/HCV-1a), 3) Subcloning of the mutated fragment in the interim replicon 
into the final fit replicon (TA/SG/Luc/HCV-1a). 
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Figure 5-20: Restriction digest of replicon APP238 pH/SG-Neo (L+I). 
 
 
The plasmid was digested using AgeI & KpnI in lane 1 with the excised larger fragment 
used as a vector for TA/SG/Luc/HCV-1a (red circle). In lane 2, APP238 pH/SG-Neo (L+I) 
was digested using AgeI & PmlI creating the TA/SG/Interim/HCV-1a of 8417bp (green 
square). Lane 3 shows linearised APP238 pH/SG-Neo (L+I) using the single cutter 
restriction enzyme AgeI.  
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Figure 5-21: Schematic illustration of a restriction digest of APP238 pH/SG-
Neo (L+I) using AgeI and KpnI. 
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Figure 5-22: pGFP-C1 as intermediate vector to introduce the Luciferase 
firefly cassette 
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Figure 5-23: Schematic illustration of TA/SG/Interim/HCV-1a with different 
mutations to be introduced. 
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Figure 5-24: E1726R mutation (GAG)-(GGG) 
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Figure 5-25: K1691R mutation (AAG) – (AGG) 
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Figure 5-26: TA/SG/Luc/HCV-1a culture adapted replicon. 
 
 
The green fragment of the TA/SG/Interim/HCV-1a contained the target mutation and 
was ligated with the TA/SG/Luc/HCV-1a vector fragment, forming the final mutated 
subgenomic replicon. 
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5.2.4.3 Transient replication assay  
To investigate the replicative fitness of replicon variants containing RAVs, a 
transient replication assay was performed to measure replication capacity in 
Huh7.5 cells via luciferase reporter gene activity using pSGR-Luc-JFHI as a 
control. The pattern of luciferase activity displayed by the pSGR-Luc-JFHI was 
similar to previously published data (Targett-Adams and McLauchlan, 2005). 
 The number of Huh7.5 cells in each assay was adjusted to avoid confluence 
at 96h; 150,000 cells in each well of a 24 well plate was found to be optimum for 
the assay. For the TA/SG/Luc/HCV-1a replicon, luciferase activity gradually 
decreased after the initial time point (4h), but enzyme levels increased from 48 
h to 72 h and then stabilized. The luciferase signal was 100 fold more than the 
activity displayed by the original APP238 pH/SG-Neo (L+I) replicon and the 
TA/SG/Luc/HCV-1a replicons encoding the GND mutation in the NS5B sequence, 
which abolishes the activity of the HCV RNA polymerase (Figure 5-27).   
 After optimisation of the transient replication assay using the 
TA/SG/Luc/HCV-1a  replicon, Huh-7.5 cells were electroporated with 1, 2.5, 5 
or 10 µg TA/SG/Luc/HCV-1a replicon RNA and the luciferase activity contained 
within cell extracts was monitored over 72 h to determine whether the amount 
of RNA used to electroporated cells influenced replication levels. By 4 h, 
luciferase activities were enhanced as the amount of RNA introduced into cells 
was increased. Enzyme levels reached at the end of the experiment were 
similar, irrespective of the amount of input RNA (data not shown). The overall 
luciferase reporter gene activity of the APP238 pH/SG-Neo (L+I) construct did 
not increase with time and remained at similar levels to the negative control 
TA/SG-Luc-1a-GND.  
 Different mutations introduced to the NS5B protein affected replication 
capacity when compared to the TA/SG/Luc/HCV-1a (WT) replicon (Figure 5-28, 
Figure 5-29, and Figure 5-30). Of these, only two maintained reduced replication 
fitness; S96T and P495A (24.43±1.7%) and (20.95±0.75%), respectively, while all 
other mutations showed less than 2% replicative fitness (Figure 5-31). 
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Figure 5-27: Optimisation of a transient replication assay for the subgenomic 
replicon TA/SG/Luc/HCV-1a. 
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RNA was electroporated into Huh-7.5 cells and luciferase activities contained within cell 
extracts prepared at 4, 24, 48, 72 h, 96h, and 120h post-electroporation were 
determined. RLU; Relative light units. This figure represents one experiment carried out 
in triplicate. 
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Figure 5-28: Replication capacity of mutated replicon (S96T, S282T). 
4 h 2 4 h 4 8 h 7 2 h 9 6 h 1 2 0 h
1 0 1
1 0 2
1 0 3
1 0 4
1 0 5
1 0 6
1 0 7
T im e  p o in t
R
L
U
T A /S G -L u c -1 a
T A /S G -L u c -1 a -G N DT A /S G -L u c -1 a -S 9 6 T
T A /S G -L u c -1 a -S 2 8 2 T
 
RNA was electroporated into Huh-7.5 cells and luciferase activities contained within cell 
extracts prepared at 4, 24, 48, 72 h, 96h, and 120h post-electroporation were 
determined. RLU, Relative light units. This represents one of four independent 
experiments with triplicates. 
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Figure 5-29: Replication capacity of the mutated replicon (G493A, P495A, 
P496A). 
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RNA was electroporated into Huh-7.5 cells and luciferase activities contained within cell 
extracts prepared at 4, 24, 48, 72 h, 96h, and 120h post-electroporation were 
determined. RLU, Relative light units. This represents one of four independent 
experiments with triplicates. 
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Figure 5-30: Replication capacity of mutated replicon (R32A, R32H).  
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RNA was electroporated into Huh-7.5 cells and luciferase activities contained within cell 
extracts prepared at 4h, 24h, 48h, 72h, 96h, and 120h post-electroporation were 
determined. RLU, Relative light units. This represents one of four independent 
experiments with triplicates. 
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Figure 5-31: Replicative fitness of replicons containing predicted RAVs. 
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Replicative fitness was calculated as a percentage= [(RLU mutant replicon@96h/ RLU 
mutant replicon@4h /(RLU WT replicon@96h/ RLU WT replicon@ 4h) X100]. Where RLU 
(relative light units) is the absolute value given by Luminometer.  
 
 
 
 
 
 
 
Chapter 5: HCV Antiviral drug resistance 
281 | P a g e  
5.3  Discussion 
In the new era of DAAs targeting HCV, there is a drive towards the routine use of 
IFN-free, all-oral combinations. Although the new regimens are effective, the 
clinical relevance of HCV drug resistance, the role of baseline natural 
polymorphism, and the potential need for resistance testing are important 
clinical questions that remain unanswered. 
 Although detectable at only relatively low percentage prevalence, the 
presence of RAVs in acutely infected, treatment-naïve patients points towards 
two significant phenomena. Firstly, resistance mutations are present within the 
quasispecies even prior to treatment. This can mainly be attributed to the 
dynamics of the viral quasispecies and the error-prone viral RNA polymerase 
(Rong and Perelson, 2010, Strahotin and Babich, 2012). Several studies have 
reported that all single RAVs and around 10% of all potential double RAVs pre-
exist in infected individuals (Pawlotsky, 2009). Secondly, minority RAVs within 
the viral population may be transmissible among humans. As this is the first 
study involving a cohort of acutely infected, treatment-naïve patients, this 
phenomenon has not been described before. It suggests that despite the reduced 
viral fitness usually reported in RAVs, they can circulate within the quasispecies 
in enough numbers to enable transmission. However, the effect of transmission 
bottleneck in which the fittest variant becomes the dominant variant cannot be 
excluded. 
 The possibility that an agent will exert a selection pressure to allow 
outgrowth of RAVs is influenced by numerous factors including the DAA’s genetic 
barrier to resistance, the level of drug exposure, and the replication fitness of 
RAVs  (Lontok et al., 2015).  
 HCV genotype 1a has a lower genetic barrier to resistance than genotype 1b 
variants, hence patients with genotype 1a can acquire RAVs faster, for instance, 
a RAM at residue R155 requires only one nucleotide change in  genotype 1a 
variants while two nucleotide changes are needed to confer resistance in HCV 
subtype 1b isolates (McCown et al., 2009, Pawlotsky, 2009). The prevalence of 
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RAVs at baseline in the studied cohort was higher in HCV/HIV co-infection group 
than in HCV mono-infection group, but the difference did not reach statistical 
significance (p=0.25). This is in line with reports that the prevalence of natural 
baseline polymorphisms varies in different populations, a higher prevalence was 
reported among hemophiliacs (OR 1.67, 95% CI [0.67–4.2]) and HCV/HIV co-
infected patients (OR 3.8, CI [0.86–16.8], but the difference in prevalence was 
not statistically significant when compared with non-hemophiliacs and HCV 
groups respectively (Lin et al., 2014).  
 In HIV infection, numerous studies reported transmitted drug resistance 
with prevalence rates ranging from 3.4% to 26%, which prompted the 
recommendation of drug resistance testing before initiating drug therapy 
(Taiwo, 2009). HCV is not expected to have a similar resistance pattern due to 
two main features: i) it has a higher replication rate that consistently introduces 
errors into the circulating variants which may fasten its reversion to WT and ii) It 
does not integrate into genomic DNA to archive RAVs (Lontok et al., 2015). 
However reports of polymorphisms at certain positions that confer resistance to 
DAAs (e.g. Q80K) indicate drug resistance testing in HCV before treatment. 
5.3.1 Prevalence of natural polymorphisms at resistance-associated 
residues. 
There is an intense debate on the relevance of naturally occurring mutations 
with respect to the development of resistance and probability of success of 
DAAs. 
5.3.1.1 Resistance to NS3 protease inhibitors. 
The majority of RAVs to HCV PIs circulate as low-frequency variants at baseline. 
This is due to the inherent fitness cost caused by the decreased catalytic activity 
of the viral protease (Pawlotsky, 2011). The naturally occurring RAVs in the NS3 
gene have been reported in several studies of HCV viral complexity using 
standard sequencing (Morsica et al., 2009, Paolucci et al., 2012, Bartolini et al., 
2013). 
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In this study, a number of mutations were detected in the NS3 region. 
V36A/G/L, F43L/I/S/V, T54A/S, Q80K/L/H/R, V55A, R155K, A156S, D168 
A/V/Y/G/E/N, F169L, and I/V170L/T substitutions were observed in co-infected 
patients. In contrast, only mutations Q80K, R155S/W, D168G/E/N were detected 
in mono-infected patients. These substitutions have been reported to confer 
resistance to SMV and PTV and were found mostly as minority variants and at low 
prevalence except Q80K. Q80K had a high prevalence at baseline in both 
HIV/HCV coinfected and HCV monoinfected patients (56.25% and 83.3% 
respectively). Other studies also reported Q80K as a common variant at baseline 
by Sanger sequencing and NGS. The prevalence of Q80K in this study was slightly 
higher than in previous reports, which reported 5-40% prevalence by Sanger and 
40-57% by NGS (Shepherd et al., 2015, Jabara et al., 2014, McCormick et al., 
2015, Ruggiero et al., 2015, Ogishi et al., 2015, Leggewie et al., 2013, Kirst et 
al., 2013). 
 Minority RAVs were detected at residues D168A/H/V/Y and R155K, which 
confer the highest level of resistance towards PTV and SMV, at 25% and 6.5% 
respectively. This result corresponds with earlier studies that high levels of 
resistance variants were present at a low level at baseline in treatment naïve 
patients or not at all in other studies (Bartels et al., 2013, Leggewie et al., 2013, 
Jabara et al., 2014, Shepherd et al., 2015).  
 Some minority variants were only observed in HIV/HCV co-infected patients 
including V36A/G/L, T54A/S, and V55A. These mutations are associated with 
low-level resistance to SMV and PTV (Lange and Zeuzem, 2013, Pilot-Matias et 
al., 2015).   
 In all analysed patients, V170I and Q86P were dominant variants. These 
substitutions represent natural polymorphisms that frequently occurs in 
genotype 1a sequences (data from the NCBI database shows that 96.71% of 
recorded HCV genotype 1a sequences contain the V170I variant and 99.34% 
contain Q86P). These two residues do not produce resistance to PIs. 
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Only one patient had a dominant Q80K mutation in HCV mono-infected (1/18) 
and HCV/HIV co-infection groups (1/16). The dominant RAVs are rarely reported 
in NS3 gene at baseline as explained above. The frequency of dominant RAVs 
reported in 507 treatment-naïve HCV genotype 1 patients was 0.3%-2.8%; most 
patients harbouring these dominant RAVs had a high viral load indicating RAVs 
may reach replicative capacities similar to non-resistant variants in vivo 
(Kuntzen et al., 2008). In a similar study using population sequencing of NS3 
region, a low prevalence of dominant RAVs was detected as  V36M was detected 
in only 0.9% of patients at baseline and R155K was detected in 0.7% of patients 
at baseline (Bartels et al., 2008). 
 The low prevalence of dominant R155K is in line with both in vitro and in 
vivo reports that have indicated that the R155K variant displays impaired fitness 
compared with WT virus. Thus, these detected dominant variants are most 
probably associated with compensatory mutations that improve the replication 
capacity of this RAV (Sarrazin et al., 2007). 
5.3.1.2 Resistance to NS5A inhibitors 
In this study, baseline resistance mutations within the NS5A region were 
detected in all samples using NGS. This result is significantly greater than that 
previously detected by population-based sequencing studies in which the 
prevalence of NS5A RAVs has been reported at around 12.5% (Paolucci et al., 
2013). 
 Substitutions at residues Q30 and Y93 produce the highest level of 
resistance of all NS5A inhibitors (>1000 fold change) (Wong et al., 2013, Lawitz 
et al., 2012, Krishnan et al., 2015a). Minority variants Y93H and Q30H/R were 
detected in patients with HIV/HCV and HCV alone, at 25% (Y93H) and 25/18.75% 
(Q30H/R) respectively. Previous studies have also shown variant Y93H at a 
similar prevalence of 7-33% in DAA-treatment naïve HCV genotype 1 patients 
(McCormick et al., 2015, Yoshimi et al., 2015, Plaza et al., 2012).  
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The other common baseline polymorphisms within NS5A are L31M and M28T. 
However, L31M/R mutations were only detected in HIV/HCV co-infected patients 
in this study at low prevalence (12.5%). The prevalence of L31M was noticeably 
higher than in previous studies using direct sequencing, where L31M was 
detected in only 3% of patients (Paolucci et al., 2013, Yoshimi et al., 2015, Wong 
et al., 2013). Apart from the difference in technology used, the small sample 
size in our study could be a reason for this discrepancy. 
 The H58P mutation was also found at high prevalence in our cohort; 50% in 
mono-infected and 31% in co-infected subjects. The result is in accordance with 
an earlier NGS study that identified H58P at high frequency, reaching 87% 
compared to only 6.2% by direct sequencing (Paolucci et al., 2013). This variant 
is a natural polymorphism that does not confer resistance in genotype 1a. The 
H/P58D variants that do confer resistance against DCV, LDV and OBV were not 
detected in any sample (Lontok et al., 2015). 
5.3.1.3 Resistance to NS5B inhibitors 
In our study cohorts, the following resistance mutations were observed at high 
prevalence, C316N, L159F, V405I, F415Y, I434M, E446Q, A553V, and S556G, 
which were above 40% prevalence for both co-infected and mono-infected 
samples. L159F and F415Y have been reported to confer low-level resistance to 
SOF of 1.9 and 1.3 fold respectively (Donaldson et al., 2015).  
 Mutation S282T was only identified at low prevalence in HIV/HCV co-
infected patients (6.25%). In previous clinical trials, the S282T mutation was not 
detected in treatment naïve individuals at baseline using deep sequencing 
(McCormick et al., 2015, Franco et al., 2013). SOF is characterized by a high 
resistance barrier. The presence of double mutations, L159F and L320F increases 
fold resistance to SOF, and this resistance can be enhanced with an additional 
S282T variant (Tong et al., 2014, Poveda et al., 2014). Meanwhile, residues S96, 
S282 and P495 were previously reported as being 100% conserved in treatment-
naïve HCV genotype 1 infected patients (Kuntzen et al., 2008).  
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Using clonal analysis, no S282 mutation was detected in viral quasispecies at 
baseline in genotype 1 HCV infected individuals who did not receive prior 
treatment (Le Pogam et al., 2012); similar results were obtained after screening 
16 HCV/HIV treatment- naïve patients at baseline using NGS (Franco et al., 
2013).  Moreover, the S282T mutation has been extremely difficult to detect in 
vivo even in patients with failure to SOF (Wyles, 2013). 
 A systematic review of the literature showed that RAVs to DSV were more 
prevalent than those for SOF. This may be related to the mechanism of action of 
DSV as an allosteric inhibitor within NS5B, resulting in a low barrier of resistance 
(Powdrill et al., 2010). RAVs to DSV were detected in all patients in this study.  
 The NS5B amino acid substitutions most commonly observed in genotype 
1a–infected patients who did not achieve SVR were M414T and S556G (Lontok et 
al., 2015). The C316N and S556G variants were present at high prevalence in the 
HIV/HCV co-infected cohort at 25% and 37.5% respectively. These two RAMs have 
been reported to confer low-level resistance of 5 and 11-fold respectively. The 
presence of the double mutation C316N + S556G increases fold resistance by up 
to 38-fold (Koev et al., 2009, Krishnan et al., 2015b). Both M414T and C316Y 
were not detected at baseline in any of the patients. 
5.3.2 Prediction of in vitro resistance mutations within NS5B   
Numerous clinical studies have suggested that acquisition of RAMs is associated 
with viral fitness cost, characterised by an inverse relationship between the 
level of resistance conferred by a mutant variant and its replicative capacity. 
V36M represent an example of this relationship. It has been characterised as a 
low-level resistance mutant while it exhibits one of the best in vivo fitness rates 
(95% of wild-type fitness) of all reported PI-RAMs (Sarrazin et al., 2007, Tong et 
al., 2008). It has previously been reported as a dominant variant in acute 
HCV/HIV co-infected patients (Leggewie et al., 2013).  
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We used a prediction model to identify residues in the NS5B region that interact 
directly with the SOF binding site. Using the model described above, we 
hypothesized that mutations at residues R32, G493, P495, and P496 could confer 
resistance to SOF. These predicted mutations were introduced into a genotype 
1a subgenomic replicon using site-directed mutagenesis. The previously 
described NS5B resistance mutations S282T and S96T were also introduced 
(Powdrill et al., 2010).  
 A simplified assay to examine transient replication of the TA/SG/Luc/HCV-
1a subgenomic replicon in Huh-7.5 cells was developed. The introduction of two 
mutations in NS4A and NS4B enhanced replication fitness around 100-fold 
compared with the H77 genotype 1a replicon (Voitenleitner et al., 2012). This 
adapted replicon construct provided a rapid assay through measuring luciferase 
readout, used as a reporter for the reliable determination of replicative 
capacity. Because of the relative ease of introduction of mutations into the 
replicon, this system could be used to quickly profile a large number of 
compounds on a panel of resistance mutations against various HCV targets.  
 Using this system, only two constructs containing the mutations S96T and 
P495A were replication competent. Replication occurred at low level only, 24% 
and 21% respectively. In keeping with the in vitro data,  only two clinical 
samples harboured mutations at residues S96 and P495 at a frequency of 1-3%, 
but none of the detected mutations have been reported to confer resistance to 
SOF or DSV. Higher prevalence of P495A/L/T was reported when a group of 27 
treatment naïve genotype 1b patients was screened for RAVs at base line using 
NGS, 33% of  patients were reported to harbour P495A/L/T mutations at a 
frequency of less than 1%, but these substitutions are not reported to be 
associated with resistance against either SOF or DSV; and no patient samples 
contained S282T mutants (Nasu et al., 2011). 
 All other constructs did not replicate and markedly reduced replication of 
the S282T construct was in agreement with previous reports (Ludmerer et al., 
2005).  
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These sites were highly conserved both in our samples and in all published 
genotype 1a full genome sequences on NCBI.  
 These findings extend and confirm previous studies that showed a low 
prevalence of the S282T mutation in vivo. It has also been reported that S282T 
reverts to wild type after cessation of treatment (Ludmerer et al., 2005). These 
results may explain the absence of breakthroughs in patients failing therapy with 
NS5B nucleos(t)ide analogues due to their high in vivo barrier for developing 
resistance and likely rapid reversion following cessation of treatment. 
5.3.3 Resistance profile in HIV/HCV co-infected patients 
The effects of HIV co-infection and HAART on HCV quasispecies variability have 
not been firmly established. Some studies suggested that greater diversity 
occurred in HCV/HIV co-infected compared to HCV mono-infected subjects 
(Tanaka et al., 2007, Blackard and Sherman, 2007), while others studies have 
reported the opposite (Jabara et al., 2014, Shuhart et al., 2006). 
 T-cell responses may play a vital role in determining genetic diversity in 
both patient groups (Jabara et al., 2014). Heterogeneity and replication 
dynamics could expand under selective forces provided by host immune response 
and antiviral agents. HIV/HCV co-infection will reduce immunological pressure 
and could limit the escape mutants, therefore, reducing diversity (Nunez et al., 
2006). Nevertheless, there is evidence that the differences are generally not 
statistically significant, similar to the data obtained here (Morsica et al., 2009, 
Paolucci et al., 2013, Trimoulet et al., 2011).  
 In this study, HCV/HIV co-infected patients had a higher number of RAVs 
compared to mono-infected patients, but the results did not achieve statistical 
significance. However, the prevalence of few RAMs has been detected at a 
higher level in patients with HCV alone (e.g. Q80K). The main limitations of our 
study were the low number of patients analysed and a lack of direct 
comparability between HCV-mono-infected and HIV co-infected patient groups. 
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Thus, it is not possible to fully establish whether HIV co-infection is an 
independent factor associated with a higher prevalence of baseline RAMs. 
5.3.4 The potential role of NGS in antiviral resistance testing 
Sanger sequencing remains the standard method to detect RAVs in clinical 
samples. Nevertheless, the Sanger sequencing method is not able to reveal 
mutations that have a frequency below 20-30% in a viral population (Palmer et 
al., 2005). Although clinical impact of minority variants on DAAs resistance is 
still under investigation, several studies have suggested that minor variants are 
clinically relevant to drug resistance. Thus, there is a need for an improved 
diagnostic tool that provides a better sensitivity in detecting the circulating 
minority HCV variants (Barzon et al., 2011).  
 NGS detected low-frequency RAVs in all our samples. A major challenge in 
SNP recalling is to eliminate different sources of errors that may occur during 
sample preparation before sequencing, during reverse transcription, in PCR 
reactions and during sequencing itself. These errors are likely to reduce the 
validity of variant detection at low frequency (Jabara et al., 2014, Thys et al., 
2015). For an accurate SNP calling, a frequency at 1% was used and a depth at 
100 reads were used as cut-offs to exclude false variants.  
 The limited read length of Illumina® sequencing technology to 200-300 bp 
was addressed by powerful alignment and assembly tools (Loman et al., 2012). 
However, this limited the ability to reconstruct the haplotypes to understand the 
synergistic effect of RAMs or the presence of compensatory mutations. In order 
to overcome this limitation different haplotype reconstruction tools (e.g. QuRe) 
were introduced but validation of these tools is still needed.  
 Despite these limitations, NGS is a potential tool for detecting minority 
variants due to its ability to produce large amounts of data in a timely manner 
(Ninomiya et al., 2012, Beerenwinkel and Zagordi, 2011, Mardis, 2011). 
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5.3.5 Clinical utility of resistance testing 
The presence of naturally occurring RAVs may hinder the efforts to eradicate 
HCV, and there is an ongoing debate as to whether resistance testing should be 
performed prior to DAA treatment in some patient groups (e.g. genotype 3 and 
cirrhotic patients). In the era of DAAs, the importance of pre-existing as well as 
selected variants during antiviral therapies may become increasingly important. 
However, treatment-naïve patients with TVR-RAVs achieved similar SVR rates 
compared to patients without RAVs (Bartels et al., 2013, Halfon and Sarrazin, 
2012). 
 The possibility of the selection for highly replication competent RAVs urged 
the implementation of stop rules in case of viral breakthrough. These variants 
probably persist for a considerable period leading to increased possibility of 
transmission to other individuals (Buhler and Bartenschlager, 2012). 
 Different RAVs are reported to be clinically relevant when present at 
baseline. Q80K was shown to reduce SVR rates when patients are treated with 
SMV in combination with IFN-based regimens (Jacobson et al., 2014). Common 
RAVs in NS5A at baseline are associated with reduced efficacy of DCV (McPhee et 
al., 2013, Dore et al., 2015). Moreover, PTV and LDV monotherapy reported a 
lower response rate in the presence of baseline RAVs (Lawitz et al., 2015a). 
Despite these reported links with treatment failure, the rates of virological 
failure are low when treatment include another agent such as SOF, which 
rendered the resistance testing unnecessary in the case of combination therapy 
(Sulkowski et al., 2014a). 
 The resistance testing before treatment with NS5A inhibitors may be of 
value in genotype 1a due to the low genetic barrier to resistance of the current 
agents; for example at M/L28T, this change requires two nucleotide changes in 
the genotype 1b sequences (L28T; CTC to ACC) but only one change in the 
genotype 1a replicon (M28T; ATG to ACG). The second generation agents may 
have a higher genetic barrier which may render baseline testing irrelevant 
(Nakamoto et al., 2014). 
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There is contradictory evidence on the value of baseline resistance testing. A 
combination of SOF and DCV ± RBV in genotype 1–3 patients was successfully 
used to treat a cohort of patients in which 16% of patients had baseline DCV-
RAVs. However only one patient had a relapse (Sulkowski et al., 2014a). Thus, 
regardless of the pre-existing baseline RAMs, high SVR rates can still be achieved 
in most patients (Lawitz et al., 2014b). A similar outcome was reported after 
treatment by PrOD combination +/- RBV (Sulkowski et al., 2015). These results 
confirmed the value of combining different classes of DAA to reduce the effect 
of pre-existing RAVs on achieving SVR. 
 The emergence of de novo TVR-RAVs and SMV-RAVs after the start of triple 
therapy was not predicted at baseline (Akuta et al., 2013). Over time, the 
majority of de novo resistant variants become undetectable (Akuta et al., 2014). 
These results confirm that baseline resistance testing could be of limited value 
in prediction of resistance to DAAs.  
 Recent EASL guidelines recommended limited HCV baseline resistance 
testing in patients infected with subtype 1a who receive a combination of 
PegIFNα, RBV and SMV because SVR rates are very high both in patients without 
and with detectable amounts of RAVs using population sequencing at baseline. In 
special groups (e.g. cirrhotic patients and those infected with genotype 3) where 
the effectiveness of SOF shows some limitations, and before retreatment after 
NS5A inhibitors treatment failure the need for resistance testing of NS5A 
inhibitors may be of value. 
5.4 Conclusions 
RAVs occurring as natural polymorphisms are frequently detected in HIV-positive 
patients with acute HCV infection. The significance of prevalence thresholds is 
not yet established and further studies to investigate the impact of RAVs are 
needed. Further large-scale studies using deep sequencing should be performed 
to investigate the effects of RAVs on the response to treatment using new drugs, 
including DAAs, monitoring the evolution of RAVs during treatment and after 
stopping treatment in cases of treatment failure.  
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The replicon model is potentially a useful tool to monitor the evolution of 
resistance variants arising from DAA therapy.  
 NS5B inhibitors have a high genetic barrier to resistance. In this chapter, 
we have shown that the TA/SG/Luc/HCV-1a replicon is a useful model for 
investigating the replication fitness of any potential RAV.  
 Antiviral resistance testing is an important subject for future research in 
the era of DAAs; NGS is a superior tool for detecting minority RAVs although the 
clinical utility of such testing needs to be investigated further. The introduction 
of new agents with higher genetic barriers of resistance should be recommended 
in combination regimens to limit the impact of RAVs in the future.  
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Chapter 6: Conclusions and further work 
6.1 Conclusions 
6.1.1  Sequencing of the HCV genotype 1a open reading frame 
HCV full genome sequencing has been a main challenge in the field for many 
years. The main obstacles are the high diversity of HCV and the presence of 
secondary structures in different regions of the genome.  
 In the series of experiments described in Chapter 3, the complete ORF was 
assembled from four amplicons produced by nested PCR using high fidelity DNA 
polymerase to achieve an efficient HCV amplification with minimal bias. The 
primer design and optimisation of PCR conditions produced a robust, rapid and 
sensitive method for amplification and sequencing of HCV genotype 1a with a 
detectability limit of 1000 copies/ml. 
 Another full genome sequencing method was validated; employing a 
metagenomic sequencing approach. It is an improved tool for detecting SNPs 
across the genome with limited systematic PCR error and without any primer 
selection bias. The latter enables the detection of all HCV genotypes as the 
metagenomic approach is not limited to genotype-specific primers. However, 
metagenomic sequencing is limited by lack of depth and potential under-
representation of minority variant in low viral load samples. This approach was 
used in the detection of RAVs as described in chapter 5.  
6.1.2 The role of NGS in studying HCV quasispecies  
The development of NGS platforms has significantly enhanced our understanding 
of intra-host viral populations, providing a far better understanding of viral 
complexity with the potential to improve on conventional methodologies in both 
research and clinical settings. 
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Pyrosequencing of amplicons covering the HVR1 region revealed the presence of 
multiple variant infections which were not detected by direct Sanger sequencing 
or clonal analysis. Pyrosequencing had a similar performance to the Illumina 
platform in detecting minority variants but had an inherently higher error rate.  
 An artificial quasispecies was created (Mock community) to assess the 
performance of different haplotype reconstruction programs in detecting 
circulating variants. Two analysis software packages were assessed and (  QuRe 
and PredictHaplo) were comparable and detected the most frequent variants in 
the mock community. To date, this is the first study of HCV quasispecies using 
these programs. 
6.1.3 The effect of viral dynamics on treatment outcome  
In chapter 4, I described how 454 pyrosequencing can be used to address HCV 
viral dynamics and impact on treatment outcome. Low viral diversity at baseline 
is a predictor of achieving SVR in HIV-infected patients with acute HCV. We 
based this observation on comparing ten patients who responded to a 
PegIFNα/RBV course with a matched group of ten patients who failed the same 
treatment. 
 In patients who failed PegIFNα/RBV treatment (15 patients; null 
responders, partial responders, and relapsers), all patients had persistent 
variants that were present in both pre- and post-treatment samples. The 
emergence of new viral variants detected by Sanger sequencing following 
treatment failure was associated with emerging dominance of pre-existing 
minority variants rather than reinfection. These results indicate that relapse and 
re-infection should be defined by phylogenetic support using sequences obtained 
using an NGS platform. 
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6.1.4 Antiviral resistance in HCV  
NGS has a potential role in screening for known antiviral resistance mutations 
and is superior to conventional sequencing methods in the detection of minority 
variants. However, the role of resistance testing in the HCV field remains 
controversial, and the impact of minority RAVs is yet to be understood. High SVR 
rates and high genetic barriers to resistance are likely to limit the requirement 
for testing in the majority of HCV patients. 
 The prevalence of naturally occurring RAVs within NS3, NS5A and NS5B was 
higher at baseline in HIV/HCV co-infected compared with HCV mono-infected 
treatment-naïve genotype 1a patients. Several RAVs mutations were detected 
predominantly as minority variants (<10%) within all of these genes.  
 A trend towards more RAVs detected at baseline occurred while the 
prevalence of few RAVs (e.g. Q80K) was higher in patients with HCV mono-
infection. Lack of statistical support for a significant difference in the 
prevalence of RAVs at baseline may be attributed to small sample size and the 
fact that both groups were not matched for other confounding factors such as 
viral load. 
 During this thesis, an extensive literature review of RAMs in the HCV 
genome that are reported to confer resistance to DAAs was carried out (SMV, 
PTV, LDV, OBV, DCV, DSV, and SOF). Chapter 5 provides a comprehensive 
summary of RAMs for currently recommended HCV DAAs. Differences between 
our findings and published resistance reviews may relate to different 
methodologies for the compilation of clinically relevant substitutions. In this 
rapidly evolving field, regular updates of RAV databases will be required. This 
database will contribute to the set up a national HCV Research UK database that 
will enable clinicians to tailor treatment strategies. 
6.1.5 Replicon based assay for RAVs replication capacity 
In chapter 5, I showed that the TA/SG/Luc/HCV-1a replicon provided a useful 
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model for investigating the replication capacity of any potential RAV. Resistance 
mutations at residues that have an interaction with the binding site of SOF were 
introduced by site-directed mutagenesis. It was shown that all of the introduced 
mutations had a viral fitness cost resulting in inefficient replication. These 
results explain the reported high genetic barrier to resistance of SOF. This also 
matches clinical trials experiences and the current recommendation that 
resistance testing at baseline is not indicated if any combination including SOF is 
used for HCV treatment. New RAVs could be tested using the same protocol in 
this genotype 1a system. 
6.2 Future work  
6.2.1 Sequencing of the HCV genotype 1a open reading frame 
HCV full genome sequencing has evolved during the period of my thesis and the 
target enrichment approach has now become a routine method in our lab. 
Future plans include exploration of other platforms for full genome sequencing, 
such as SMRT sequencing (Pacific Bioscience). These alternative platforms allow 
longer read lengths but require approaches to decrease higher error rates.  
6.2.2  The effect of viral dynamics on treatment outcome  
After exploring the role of viral diversity in predicting treatment outcome in this 
unique cohort, further studies are needed to investigate the role of viral 
diversity in spontaneous clearance to determine whether it could be a predictor 
of spontaneous clearance in this population. 
 A group of spontaneous clearers will be sequenced using NGS in parallel 
with a group of progressors from the same cohort. Both groups will be matched 
for age, viral load, nadir CD4, duration of infection and genotype. We 
hypothesise that HCV diversification and evolution predicts the outcome of acute 
infection in this cohort.  
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6.2.3 Mock communities  
Further mock community analysis will enable benchmarking of current haplotype 
reconstruction programs (e.g. QuRe). The mock community used during this 
thesis represented a low diversity sample. Further communities are designed to 
have higher diversity and larger genetic distance between different variants and 
include a different genotype with sequence divergence 0-45%. Fifteen genotype 
1a samples have already been amplified using the amplicon 1 primer set shown 
earlier with an average size 2.5kb and an amplicon with an average size of 3kb 
from one genotype 3 patient (Figure 6-1). 
 The frequency of variants within the mock communities are as follow: 
Mock 1; 40 clones with uniform abundance 
Mock 2; 40 clones with log-normal abundance 
Mock 3; 13 clones with log-normal abundance  
Mock 4; 60 clones with uniform abundance 
Mock 5; 60 clones with log-normal abundance  
 NGS data will be analysed using the optimised bioinformatics pipeline, and 
different haplotype reconstruction programs will be evaluated to find the best 
available software to offer a precise and sensitive tool that can give a nearly 
accurate estimation of the circulating variants and permit linkage studies of 
different mutations and its linkage on the same haplotypes. This project will be 
in collaboration with Dr Melanie Schirmer, Broad Institute, USA. 
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Figure 6-1: The structure of mock communities 
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6.2.4 HCV antiviral resistance 
Further large-scale studies using NGS should be performed to investigate the 
effects of RAVs on response to treatment using DAAs. These studies must target 
larger populations of HCV-infected patients in particular and patients with 
difficult to treat genotypes (genotype 3), patients with cirrhosis and those with 
previous DAA treatment failure.  
 The sequencing platform used will be Illumina using optimised 
bioinformatics pipelines. In order to ensure accurate analysis of antiviral 
resistance, the RAV database created during this thesis will be updated regularly 
(4 monthly) to include any new resistance mutations or DAAs. 
 Patients who fail DAA treatments will provide the opportunity to study 
resistance further, including the role of frequency threshold of baseline RAVs 
and the role of minority variants in predicting SVR. Currently, all samples from 
patients who failed DAA treatment referred to West of Scotland Specialist 
Virology Centre in Glasgow are stored pending ethical approval to be included in 
an antiviral resistance study including monitoring the evolution of RAVs after the 
end of therapy. This study will offer new insights into the evolution of viral 
populations pre- and post-treatment.    
6.2.5 Cost - effectiveness of NGS in the diagnostic setting 
Further experiments are required to validate the use of NGS in diagnostic 
virology laboratories and define an error threshold specific to platforms in order 
to improve the specificity of NGS and to exclude any artefactual variants that 
may have an implication on planning the treatment strategy. 
 Once NGS is upscaled in the laboratory setting, there will be a reduction in 
the running costs. For this reason, major clinical virology laboratories in the USA 
and the UK (Public Health England) are currently optimising this technology.  
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During this thesis, as well as identifying multiple strain infections, we employed 
NGS to identify major and minor resistance associated variants that were not 
detected by Sanger sequencing.  
 A study at the West of Scotland Specialist Virology Centre (WOSSVC) is 
currently submitted for funding; it aims to compare the performance, turn-
around time, and costs of NGS against Sanger sequencing.  
 The study will validate the use of NGS as a diagnostic virology tool for 
genotyping and the detection and monitoring of HIV and HCV high and low 
abundance RAVs. The samples used in this study will be amplicons generated as 
part of the routine diagnostic service (targeting the NS3 region of HCV genotype 
1a and Pol gene of HIV genome) will be anonymised and attributed a study 
number. Based on a study power of 80%, a sample size of 100 samples tested by 
both techniques was estimated to detect a significant difference between both 
techniques in detecting minor variants. The project workflow is shown in (Figure 
6-2). 
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Figure 6-2: Workflow of cost-effectiveness study of NGS in diagnostic setting 
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Appendices 
7.1 The viral complexity in SVR group  
 
Maximum likelihood tree showing the variants the SVR group detailed in Section 
4.2.1.4. The bootstrap values are shown next to the branch points (1,000 
replicates); only values higher than 70% are shown.  
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7.2 The viral complexity in Non-SVR (TF) group 
 
Maximum likelihood tree showing the variants the SVR group detailed in Section 
4.2.1.4. The bootstrap values are shown next to the branch points (1,000 
replicates); only values higher than 70% are shown.  
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7.3 Poisson Fitter of variants detected in P6 
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7.4 Poisson Fitter of variants detected in P9  
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7.5 Poisson Fitter of variants detected in P10 
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7.6 Poisson Fitter of variants detected in P15 
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7.7 Poisson Fitter of variants detected in P26 
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7.8 Poisson Fitter of variants detected in P31(TF group) 
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7.9 Poisson Fitter of variants detected in P57 
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7.10 Poisson Fitter of variants detected in P63 
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7.11 Poisson Fitter of variants detected in P75 
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7.12 Poisson Fitter of variants detected in P81 
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7.13 Poisson Fitter of variants detected in P103 
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7.14 Poisson Fitter of variants detected in P108 
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7.15 Poisson Fitter of variants detected in P112 
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7.16 Poisson Fitter of variants detected in P114 
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7.17 Poisson Fitter of variants detected in P131 
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7.18 Poisson Fitter of variants detected in P141 
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7.19 Reported resistance mutations to PTV.  
Mutation Data source  Resistance Sequencing References 
V36A In vitro 3-fold Sanger 5 
V36L Clinical 2-fold  Sanger/NGS 5,6 
V36M Clinical/ in vitro 2-fold  Sanger/NGS 5,6,8 
V36G Clinical   Sanger/NGS 7 
F43L In vitro 20-fold  Sanger 5,11 
T54S Clinical/ in vitro 0.4-fold  Sanger/NGS 5,6 
T54A In vitro 1-fold  Sanger 5,8 
V55I In vitro 1-fold  Sanger 5,7 
V55A Clinical/ in vitro ≤ 4-fold Sanger/NGS 6,8 
Y56H Clinical NA   12 
Q80K Clinical/ in vitro 3-fold  Sanger/NGS 6,8,11 
Q80L Clinical/ in vitro 2-fold Sanger/NGS 6 
Q80R Clinical/ in vitro 2-fold Sanger/NGS 6,8 
R155K Clinical/ in vitro 37-43 fold (1a) Sanger/NGS 1,2,3,5,7,8,9,10,11,12 
R155G Clinical/ in vitro 16-fold Sanger/NGS 2,11 
R155S In vitro 7-fold   11 
R155T In vitro 7-fold    8 
R155W In vitro 11-fold  Sanger 5 
R155Q In vitro ≥ 4-fold Sanger 5,8 
A156T In vitro 17-fold (1a); 7-fold (1b) Sanger 5,11,12 
A156S In vitro 0.5-fold  Sanger 5,8 
D168A Clinical/ in vitro 59-fold(1a); 27-fold  Sanger 2,8,11,12 
D168Y 
In vitro 219-fold (1a); 337-fold 
(1b) 
Sanger 
5,11,12 
D168N In vitro 13-fold Sanger 11 
D168E Clinical/ in vitro 14-fold (1a); 4-fold (1b) Sanger/NGS 5,6,11 
D168H In vitro 62-fold (1a); 76-fold (1b) Sanger 5,8,11 
D168T In vitro 49-fold Sanger 5,8 
D168F Clinical/ in vitro NA Sanger 9,11 
D168K Clinical NA   12 
V/I170A Clinical/ in vitro 1-fold Sanger/NGS 5,6,8 
V/I170T Clinical NA Sanger/NGS 6 
V36M+R155K In vitro 79-fold  Sanger 5 
Q80K+R155K In vitro 19-fold  Sanger 5 
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7.20 References for reported PTV resistance associated 
variants.  
1 Abstract #779 AASLD 2012 
2 Pilot-Matias, T et al., 2011 J Hepatology 
3 Abstract #1936 AASLD 2014 
4 Pilot-Matias, T et al 2011 J Hepatology 
5 
Pilot-Matias, T et al., 2015 J Antimicrobial Agents and 
Chemotherapy 
6 Beloukas A et al., 2015 
7 Wyles, D 2013 JID Antiviral Resistance and HCV Therapy 
8 Halfon P et al., 2011 J Hepatology 
9 Krishnan P et al., 2015 J Hepatology 
10 Krishnan P et al., 2015 J Antibacterial Agents and Chemotherapy 
11 www.accessdata.fda.gov/drugsatfda_docs/label/2014/206619lbl.pdf 
12 Gentile I et al., Current Medicinal Chemistry 2014 
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7.21 Reported resistance mutations to SMV.  
Mutation Data source  Resistance Sequencing References 
V36A Clinical/in vitro 2.8 fold Pyrosequencing 1,2 
V36M Clinical/in vitro 2 fold Pyrosequencing 1,2 
V36L Clinical/in vitro 1.7 fold Direct 1,8,9 
F43I In vitro 89 fold RT-PCR 1 
F43S In vitro 12 fold Direct 1,6 
F43V In vitro 99 fold RT-PCR 1 
T54A Clinical/in vitro 0.6 fold Direct 8 
T54S Clinical/in vitro 1.2 fold Direct 8 
Q80G Clinical/in vitro 1.8 fold Direct 8 
Q80H In vitro 3.6 fold RT-PCR 1 
Q80K Clinical/in vitro 7.7 folds/8 fold Direct/Deep 1,3-5,8-10 
Q80L Clinical   454 Deep  10 
Q80R Clinical/in vitro 6.9 folds Direct/Deep 1,6,8,10 
R155G Clinical/in vitro 20 folds Deep 1,10 
R155K Clinical/in vitro 30 folds Deep 1,10,11 
R155R In vitro   454 Deep  10 
R155T In vitro 24 folds RT-PCR 1 
A156G In vitro 16 folds RT-PCR 1,6 
A156T In vitro 44 folds RT-PCR 1,6 
A156V  Clinical/in vitro 177 folds Pyrosequencing 1,2,11 
D168A Clinical/in vitro 594 folds Deep 1,3,10,11 
D168D In vitro   454 Deep  10 
D168E Clinical/in vitro 40 folds Deep 1,6,9,10 
D168G Clinical/in vitro 4.4 folds Deep 1,10 
D168H Clinical/in vitro 368 folds Deep 1,3,10 
D168I In vitro 1,807 folds RT-PCR 1 
D168N Clinical/in vitro 6.6 folds Deep 1,10 
D168T Clinical/in vitro 308 folds RT-PCR 1,3 
D168V Clinical/in vitro 2,591 folds Deep 1,3,9,10 
D168Q Clinical/in vitro 384/700 folds Direct 3, 8, 9 
D168Y In vitro 666 folds RT-PCR 1 
V/I170A Clinical/in vitro 1.8 folds RT-PCR 1,3 
V/I170L Clinical/in vitro     3 
V/I170T Clinical/in vitro 5.4 folds RT-PCR 1,3 
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7.22 References for reported SMV resistance associated 
variants.  
1 
Lenz et al., 2010 Antimicrobial agents and 
chemotherapy 
2 Jabara et al., 2014 Antimicrobial agents 
3 Proveda et al., 2014 Antiviral Research 
4 Bichoupan & Dieterich 2014 Drugs 
5 Pawlotsky J.M., 2014 Gastroenterology 
6 Schneider & Sarrazin 2014 Antiviral Research 
8 Palanisamy et al., 2013 Antiviral Research 
9 Lenz et al., 2013 Journal of Hepatology 
10 Lenz et al., 2010 Gastroenterology 
11 Xue et al., 2012 Antiviral Research 
12 Lawitz et al., 2013 Gastroenterology 
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7.23 Reported resistance mutations to DCV.  
Mutation Data source  Resistance Sequencing Reference 
M/F28S Clinical/In vitro   Sanger 2,4,7 
M28A In vitro  4,591 fold Sanger 21 
M28G Clinical   Sanger 13 
M28I Clinical/In vitro 1.2 fold Replicon  4,13 
M28T Clinical/In vitro 390 fold, 683 fold Sanger 4,11,13,21,22 
M28V Clinical/In vitro  1.3 fold Sanger 4,11-13,21 
Q30E Clinical/In vitro  6217 fold Sanger 
2,4,7,11-
13,18,19,21,22 
Q30G Clinical/In vitro  2,055 fold Sanger 13,19 
Q30H Clinical/In vitro 400 folds Sanger 4,10,11,13,19,21,22 
Q/A30K Clinical/In vitro  3,732 fold (1a) Sanger 
11,13,14,18,19,21,2
2 
Q30L In vitro 3.6 folds Sanger 19 
Q30P In vitro   Sanger 19 
Q30R Clinical/In vitro  252 fold (1a) Sanger/NGS 4,8-13,18,19,21,22 
L31M Clinical/In vitro  878 fold (1a) Sanger/NGS 1,2,4,10-16,19,21,22 
L31V Clinical/In vitro 458/710 fold Sanger/NGS 
1,2,4,7,10,12-
16,19,21,22 
L31R Clinical   Sanger 13 
P32L Clinical/In vitro 16 fold  Sanger 2,4,8,10,19,22 
H58D Clinical/In vitro  483 fold Sanger 11,13,19,21 
H58P In vitro  2 fold Sanger 21 
E62D  In vitro 2 fold Replicon  13 
Y93C Clinical/In vitro  520 fold (1a) Sanger 4,10-13,19,21,22 
Y93H Clinical/In vitro  24 fold Sanger/NGS 
1,2,4,7,8,10,11,13-
16,18,19,21,22 
Y93N Clinical/In vitro  28 fold Sanger 
2,4,11-
13,18,19,21,22 
M28T + Q30H In vitro  103,767 folds 
Replicon 
system 
22 
M28T + Q30R In vitro   Sanger 19 
Q30H + Y93H In vitro  92,217 folds 
Replicon 
system 
22 
Q30R + L31M In vitro  9400 folds Sanger 12 
Q30R + L31V In vitro  >33, 333 folds Sanger 12 
Q30R + H58D In vitro   Sanger 11 
Q30R + E62D In vitro 
High level 
resistance 
Sanger 18 
Q30R + Y93C In vitro 
High level 
resistance 
Sanger 11 
L31V + H58P In vitro 
High level 
resistance 
Sanger 12 
L31V + Y93C in vitro 
High level 
resistance 
Sanger 12 
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7.24 References for reported DCV resistance associated 
variants.  
1 Kosako et al 2014 Journal of Viral Hepatitis 
2 Wang et al., 2014 Antimicrobial Agents Chemotherapy 
4 Nakamoto et al., 2014 World J Gastroenterol 
7 Schneider & Sarrazin 2014 Antiviral Research  
8 
Murakami et al., 2014 Antimicrobial Agents 
Chemotherapy 
10 Lee C 2013 Drug Des Devel Ther 
11 Wong et al., 2013 Antimicrob Agents Chemotherapy 
12 McPhee et al., 2013 Hepatology 
13 Wang et al., 2013 Antimicrobial Agents Chemotherapy 
14 Hernandez et al., 2013 J.Clin Virol 
16 Suzuki et al., 2012 J Clin Virology 
18 Sun et al., 2012 Hepatology 
19 Wang et al.,. 2012 Antimicrobial Agents Chemotherapy 
20 Nettles et al., 2011 Hepatology 
21 Fridell et al., 2011 Hepatology 
22 Fridell et al., 2010 Hepatology 
23 Bunchorntavakul & Reddy 2015 Aliment Pharmacol Ther 
24 Yoshimi et al., 2015 J Med Virol 
25 Bartolini et al., 2015 J Clin Virology 
26 Miura et al., 2014 Hepatology Research 
27 Dore et al., 2015 Gastroenterology 
28 Peres-da-Silva et al., 2014 J Antimircrob Chemother 
29 Hirotsu Y et al., 2015 Hepatol Int 
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7.25 Reported resistance associated mutations to LDV 
Mutatio
n 
Data Source Resistance Sequencing Reference 
K24G Clinical   10-50 fold Sanger/NGS 3,12 
K24N Clinical  10-50 fold Sanger/NGS 3,12 
K24R Clinical  2.5-10 fold Sanger/NGS 3,12,28 
K26E Clinical   Sanger 27 
M28A Clinical >1000 fold  NGS 12 
M28G Clinical >1000 fold NGS 12 
M28T In vitro/ Clinical >30-fold  Sanger/NGS 3,5,11,12,21,32,34 
M28V Clinical   Sanger/NGS 3 
Q30E In vitro/ Clinical  5458 fold  Sanger/NGS 3,5,12,21 
Q30G Clinical 100-1000 
fold  
NGS 12 
Q30H Invitro/ Clinical 100-1000 
fold 
Sanger/NGS 5,8,11,12,21,28,32,34 
Q30K Clinical >1000 fold  NGS 12 
Q30L Clinical  2.5-10 fold NGS 12 
Q30M Clinical 183 fold  Sanger 3 
Q30R In vitro/ Clinical >100-fold  Sanger/NGS 3,5,12,21,25,31,32,34 
Q30T Clinical  2.5-10 fold NGS 12 
L31I Clinical 100-1000 
fold 
Sanger/NGS 12, 25, 28 
L31M In vitro/ Clinical >100-fold  Sanger/NGS 
3,5,7,11,12,16,21,22,23,24 
25,28,34,32,35 
L31V Clinical 100-1000 
fold  
NGS 12,34 
P32L Clinical 100-1000 
fold  
NGS 12 
S38F Clinical 50-100 fold  Sanger/NGS 12, 25 
H58D Clinical   1177 fold Sanger/NGS 3,12 
P58D Clinical 100-1000 
fold 
NGS 12 
A92K Clinical >1000 fold  NGS 12 
A92T Clinical 10-50 fold NGS 12 
Y93C In vitro/ Clinical >100-fold Sanger/NGS 3,5,11,12,21,33 
Y93F Clinical 10-50 fold NGS 12 
Y93H Invitro/ Clinical ≥1000-fold  Sanger/NGS 
1,3,5,6,8,11,12,16,21,28,31,3
2,34,35 
Y93N Clinical 14706 fold  Sanger/NGS 2,3,11,12,31 
Y93S Clinical >1000 fold  NGS 12,31 
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7.26 References for reported LDV resistance associated 
variants.  
1 Osinusi, A, et al 2015 JAMA 
2 Nakamoto, Shingo et al., 2014 World J Gastroenterol 
3 Wong KA et al., 2013 JASM 
4 Kwong HJ et al., 2015 Plos One 
5 Lawitz EJ et al., 2012 J Hepatol 
6 Hernandez D et al., 2013 J Clinical Virology 
7 Lim PJ & Gallay A 2014 Current Opinion in Virology 
8 Gentile I, et al., 2014 Expert Opinion 
9 S Sierrei et al., Antiviral Therapy an Infectious Disease 2015 
10 E. Poveda et al., 2014 Antiviral Research 
11 Cook, J et al., 2015 CROI 2015 
12 Dvory-Sobol, H et al.,  EASL 2015 
13 Afdhal N et al., 2014 N ENGL J MED 
14 Link JO et al., 2013 ACS Publications 
15 LindstrÖm et al., 2015 Infectious Diseases  
16 Afdhal N et al., 2014 N Engl J Med 
17 Kowdley KV et al., 2014 N Engl J Med 
18 Kohler et al., 2014 Infection and Drug Resistance Dovepress 
19 Wyles DL et al., 2014 Hepatology 
20 Noel B et al., 2015 Dovepress drug design, development and therapy 
21 Cheng G et al., 2012 EASL  
22 Sarrazin C et al., 2014 AASLD 
23 Larousse JA et al., 2015 Virology Journal 
24 Paolucci S et al., 2013 Virology Journal 
25 Wong KA et al., 2012 J Hepatology 
26 Hebner C et al., 2013 AASLD 
27 Kitrinos et al., 2014 AASLD 
28 Svarovskaia E et al., 2015 EASL 
29 Sarrazin C et al., 2015 EASL P0773 
30 Mizokami M et al., 2015 The Lancet Infect Dis 
31 Wyles D et al., 2015 EASL 
32 Lawitz E et al., 2015 EASL 
33 Abergel A et al., 2015 EASL 
34 Bourliere M et al., 2015 Lancet Infect Dis 
35 Gane E et al., 2015 ISVHLD 
36 Lawitz E et al., 2014 APASL 
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7.27 Reported resistance associated mutations to OBV 
Mutation Data Source Resistance Sequencing References 
L28M Clinical/In vitro 2-fold (1b) Sanger 1,11,25 
L28T In vitro 661-fold Sanger 1 
M28T Clinical/In vitro 8965-fold Sanger 1,3,6,9,12,19,22,24,34 
M28V Clinical/In vitro 58-fold Sanger 1,3,7,12,22,24,34 
Q30E Clinical 
 
Sanger 1,12 
Q30H In vitro 3-fold Sanger 1 
Q30K Clinical 
 
Sanger 12 
Q30R Clinical/In vitro 800-fold Sanger 1,3,6,7,8,9,12,16,18,22,24,34 
L31F In vitro 10-fold Sanger 1 
L31M Clinical/In vitro 2-fold Sanger 1,3,6,24,25 
L31V Clinical/In vitro 8-fold (1b) Sanger 1,18,24 
H58D In vitro 243-fold Sanger 1 
Y93C Clinical/In vitro 1675-fold Sanger 1,18,24,25 
Y93H Clinical/In vitro 41383-fold Sanger 
1,3,6,7,8,11,13,16,18,19,22,24,2
5,34 
Y93L In vitro 
 
Sanger 14 
Y93N Clinical/In vitro 66740-fold Sanger 1,18,21,24 
Y93S Clinical/In vitro 1013-fold Sanger 1 
L28M+L31F In vitro 569-fold Sanger 1 
L28V+L31F In vitro 2170-fold Sanger 1 
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7.28 References for reported OBV resistance associated 
variants.  
1 Krishnan P et al., 2015 J Antimicrobial Agents and Chemotherapy 
2 De Goey et al., 2014 J Med Chem 
3 Stirnimann G 2014 Expert Opin Pharmacother 
4 Hezode C et al., 2014 Liver Congr. Oral Present 
5 Kwo P et al., 2014 Liver Congr. Oral Present 
6 Feld JJ, et al., 2014 N Engl J Med 
7 Zeuzem S, et al., 2014 N Engl J Med 
8 Poordad F, et al., 2014 N Engl J  Med 
9 Ferenci P, et al., 2014 N Engl J Med 
10 Krishnan P et al., 2014 J Hepatology 
11 Schnell G et al., 2014 AASLD 
12 Krishnan P et al., 2015 J Hepatology EASL Conference Oral Presentation 
13 Andreone P et al., 2014 J gastroenterology 
14 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206619lbl.pdf 
15 Aisso Larousse et al., 2015 Virology journal 
16 Linstrom Ida et al., 2015 Infectious Diseases 
17 Gentile I et al., 2014 Expert Rev. Anti Infect. Ther 
18 Krishnan P et al., 2015 J Antimicrobial Agents and Chemotherapy 
19 Sulkowski M.S et al., 2015 J American Medical Association 
20 Krishnan P et al., 2014 AASLD 
21 Leenheer D et al., 2014 Antiviral Therapy International Workshop  
22 Lawitz E et al., 2012 J Hepatology 
23 Pilot-Matias T et al., 2012 J Hepatology 
24 Krishnan P et al., 2014 J Hepatology 
26 Stanislas Pol et al., 2014 AASLD 
27 Chayama K et al., 2015 APASL 
  28 Wyles D et al., 2014 AASLD 
  29 
Eron JJ et al., 2014 ICAAC; Sulkowski MS et al. 2014 International AIDS 
Conference 
  30 Bernstein et al., 2014 ICAAC 
31 Poordad F et al., 2014 EASL  
32 Feld JJ et al., 2014 EASL 
33 Sullivan JG et al., 2012 EASL 
34 Klibanov OM et al., 2015 Annals of Pharmacotherapy 
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7.29 Reported resistance-associated mutations to SOF 
Mutation Data source Resistance Sequencing Reference 
L159F Clinical/In vitro 1.9 fold (1a) Sanger/NGS 1,2,3,4,7 
S282R Clinical 
 
Sanger/NGS 4 
S282T Clinical/In vitro 13.5 fold Sanger/NGS 1,2,3,4,5,6,7,8 
L320F Clinical/In vitro 2.7 fold Sanger/NGS 4,7 
V321A Clinical 
 
Sanger/NGS 1,2 
V321I Clinical 
 
Sanger/NGS 3,4 
F415Y In vitro 1.3 fold Sanger 8 
L159F + S282T Clinical/In vitro 30 fold (1a) Sanger 7 
L159F + L316N In vitro 
 
Sanger/NGS 1,3,4 
L159F + L320F In vitro 4.3 fold (1a) Sanger/NGS 1,3,7 
S282T + L320F In vitro 41 fold (1a) Sanger 7 
S282T + I434M In vitro 
 
Sanger 8 
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7.30 References for reported SOF resistance associated 
variants.  
1 Tong & Kwong 2014 Clin Infect Disease 
2 Svarovskaia et al., 2014 Clin Infect Dis 
3 Margeridon-Thermet et al., 2014 PLosOne 
4 Donaldson et al., 2014 Hepatology 
5 Di Maio et al., 2014 Antimicrobial Agents Chemotherapy 
6 Schneider & Sarrazin 2014 Antiviral Research 
7 Tong et al., 2014 J. Infect Disease 
8 Lam et al., 2012 Antimicrobial Agents Chemotherapy 
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7.31 Reported resistance-associated mutations to DSV 
Mutation Data source  Resistance Sequencing Reference 
S556G Clinical/In vitro 30-84-fold Sanger 
1,2,3,4,5,6,8,12,13,14,15,1
7, 18,19,20,21,22,23,25 
S556N Clinical 29-fold  Sanger 1,2 
S556R Clinical/In vitro   Sanger 1,6,15 
S556G In vitro   Sanger 2,6 
S565F In vitro 17-fold Sanger 2 
M414T Clinical/In vitro 32-61-fold  Sanger 1,2,3,4,5,6,12,14,15 
M414I Clinical/In vitro 8-fold  Sanger 1,6,7,14,15 
M414L Clinical   Sanger 1,14 
M414V Clinical/In vitro 6-fold  Sanger 3,5,12,14 
D559G Clinical/In vitro   Sanger 1,2,3,6,12,14,15 
D559N Clinical   Sanger 15,18 
C316Y Clinical/In vitro 1472 fold  Sanger 1,2,3,4,5,6,7,10,12,14,15 
C316K Clinical   Sanger 1 
C316N Clinical/In vitro 5-fold (1b) Sanger 1,2,10,19,21,25 
C316W clinical   Sanger 1 
C316H In vitro   Sanger 6 
E446K/Q Clinical/In vitro   Sanger 1,6,15 
A553T Clinical/In vitro 152-fold  Sanger 1,6,15 
A553V In vitro 24-120-fold  Sanger 2,5,6 
A553D Clinical   Sanger 15 
G554S Clinical/In vitro 198-fold Sanger 1,3,6,14,15,16,24 
G558R Clinical/In vitro   Sanger 1,15 
S368A In vitro   Sanger 1 
S368T In vitro 65-fold (1b) Sanger 2,3,5,6 
N411S In vitro 84-fold (1b) Sanger 1,2,5,6 
C445F In vitro 16-fold  Sanger 1,2 
S556G In vitro 11-fold  Sanger 1,2,5 
A395G In vitro 10-fold (1a) Sanger 2,5 
N444K In vitro 23-fold (1a) Sanger 2,5 
Y448C Clinical/In vitro 400-940- fold  Sanger 1,2,3,4,5,6,12 
Y448H Clinical/In vitro 250-975- fold Sanger 1,2,3,4,5,6,12 
C451R In vitro 1-fold Sanger 1,2,5 
C451S In vitro 16-fold Sanger 2 
C451G/T In vitro   Sanger 2 
I585V In vitro 16-fold  Sanger 2 
Y561H Clinical/In vitro   Sanger 6,18 
P495A In vitro 2.4-fold  Sanger 2 
P495S In vitro 1.1-fold  Sanger 2 
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7.32 References for reported DSV resistance associated 
variants.  
1 Krishnan P et al., 2015 J AAC  
2 Kati W et al., 2014 J Antimicrobial Agents and Chemotherapy 
3 Trivella JP 2015 Expert Opin. Pharmacother 
4 Rodriguez-Torres, M et al., 2009 AASLD 2009 
5 Koev G et al., 2009 EASL 44th annual meeting 
6 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206619lbl.pdf 
7 Poordad F et al., 2014 NEJM 
8 Ferenci P et al., 2014 NEJM 
9 Pilot-Matias T et al., 2012 Poster J Hepatology 
10 Plaza Z et al., 2011 J Antimicrob Chemother 
11 Middleton T et al., 2011 J Hepatology 
12 Middleton T et al., 2010 J Hepatology  
13 Krishnan P 2014 AASLD 
14 Pilot-Matias T et al., 2012 AASLD 
15 Krishnan P EASL 2015 
16 Mantry P et al., AASLD 2014 
17 Wyles D et al., 2014 AASLD 
18 Feld J.J et al., 2014 EASL  
19 Zeuzem S et al., 2014 EASL 
20 Feld J.J et al., 2014 EASL  
21 Zeuzem S et al., 2014 EASL 
22 Sulkowski MS et al., 2014 International AIDS Conference 
23 Sulkowski MS et al., 2015 JAMA 
24 Kwo P et al., 2014 N Engl J Med 
25 Andreone P et al., 2014 Gastroenterology 
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7.33 pJET1.2/blunt plasmid map 
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